Nanoparticle Vaccines Against Infectious Diseases
Identifieur interne : 000A90 ( Pmc/Corpus ); précédent : 000A89; suivant : 000A91Nanoparticle Vaccines Against Infectious Diseases
Auteurs : Rashmirekha Pati ; Maxim Shevtsov ; Avinash SonawaneSource :
- Frontiers in Immunology [ 1664-3224 ] ; 2018.
Abstract
Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.
Url:
DOI: 10.3389/fimmu.2018.02224
PubMed: 30337923
PubMed Central: 6180194
Links to Exploration step
PMC:6180194Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Nanoparticle Vaccines Against Infectious Diseases</title><author><name sortKey="Pati, Rashmirekha" sort="Pati, Rashmirekha" uniqKey="Pati R" first="Rashmirekha" last="Pati">Rashmirekha Pati</name><affiliation><nlm:aff id="aff1"><institution>School of Biotechnology, KIIT University</institution>,<addr-line>Bhubaneswar</addr-line>,<country>India</country></nlm:aff></affiliation></author><author><name sortKey="Shevtsov, Maxim" sort="Shevtsov, Maxim" uniqKey="Shevtsov M" first="Maxim" last="Shevtsov">Maxim Shevtsov</name><affiliation><nlm:aff id="aff2"><institution>Institute of Cytology of the Russian Academy of Sciences (RAS)</institution>,<addr-line>St. Petersburg</addr-line>,<country>Russia</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff3"><institution>Klinikum Rechts der Isar, Technical University of Munich</institution>,<addr-line>Munich</addr-line>,<country>Germany</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff4"><institution>First Pavlov State Medical University of St.Petersburg</institution>,<addr-line>St. Petersburg</addr-line>,<country>Russia</country></nlm:aff></affiliation></author><author><name sortKey="Sonawane, Avinash" sort="Sonawane, Avinash" uniqKey="Sonawane A" first="Avinash" last="Sonawane">Avinash Sonawane</name><affiliation><nlm:aff id="aff1"><institution>School of Biotechnology, KIIT University</institution>,<addr-line>Bhubaneswar</addr-line>,<country>India</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff5"><institution>Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore</institution>,<addr-line>Indore</addr-line>,<country>India</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">30337923</idno><idno type="pmc">6180194</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180194</idno><idno type="RBID">PMC:6180194</idno><idno type="doi">10.3389/fimmu.2018.02224</idno><date when="2018">2018</date><idno type="wicri:Area/Pmc/Corpus">000A90</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000A90</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Nanoparticle Vaccines Against Infectious Diseases</title><author><name sortKey="Pati, Rashmirekha" sort="Pati, Rashmirekha" uniqKey="Pati R" first="Rashmirekha" last="Pati">Rashmirekha Pati</name><affiliation><nlm:aff id="aff1"><institution>School of Biotechnology, KIIT University</institution>,<addr-line>Bhubaneswar</addr-line>,<country>India</country></nlm:aff></affiliation></author><author><name sortKey="Shevtsov, Maxim" sort="Shevtsov, Maxim" uniqKey="Shevtsov M" first="Maxim" last="Shevtsov">Maxim Shevtsov</name><affiliation><nlm:aff id="aff2"><institution>Institute of Cytology of the Russian Academy of Sciences (RAS)</institution>,<addr-line>St. Petersburg</addr-line>,<country>Russia</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff3"><institution>Klinikum Rechts der Isar, Technical University of Munich</institution>,<addr-line>Munich</addr-line>,<country>Germany</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff4"><institution>First Pavlov State Medical University of St.Petersburg</institution>,<addr-line>St. Petersburg</addr-line>,<country>Russia</country></nlm:aff></affiliation></author><author><name sortKey="Sonawane, Avinash" sort="Sonawane, Avinash" uniqKey="Sonawane A" first="Avinash" last="Sonawane">Avinash Sonawane</name><affiliation><nlm:aff id="aff1"><institution>School of Biotechnology, KIIT University</institution>,<addr-line>Bhubaneswar</addr-line>,<country>India</country></nlm:aff></affiliation><affiliation><nlm:aff id="aff5"><institution>Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore</institution>,<addr-line>Indore</addr-line>,<country>India</country></nlm:aff></affiliation></author></analytic><series><title level="j">Frontiers in Immunology</title><idno type="eISSN">1664-3224</idno><imprint><date when="2018">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Dye, C" uniqKey="Dye C">C Dye</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Kahn, Re" uniqKey="Kahn R">RE Kahn</name></author><author><name sortKey="Ma, W" uniqKey="Ma W">W Ma</name></author><author><name sortKey="Richt, Ja" uniqKey="Richt J">JA Richt</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Braden, Cr" uniqKey="Braden C">CR Braden</name></author><author><name sortKey="Dowell, Sf" uniqKey="Dowell S">SF Dowell</name></author><author><name sortKey="Jernigan, Db" uniqKey="Jernigan D">DB Jernigan</name></author><author><name sortKey="Hughes, Jm" uniqKey="Hughes J">JM Hughes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wejse, C" uniqKey="Wejse C">C Wejse</name></author><author><name sortKey="Patsche, Cb" uniqKey="Patsche C">CB Patsche</name></author><author><name sortKey="Kuhle, A" uniqKey="Kuhle A">A Kühle</name></author><author><name sortKey="Bamba, Fjv" uniqKey="Bamba F">FJV Bamba</name></author><author><name sortKey="Mendes, Ms" uniqKey="Mendes M">MS Mendes</name></author><author><name sortKey="Lemvik, G" uniqKey="Lemvik G">G Lemvik</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Greenwood, B" uniqKey="Greenwood B">B Greenwood</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ada, Gl" uniqKey="Ada G">GL Ada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Atkins, Hs" uniqKey="Atkins H">HS Atkins</name></author><author><name sortKey="Morton, M" uniqKey="Morton M">M Morton</name></author><author><name sortKey="Griffin, Kf" uniqKey="Griffin K">KF Griffin</name></author><author><name sortKey="Stokes, Mgm" uniqKey="Stokes M">MGM Stokes</name></author><author><name sortKey="Nataro, Jp" uniqKey="Nataro J">JP Nataro</name></author><author><name sortKey="Titball, Rw" uniqKey="Titball R">RW Titball</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beverley, Pcl" uniqKey="Beverley P">PCL Beverley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ulmer, Jb" uniqKey="Ulmer J">JB Ulmer</name></author><author><name sortKey="Donnelly, Jj" uniqKey="Donnelly J">JJ Donnelly</name></author><author><name sortKey="Parker, Se" uniqKey="Parker S">SE Parker</name></author><author><name sortKey="Rhodes, Gh" uniqKey="Rhodes G">GH Rhodes</name></author><author><name sortKey="Felgner, Pl" uniqKey="Felgner P">PL Felgner</name></author><author><name sortKey="Dwarki, Vj" uniqKey="Dwarki V">VJ Dwarki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scallan, Cd" uniqKey="Scallan C">CD Scallan</name></author><author><name sortKey="Tingley, Dw" uniqKey="Tingley D">DW Tingley</name></author><author><name sortKey="Lindbloom, Jd" uniqKey="Lindbloom J">JD Lindbloom</name></author><author><name sortKey="Toomey, Js" uniqKey="Toomey J">JS Toomey</name></author><author><name sortKey="Tucker, Sn" uniqKey="Tucker S">SN Tucker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Altenburg, Af" uniqKey="Altenburg A">AF Altenburg</name></author><author><name sortKey="Kreijtz, Jh" uniqKey="Kreijtz J">JH Kreijtz</name></author><author><name sortKey="De, Vries Rd" uniqKey="De V">Vries RD de</name></author><author><name sortKey="Song, F" uniqKey="Song F">F Song</name></author><author><name sortKey="Fux, R" uniqKey="Fux R">R Fux</name></author><author><name sortKey="Rimmelzwaan, Gf" uniqKey="Rimmelzwaan G">GF Rimmelzwaan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nascimento, Ip" uniqKey="Nascimento I">IP Nascimento</name></author><author><name sortKey="Leite, Lcc" uniqKey="Leite L">LCC Leite</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Donnelly, Jj" uniqKey="Donnelly J">JJ Donnelly</name></author><author><name sortKey="Wahren, B" uniqKey="Wahren B">B Wahren</name></author><author><name sortKey="Liu, Ma" uniqKey="Liu M">MA Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Skibinski, Da" uniqKey="Skibinski D">DA Skibinski</name></author><author><name sortKey="Baudner, Bc" uniqKey="Baudner B">BC Baudner</name></author><author><name sortKey="Singh, M" uniqKey="Singh M">M Singh</name></author><author><name sortKey="O Hagan, Dt" uniqKey="O Hagan D">DT O'Hagan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Huber, Vc" uniqKey="Huber V">VC Huber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Means, Tk" uniqKey="Means T">TK Means</name></author><author><name sortKey="Hayashi, F" uniqKey="Hayashi F">F Hayashi</name></author><author><name sortKey="Smith, Kd" uniqKey="Smith K">KD Smith</name></author><author><name sortKey="Aderem, A" uniqKey="Aderem A">A Aderem</name></author><author><name sortKey="Luster, Ad" uniqKey="Luster A">AD Luster</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mogensen, Th" uniqKey="Mogensen T">TH Mogensen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Randolph, Gj" uniqKey="Randolph G">GJ Randolph</name></author><author><name sortKey="Ochando, J" uniqKey="Ochando J">J Ochando</name></author><author><name sortKey="Partida Sanchez, S" uniqKey="Partida Sanchez S">S Partida-Sánchez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Smith, Dm" uniqKey="Smith D">DM Smith</name></author><author><name sortKey="Simon, Jk" uniqKey="Simon J">JK Simon</name></author><author><name sortKey="Baker, Jr" uniqKey="Baker J">JR Baker</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fifis, T" uniqKey="Fifis T">T Fifis</name></author><author><name sortKey="Gamvrellis, A" uniqKey="Gamvrellis A">A Gamvrellis</name></author><author><name sortKey="Crimeen Irwin, B" uniqKey="Crimeen Irwin B">B Crimeen-Irwin</name></author><author><name sortKey="Pietersz, Ga" uniqKey="Pietersz G">GA Pietersz</name></author><author><name sortKey="Li, J" uniqKey="Li J">J Li</name></author><author><name sortKey="Mottram, Pl" uniqKey="Mottram P">PL Mottram</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mottram, Pl" uniqKey="Mottram P">PL Mottram</name></author><author><name sortKey="Leong, D" uniqKey="Leong D">D Leong</name></author><author><name sortKey="Crimeen Irwin, B" uniqKey="Crimeen Irwin B">B Crimeen-Irwin</name></author><author><name sortKey="Gloster, S" uniqKey="Gloster S">S Gloster</name></author><author><name sortKey="Xiang, Sd" uniqKey="Xiang S">SD Xiang</name></author><author><name sortKey="Meanger, J" uniqKey="Meanger J">J Meanger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scholer, N" uniqKey="Scholer N">N Schöler</name></author><author><name sortKey="Hahn, H" uniqKey="Hahn H">H Hahn</name></author><author><name sortKey="Muller, Rh" uniqKey="Muller R">RH Müller</name></author><author><name sortKey="Liesenfeld, O" uniqKey="Liesenfeld O">O Liesenfeld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Scholer, N" uniqKey="Scholer N">N Schöler</name></author><author><name sortKey="Olbrich, C" uniqKey="Olbrich C">C Olbrich</name></author><author><name sortKey="Tabatt, K" uniqKey="Tabatt K">K Tabatt</name></author><author><name sortKey="Muller, Rh" uniqKey="Muller R">RH Müller</name></author><author><name sortKey="Hahn, H" uniqKey="Hahn H">H Hahn</name></author><author><name sortKey="Liesenfeld, O" uniqKey="Liesenfeld O">O Liesenfeld</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vallhov, H" uniqKey="Vallhov H">H Vallhov</name></author><author><name sortKey="Qin, J" uniqKey="Qin J">J Qin</name></author><author><name sortKey="Johansson, Sm" uniqKey="Johansson S">SM Johansson</name></author><author><name sortKey="Ahlborg, N" uniqKey="Ahlborg N">N Ahlborg</name></author><author><name sortKey="Muhammed, Ma" uniqKey="Muhammed M">MA Muhammed</name></author><author><name sortKey="Scheynius, A" uniqKey="Scheynius A">A Scheynius</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shvedova, Aa" uniqKey="Shvedova A">AA Shvedova</name></author><author><name sortKey="Kisin, Er" uniqKey="Kisin E">ER Kisin</name></author><author><name sortKey="Mercer, R" uniqKey="Mercer R">R Mercer</name></author><author><name sortKey="Murray, Ar" uniqKey="Murray A">AR Murray</name></author><author><name sortKey="Johnson, Vj" uniqKey="Johnson V">VJ Johnson</name></author><author><name sortKey="Potapovich, Ai" uniqKey="Potapovich A">AI Potapovich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Ishida, T" uniqKey="Ishida T">T Ishida</name></author><author><name sortKey="Kiwada, H" uniqKey="Kiwada H">H Kiwada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ishida, T" uniqKey="Ishida T">T Ishida</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Shimizu, T" uniqKey="Shimizu T">T Shimizu</name></author><author><name sortKey="Nawata, K" uniqKey="Nawata K">K Nawata</name></author><author><name sortKey="Kiwada, H" uniqKey="Kiwada H">H Kiwada</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Irvine, Dj" uniqKey="Irvine D">DJ Irvine</name></author><author><name sortKey="Swartz, Ma" uniqKey="Swartz M">MA Swartz</name></author><author><name sortKey="Szeto, Gl" uniqKey="Szeto G">GL Szeto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pusic, K" uniqKey="Pusic K">K Pusic</name></author><author><name sortKey="Aguilar, Z" uniqKey="Aguilar Z">Z Aguilar</name></author><author><name sortKey="Mcloughlin, J" uniqKey="Mcloughlin J">J McLoughlin</name></author><author><name sortKey="Kobuch, S" uniqKey="Kobuch S">S Kobuch</name></author><author><name sortKey="Xu, H" uniqKey="Xu H">H Xu</name></author><author><name sortKey="Tsang, M" uniqKey="Tsang M">M Tsang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lim, Js" uniqKey="Lim J">JS Lim</name></author><author><name sortKey="Lee, K" uniqKey="Lee K">K Lee</name></author><author><name sortKey="Choi, Jn" uniqKey="Choi J">JN Choi</name></author><author><name sortKey="Hwang, Yk" uniqKey="Hwang Y">YK Hwang</name></author><author><name sortKey="Yun, My" uniqKey="Yun M">MY Yun</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Akagi, T" uniqKey="Akagi T">T Akagi</name></author><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Uto, T" uniqKey="Uto T">T Uto</name></author><author><name sortKey="Baba, M" uniqKey="Baba M">M Baba</name></author><author><name sortKey="Akashi, M" uniqKey="Akashi M">M Akashi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Prego, C" uniqKey="Prego C">C Prego</name></author><author><name sortKey="Paolicelli, P" uniqKey="Paolicelli P">P Paolicelli</name></author><author><name sortKey="Diaz, B" uniqKey="Diaz B">B Díaz</name></author><author><name sortKey="Vicente, S" uniqKey="Vicente S">S Vicente</name></author><author><name sortKey="Sanchez, A" uniqKey="Sanchez A">A Sánchez</name></author><author><name sortKey="Gonzalez Fernandez, A" uniqKey="Gonzalez Fernandez A">Á González-Fernández</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shen, H" uniqKey="Shen H">H Shen</name></author><author><name sortKey="Ackerman, Al" uniqKey="Ackerman A">AL Ackerman</name></author><author><name sortKey="Cody, V" uniqKey="Cody V">V Cody</name></author><author><name sortKey="Giodini, A" uniqKey="Giodini A">A Giodini</name></author><author><name sortKey="Hinson, Er" uniqKey="Hinson E">ER Hinson</name></author><author><name sortKey="Cresswell, P" uniqKey="Cresswell P">P Cresswell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Diwan, M" uniqKey="Diwan M">M Diwan</name></author><author><name sortKey="Tafaghodi, M" uniqKey="Tafaghodi M">M Tafaghodi</name></author><author><name sortKey="Samuel, J" uniqKey="Samuel J">J Samuel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mintern, Jd" uniqKey="Mintern J">JD Mintern</name></author><author><name sortKey="Percival, C" uniqKey="Percival C">C Percival</name></author><author><name sortKey="Kamphuis, Mmj" uniqKey="Kamphuis M">MMJ Kamphuis</name></author><author><name sortKey="Chin, Wj" uniqKey="Chin W">WJ Chin</name></author><author><name sortKey="Caruso, F" uniqKey="Caruso F">F Caruso</name></author><author><name sortKey="Johnston, Apr" uniqKey="Johnston A">APR Johnston</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, X" uniqKey="Wang X">X Wang</name></author><author><name sortKey="Uto, T" uniqKey="Uto T">T Uto</name></author><author><name sortKey="Akagi, T" uniqKey="Akagi T">T Akagi</name></author><author><name sortKey="Akashi, M" uniqKey="Akashi M">M Akashi</name></author><author><name sortKey="Baba, M" uniqKey="Baba M">M Baba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Richards, Rl" uniqKey="Richards R">RL Richards</name></author><author><name sortKey="Rao, M" uniqKey="Rao M">M Rao</name></author><author><name sortKey="Wassef, Nm" uniqKey="Wassef N">NM Wassef</name></author><author><name sortKey="Glenn, Gm" uniqKey="Glenn G">GM Glenn</name></author><author><name sortKey="Rothwell, Sw" uniqKey="Rothwell S">SW Rothwell</name></author><author><name sortKey="Alving, Cr" uniqKey="Alving C">CR Alving</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tyler, M" uniqKey="Tyler M">M Tyler</name></author><author><name sortKey="Tumban, E" uniqKey="Tumban E">E Tumban</name></author><author><name sortKey="Peabody, Ds" uniqKey="Peabody D">DS Peabody</name></author><author><name sortKey="Chackerian, B" uniqKey="Chackerian B">B Chackerian</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Slupetzky, K" uniqKey="Slupetzky K">K Slupetzky</name></author><author><name sortKey="Gambhira, R" uniqKey="Gambhira R">R Gambhira</name></author><author><name sortKey="Culp, Td" uniqKey="Culp T">TD Culp</name></author><author><name sortKey="Shafti Keramat, S" uniqKey="Shafti Keramat S">S Shafti-Keramat</name></author><author><name sortKey="Schellenbacher, C" uniqKey="Schellenbacher C">C Schellenbacher</name></author><author><name sortKey="Christensen, Nd" uniqKey="Christensen N">ND Christensen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manish, M" uniqKey="Manish M">M Manish</name></author><author><name sortKey="Rahi, A" uniqKey="Rahi A">A Rahi</name></author><author><name sortKey="Kaur, M" uniqKey="Kaur M">M Kaur</name></author><author><name sortKey="Bhatnagar, R" uniqKey="Bhatnagar R">R Bhatnagar</name></author><author><name sortKey="Singh, S" uniqKey="Singh S">S Singh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Feng, G" uniqKey="Feng G">G Feng</name></author><author><name sortKey="Jiang, Q" uniqKey="Jiang Q">Q Jiang</name></author><author><name sortKey="Xia, M" uniqKey="Xia M">M Xia</name></author><author><name sortKey="Lu, Y" uniqKey="Lu Y">Y Lu</name></author><author><name sortKey="Qiu, W" uniqKey="Qiu W">W Qiu</name></author><author><name sortKey="Zhao, D" uniqKey="Zhao D">D Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Das, I" uniqKey="Das I">I Das</name></author><author><name sortKey="Padhi, A" uniqKey="Padhi A">A Padhi</name></author><author><name sortKey="Mukherjee, S" uniqKey="Mukherjee S">S Mukherjee</name></author><author><name sortKey="Dash, Dp" uniqKey="Dash D">DP Dash</name></author><author><name sortKey="Kar, S" uniqKey="Kar S">S Kar</name></author><author><name sortKey="Sonawane, A" uniqKey="Sonawane A">A Sonawane</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Abraham, E" uniqKey="Abraham E">E Abraham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alving, Cr" uniqKey="Alving C">CR Alving</name></author><author><name sortKey="Richards, Rl" uniqKey="Richards R">RL Richards</name></author><author><name sortKey="Moss, J" uniqKey="Moss J">J Moss</name></author><author><name sortKey="Alving, Li" uniqKey="Alving L">LI Alving</name></author><author><name sortKey="Clements, Jd" uniqKey="Clements J">JD Clements</name></author><author><name sortKey="Shiba, T" uniqKey="Shiba T">T Shiba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, W" uniqKey="Zhao W">W Zhao</name></author><author><name sortKey="Wu, W" uniqKey="Wu W">W Wu</name></author><author><name sortKey="Xu, X" uniqKey="Xu X">X Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Makidon, Pe" uniqKey="Makidon P">PE Makidon</name></author><author><name sortKey="Knowlton, J" uniqKey="Knowlton J">J Knowlton</name></author><author><name sortKey="Groom, J V" uniqKey="Groom J">J V Groom</name></author><author><name sortKey="Blanco, Lp" uniqKey="Blanco L">LP Blanco</name></author><author><name sortKey="Lipuma, Jj" uniqKey="Lipuma J">JJ LiPuma</name></author><author><name sortKey="Bielinska, Au" uniqKey="Bielinska A">AU Bielinska</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bielinska, Au" uniqKey="Bielinska A">AU Bielinska</name></author><author><name sortKey="Janczak, Kw" uniqKey="Janczak K">KW Janczak</name></author><author><name sortKey="Landers, Jj" uniqKey="Landers J">JJ Landers</name></author><author><name sortKey="Makidon, P" uniqKey="Makidon P">P Makidon</name></author><author><name sortKey="Sower, Le" uniqKey="Sower L">LE Sower</name></author><author><name sortKey="Peterson, Jw" uniqKey="Peterson J">JW Peterson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamath, At" uniqKey="Kamath A">AT Kamath</name></author><author><name sortKey="Rochat, Af" uniqKey="Rochat A">AF Rochat</name></author><author><name sortKey="Christensen, D" uniqKey="Christensen D">D Christensen</name></author><author><name sortKey="Agger, Em" uniqKey="Agger E">EM Agger</name></author><author><name sortKey="Andersen, P" uniqKey="Andersen P">P Andersen</name></author><author><name sortKey="Lambert, Ph" uniqKey="Lambert P">PH Lambert</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen, Ys" uniqKey="Chen Y">YS Chen</name></author><author><name sortKey="Hung, Yc" uniqKey="Hung Y">YC Hung</name></author><author><name sortKey="Lin, Wh" uniqKey="Lin W">WH Lin</name></author><author><name sortKey="Huang, Gs" uniqKey="Huang G">GS Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tao, W" uniqKey="Tao W">W Tao</name></author><author><name sortKey="Gill, Hs" uniqKey="Gill H">HS Gill</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu, L" uniqKey="Xu L">L Xu</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Chen, Z" uniqKey="Chen Z">Z Chen</name></author><author><name sortKey="Li, W" uniqKey="Li W">W Li</name></author><author><name sortKey="Liu, Y" uniqKey="Liu Y">Y Liu</name></author><author><name sortKey="Wang, L" uniqKey="Wang L">L Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Raghuvanshi, Rs" uniqKey="Raghuvanshi R">RS Raghuvanshi</name></author><author><name sortKey="Katare, Yk" uniqKey="Katare Y">YK Katare</name></author><author><name sortKey="Lalwani, K" uniqKey="Lalwani K">K Lalwani</name></author><author><name sortKey="Ali, Mm" uniqKey="Ali M">MM Ali</name></author><author><name sortKey="Singh, O" uniqKey="Singh O">O Singh</name></author><author><name sortKey="Panda, Ak" uniqKey="Panda A">AK Panda</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thomas, C" uniqKey="Thomas C">C Thomas</name></author><author><name sortKey="Rawat, A" uniqKey="Rawat A">A Rawat</name></author><author><name sortKey="Hope Weeks, L" uniqKey="Hope Weeks L">L Hope-Weeks</name></author><author><name sortKey="Ahsan, F" uniqKey="Ahsan F">F Ahsan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Borges, O" uniqKey="Borges O">O Borges</name></author><author><name sortKey="Cordeiro Da Silva, A" uniqKey="Cordeiro Da Silva A">A Cordeiro-da-Silva</name></author><author><name sortKey="Tavares, J" uniqKey="Tavares J">J Tavares</name></author><author><name sortKey="Santarem, N" uniqKey="Santarem N">N Santarém</name></author><author><name sortKey="De, Sousa A" uniqKey="De S">Sousa A de</name></author><author><name sortKey="Borchard, G" uniqKey="Borchard G">G Borchard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, K" uniqKey="Zhao K">K Zhao</name></author><author><name sortKey="Chen, G" uniqKey="Chen G">G Chen</name></author><author><name sortKey="Shi, X" uniqKey="Shi X">X Shi</name></author><author><name sortKey="Gao, T" uniqKey="Gao T">T Gao</name></author><author><name sortKey="Li, W" uniqKey="Li W">W Li</name></author><author><name sortKey="Zhao, Y" uniqKey="Zhao Y">Y Zhao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ball, Jm" uniqKey="Ball J">JM Ball</name></author><author><name sortKey="Hardy, Me" uniqKey="Hardy M">ME Hardy</name></author><author><name sortKey="Atmar, Rl" uniqKey="Atmar R">RL Atmar</name></author><author><name sortKey="Conner, Me" uniqKey="Conner M">ME Conner</name></author><author><name sortKey="Estes, Mk" uniqKey="Estes M">MK Estes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ball, Jm" uniqKey="Ball J">JM Ball</name></author><author><name sortKey="Graham, Dy" uniqKey="Graham D">DY Graham</name></author><author><name sortKey="Opekun, Ar" uniqKey="Opekun A">AR Opekun</name></author><author><name sortKey="Gilger, Ma" uniqKey="Gilger M">MA Gilger</name></author><author><name sortKey="Guerrero, Ra" uniqKey="Guerrero R">RA Guerrero</name></author><author><name sortKey="Estes, Mk" uniqKey="Estes M">MK Estes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bright, Ra" uniqKey="Bright R">RA Bright</name></author><author><name sortKey="Carter, Dm" uniqKey="Carter D">DM Carter</name></author><author><name sortKey="Daniluk, S" uniqKey="Daniluk S">S Daniluk</name></author><author><name sortKey="Toapanta, Fr" uniqKey="Toapanta F">FR Toapanta</name></author><author><name sortKey="Ahmad, A" uniqKey="Ahmad A">A Ahmad</name></author><author><name sortKey="Gavrilov, V" uniqKey="Gavrilov V">V Gavrilov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Quan, Fs" uniqKey="Quan F">FS Quan</name></author><author><name sortKey="Huang, C" uniqKey="Huang C">C Huang</name></author><author><name sortKey="Compans, Rw" uniqKey="Compans R">RW Compans</name></author><author><name sortKey="Kang, Sm" uniqKey="Kang S">SM Kang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Matassov, D" uniqKey="Matassov D">D Matassov</name></author><author><name sortKey="Cupo, A" uniqKey="Cupo A">A Cupo</name></author><author><name sortKey="Galarza, Jm" uniqKey="Galarza J">JM Galarza</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bright, Ra" uniqKey="Bright R">RA Bright</name></author><author><name sortKey="Carter, Dm" uniqKey="Carter D">DM Carter</name></author><author><name sortKey="Crevar, Cj" uniqKey="Crevar C">CJ Crevar</name></author><author><name sortKey="Toapanta, Fr" uniqKey="Toapanta F">FR Toapanta</name></author><author><name sortKey="Steckbeck, Jd" uniqKey="Steckbeck J">JD Steckbeck</name></author><author><name sortKey="Cole, Ks" uniqKey="Cole K">KS Cole</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mahmood, K" uniqKey="Mahmood K">K Mahmood</name></author><author><name sortKey="Bright, Ra" uniqKey="Bright R">RA Bright</name></author><author><name sortKey="Mytle, N" uniqKey="Mytle N">N Mytle</name></author><author><name sortKey="Carter, Dm" uniqKey="Carter D">DM Carter</name></author><author><name sortKey="Crevar, Cj" uniqKey="Crevar C">CJ Crevar</name></author><author><name sortKey="Achenbach, Je" uniqKey="Achenbach J">JE Achenbach</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guo, L" uniqKey="Guo L">L Guo</name></author><author><name sortKey="Lu, X" uniqKey="Lu X">X Lu</name></author><author><name sortKey="Kang, Sm" uniqKey="Kang S">SM Kang</name></author><author><name sortKey="Chen, C" uniqKey="Chen C">C Chen</name></author><author><name sortKey="Compans, Rw" uniqKey="Compans R">RW Compans</name></author><author><name sortKey="Yao, Q" uniqKey="Yao Q">Q Yao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Geldmacher, A" uniqKey="Geldmacher A">A Geldmacher</name></author><author><name sortKey="Skrastina, D" uniqKey="Skrastina D">D Skrastina</name></author><author><name sortKey="Borisova, G" uniqKey="Borisova G">G Borisova</name></author><author><name sortKey="Petrovskis, I" uniqKey="Petrovskis I">I Petrovskis</name></author><author><name sortKey="Kruger, Dh" uniqKey="Kruger D">DH Krüger</name></author><author><name sortKey="Pumpens, P" uniqKey="Pumpens P">P Pumpens</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sadeyen, Jr" uniqKey="Sadeyen J">JR Sadeyen</name></author><author><name sortKey="Tourne, S" uniqKey="Tourne S">S Tourne</name></author><author><name sortKey="Shkreli, M" uniqKey="Shkreli M">M Shkreli</name></author><author><name sortKey="Sizaret, Py" uniqKey="Sizaret P">PY Sizaret</name></author><author><name sortKey="Coursaget, P" uniqKey="Coursaget P">P Coursaget</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Paz, De La Rosa G" uniqKey="Paz D">De la Rosa G Paz</name></author><author><name sortKey="Monroy Garcia, A" uniqKey="Monroy Garcia A">A Monroy-García</name></author><author><name sortKey="Mora Garcia, M De L" uniqKey="Mora Garcia M">M de L Mora-García</name></author><author><name sortKey="Pe A, Cgr" uniqKey="Pe A C">CGR Peña</name></author><author><name sortKey="Hernandez Montes, J" uniqKey="Hernandez Montes J">J Hernández-Montes</name></author><author><name sortKey="Weiss Steider, B" uniqKey="Weiss Steider B">B Weiss-Steider</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oh, Yk" uniqKey="Oh Y">YK Oh</name></author><author><name sortKey="Sohn, T" uniqKey="Sohn T">T Sohn</name></author><author><name sortKey="Park, Js" uniqKey="Park J">JS Park</name></author><author><name sortKey="Kang, Mj" uniqKey="Kang M">MJ Kang</name></author><author><name sortKey="Choi, Hg" uniqKey="Choi H">HG Choi</name></author><author><name sortKey="Kim, Ja" uniqKey="Kim J">JA Kim</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="O Neal, Cm" uniqKey="O Neal C">CM O'Neal</name></author><author><name sortKey="Crawford, Se" uniqKey="Crawford S">SE Crawford</name></author><author><name sortKey="Estes, Mk" uniqKey="Estes M">MK Estes</name></author><author><name sortKey="Conner, Me" uniqKey="Conner M">ME Conner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Parez, N" uniqKey="Parez N">N Parez</name></author><author><name sortKey="Fourgeux, C" uniqKey="Fourgeux C">C Fourgeux</name></author><author><name sortKey="Mohamed, A" uniqKey="Mohamed A">A Mohamed</name></author><author><name sortKey="Dubuquoy, C" uniqKey="Dubuquoy C">C Dubuquoy</name></author><author><name sortKey="Pillot, M" uniqKey="Pillot M">M Pillot</name></author><author><name sortKey="Dehee, A" uniqKey="Dehee A">A Dehee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roy, P" uniqKey="Roy P">P Roy</name></author><author><name sortKey="Bishop, Dh" uniqKey="Bishop D">DH Bishop</name></author><author><name sortKey="Leblois, H" uniqKey="Leblois H">H LeBlois</name></author><author><name sortKey="Erasmus, Bj" uniqKey="Erasmus B">BJ Erasmus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Deml, L" uniqKey="Deml L">L Deml</name></author><author><name sortKey="Kratochwil, G" uniqKey="Kratochwil G">G Kratochwil</name></author><author><name sortKey="Osterrieder, N" uniqKey="Osterrieder N">N Osterrieder</name></author><author><name sortKey="Knuchel, R" uniqKey="Knuchel R">R Knüchel</name></author><author><name sortKey="Wolf, H" uniqKey="Wolf H">H Wolf</name></author><author><name sortKey="Wagner, R" uniqKey="Wagner R">R Wagner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Crooks, Et" uniqKey="Crooks E">ET Crooks</name></author><author><name sortKey="Moore, Pl" uniqKey="Moore P">PL Moore</name></author><author><name sortKey="Franti, M" uniqKey="Franti M">M Franti</name></author><author><name sortKey="Cayanan, Cs" uniqKey="Cayanan C">CS Cayanan</name></author><author><name sortKey="Zhu, P" uniqKey="Zhu P">P Zhu</name></author><author><name sortKey="Jiang, P" uniqKey="Jiang P">P Jiang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Buonaguro, L" uniqKey="Buonaguro L">L Buonaguro</name></author><author><name sortKey="Visciano, Ml" uniqKey="Visciano M">ML Visciano</name></author><author><name sortKey="Tornesello, Ml" uniqKey="Tornesello M">ML Tornesello</name></author><author><name sortKey="Tagliamonte, M" uniqKey="Tagliamonte M">M Tagliamonte</name></author><author><name sortKey="Biryahwaho, B" uniqKey="Biryahwaho B">B Biryahwaho</name></author><author><name sortKey="Buonaguro, Fm" uniqKey="Buonaguro F">FM Buonaguro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, Bz" uniqKey="Wang B">BZ Wang</name></author><author><name sortKey="Liu, W" uniqKey="Liu W">W Liu</name></author><author><name sortKey="Kang, Sm" uniqKey="Kang S">SM Kang</name></author><author><name sortKey="Alam, M" uniqKey="Alam M">M Alam</name></author><author><name sortKey="Huang, C" uniqKey="Huang C">C Huang</name></author><author><name sortKey="Ye, L" uniqKey="Ye L">L Ye</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pimentel, Tapf" uniqKey="Pimentel T">TAPF Pimentel</name></author><author><name sortKey="Yan, Z" uniqKey="Yan Z">Z Yan</name></author><author><name sortKey="Jeffers, Sa" uniqKey="Jeffers S">SA Jeffers</name></author><author><name sortKey="Holmes, K V" uniqKey="Holmes K">K V Holmes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaba, Sa" uniqKey="Kaba S">SA Kaba</name></author><author><name sortKey="Brando, C" uniqKey="Brando C">C Brando</name></author><author><name sortKey="Guo, Q" uniqKey="Guo Q">Q Guo</name></author><author><name sortKey="Mittelholzer, C" uniqKey="Mittelholzer C">C Mittelholzer</name></author><author><name sortKey="Raman, S" uniqKey="Raman S">S Raman</name></author><author><name sortKey="Tropel, D" uniqKey="Tropel D">D Tropel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kazanji, M" uniqKey="Kazanji M">M Kazanji</name></author><author><name sortKey="Laurent, F" uniqKey="Laurent F">F Laurent</name></author><author><name sortKey="Pery, P" uniqKey="Pery P">P Péry</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wang, T" uniqKey="Wang T">T Wang</name></author><author><name sortKey="Zou, M" uniqKey="Zou M">M Zou</name></author><author><name sortKey="Jiang, H" uniqKey="Jiang H">H Jiang</name></author><author><name sortKey="Ji, Z" uniqKey="Ji Z">Z Ji</name></author><author><name sortKey="Gao, P" uniqKey="Gao P">P Gao</name></author><author><name sortKey="Cheng, G" uniqKey="Cheng G">G Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhou, X" uniqKey="Zhou X">X Zhou</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Yu, X" uniqKey="Yu X">X Yu</name></author><author><name sortKey="Zha, X" uniqKey="Zha X">X Zha</name></author><author><name sortKey="Fu, Q" uniqKey="Fu Q">Q Fu</name></author><author><name sortKey="Liu, B" uniqKey="Liu B">B Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Turkevich, J" uniqKey="Turkevich J">J Turkevich</name></author><author><name sortKey="Stevenson, Pc" uniqKey="Stevenson P">PC Stevenson</name></author><author><name sortKey="Hillier, J" uniqKey="Hillier J">J Hillier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Silva, Cl" uniqKey="Silva C">CL Silva</name></author><author><name sortKey="Bonato, Vld" uniqKey="Bonato V">VLD Bonato</name></author><author><name sortKey="Coelho Castelo, Aam" uniqKey="Coelho Castelo A">AAM Coelho-Castelo</name></author><author><name sortKey="De, Souza Ao" uniqKey="De S">Souza AO De</name></author><author><name sortKey="Santos, Sa" uniqKey="Santos S">SA Santos</name></author><author><name sortKey="Lima, Km" uniqKey="Lima K">KM Lima</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Villa, Ch" uniqKey="Villa C">CH Villa</name></author><author><name sortKey="Dao, T" uniqKey="Dao T">T Dao</name></author><author><name sortKey="Ahearn, I" uniqKey="Ahearn I">I Ahearn</name></author><author><name sortKey="Fehrenbacher, N" uniqKey="Fehrenbacher N">N Fehrenbacher</name></author><author><name sortKey="Casey, E" uniqKey="Casey E">E Casey</name></author><author><name sortKey="Rey, Da" uniqKey="Rey D">DA Rey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yu, M" uniqKey="Yu M">M Yu</name></author><author><name sortKey="Jambhrunkar, S" uniqKey="Jambhrunkar S">S Jambhrunkar</name></author><author><name sortKey="Thorn, P" uniqKey="Thorn P">P Thorn</name></author><author><name sortKey="Chen, J" uniqKey="Chen J">J Chen</name></author><author><name sortKey="Gu, W" uniqKey="Gu W">W Gu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xia, T" uniqKey="Xia T">T Xia</name></author><author><name sortKey="Kovochich, M" uniqKey="Kovochich M">M Kovochich</name></author><author><name sortKey="Liong, M" uniqKey="Liong M">M Liong</name></author><author><name sortKey="Meng, H" uniqKey="Meng H">H Meng</name></author><author><name sortKey="Kabehie, S" uniqKey="Kabehie S">S Kabehie</name></author><author><name sortKey="George, S" uniqKey="George S">S George</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, X" uniqKey="He X">X He</name></author><author><name sortKey="Wang, K" uniqKey="Wang K">K Wang</name></author><author><name sortKey="Tan, W" uniqKey="Tan W">W Tan</name></author><author><name sortKey="Liu, B" uniqKey="Liu B">B Liu</name></author><author><name sortKey="Lin, X" uniqKey="Lin X">X Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, X" uniqKey="Li X">X Li</name></author><author><name sortKey="Deng, X" uniqKey="Deng X">X Deng</name></author><author><name sortKey="Huang, Z" uniqKey="Huang Z">Z Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Demento, Sl" uniqKey="Demento S">SL Demento</name></author><author><name sortKey="Cui, W" uniqKey="Cui W">W Cui</name></author><author><name sortKey="Criscione, Jm" uniqKey="Criscione J">JM Criscione</name></author><author><name sortKey="Stern, E" uniqKey="Stern E">E Stern</name></author><author><name sortKey="Tulipan, J" uniqKey="Tulipan J">J Tulipan</name></author><author><name sortKey="Kaech, Sm" uniqKey="Kaech S">SM Kaech</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lima, Vm" uniqKey="Lima V">VM Lima</name></author><author><name sortKey="Bonato, Vl" uniqKey="Bonato V">VL Bonato</name></author><author><name sortKey="Lima, Km" uniqKey="Lima K">KM Lima</name></author><author><name sortKey="Dos, Santos Sa" uniqKey="Dos S">Santos SA Dos</name></author><author><name sortKey="Dos, Santos Rr" uniqKey="Dos S">Santos RR Dos</name></author><author><name sortKey="Goncalves, Ed" uniqKey="Goncalves E">ED Gonçalves</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hasegawa, K" uniqKey="Hasegawa K">K Hasegawa</name></author><author><name sortKey="Noguchi, Y" uniqKey="Noguchi Y">Y Noguchi</name></author><author><name sortKey="Koizumi, F" uniqKey="Koizumi F">F Koizumi</name></author><author><name sortKey="Uenaka, A" uniqKey="Uenaka A">A Uenaka</name></author><author><name sortKey="Tanaka, M" uniqKey="Tanaka M">M Tanaka</name></author><author><name sortKey="Shimono, M" uniqKey="Shimono M">M Shimono</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, P" uniqKey="Li P">P Li</name></author><author><name sortKey="Luo, Z" uniqKey="Luo Z">Z Luo</name></author><author><name sortKey="Liu, P" uniqKey="Liu P">P Liu</name></author><author><name sortKey="Gao, N" uniqKey="Gao N">N Gao</name></author><author><name sortKey="Zhang, Y" uniqKey="Zhang Y">Y Zhang</name></author><author><name sortKey="Pan, H" uniqKey="Pan H">H Pan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Honda Okubo, Y" uniqKey="Honda Okubo Y">Y Honda-Okubo</name></author><author><name sortKey="Saade, F" uniqKey="Saade F">F Saade</name></author><author><name sortKey="Petrovsky, N" uniqKey="Petrovsky N">N Petrovsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saade, F" uniqKey="Saade F">F Saade</name></author><author><name sortKey="Honda Okubo, Y" uniqKey="Honda Okubo Y">Y Honda-Okubo</name></author><author><name sortKey="Trec, S" uniqKey="Trec S">S Trec</name></author><author><name sortKey="Petrovsky, N" uniqKey="Petrovsky N">N Petrovsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gotze, O" uniqKey="Gotze O">O Götze</name></author><author><name sortKey="Muller Eberhard, Hj" uniqKey="Muller Eberhard H">HJ Müller-Eberhard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pawar, D" uniqKey="Pawar D">D Pawar</name></author><author><name sortKey="Mangal, S" uniqKey="Mangal S">S Mangal</name></author><author><name sortKey="Goswami, R" uniqKey="Goswami R">R Goswami</name></author><author><name sortKey="Jaganathan, Ks" uniqKey="Jaganathan K">KS Jaganathan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sonaje, K" uniqKey="Sonaje K">K Sonaje</name></author><author><name sortKey="Chuang, Ey" uniqKey="Chuang E">EY Chuang</name></author><author><name sortKey="Lin, Kj" uniqKey="Lin K">KJ Lin</name></author><author><name sortKey="Yen, Tc" uniqKey="Yen T">TC Yen</name></author><author><name sortKey="Su, Fy" uniqKey="Su F">FY Su</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De, Titta A" uniqKey="De T">Titta A de</name></author><author><name sortKey="Ballester, M" uniqKey="Ballester M">M Ballester</name></author><author><name sortKey="Julier, Z" uniqKey="Julier Z">Z Julier</name></author><author><name sortKey="Nembrini, C" uniqKey="Nembrini C">C Nembrini</name></author><author><name sortKey="Jeanbart, L" uniqKey="Jeanbart L">L Jeanbart</name></author><author><name sortKey="Van, Der Vlies Aj" uniqKey="Van D">der Vlies AJ van</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mohammed, Ma" uniqKey="Mohammed M">MA Mohammed</name></author><author><name sortKey="Syeda, Jtm" uniqKey="Syeda J">JTM Syeda</name></author><author><name sortKey="Wasan, Km" uniqKey="Wasan K">KM Wasan</name></author><author><name sortKey="Wasan, Ek" uniqKey="Wasan E">EK Wasan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sharma, A" uniqKey="Sharma A">A Sharma</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Storm, G" uniqKey="Storm G">G Storm</name></author><author><name sortKey="Crommelin, Dj" uniqKey="Crommelin D">DJ Crommelin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tyagi, Rk" uniqKey="Tyagi R">RK Tyagi</name></author><author><name sortKey="Garg, Nk" uniqKey="Garg N">NK Garg</name></author><author><name sortKey="Sahu, T" uniqKey="Sahu T">T Sahu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moon, Jj" uniqKey="Moon J">JJ Moon</name></author><author><name sortKey="Suh, H" uniqKey="Suh H">H Suh</name></author><author><name sortKey="Bershteyn, A" uniqKey="Bershteyn A">A Bershteyn</name></author><author><name sortKey="Stephan, Mt" uniqKey="Stephan M">MT Stephan</name></author><author><name sortKey="Liu, H" uniqKey="Liu H">H Liu</name></author><author><name sortKey="Huang, B" uniqKey="Huang B">B Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ichihashi, T" uniqKey="Ichihashi T">T Ichihashi</name></author><author><name sortKey="Satoh, T" uniqKey="Satoh T">T Satoh</name></author><author><name sortKey="Sugimoto, C" uniqKey="Sugimoto C">C Sugimoto</name></author><author><name sortKey="Kajino, K" uniqKey="Kajino K">K Kajino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ribeiro, Am" uniqKey="Ribeiro A">AM Ribeiro</name></author><author><name sortKey="Souza, Aco" uniqKey="Souza A">ACO Souza</name></author><author><name sortKey="Amaral, Ac" uniqKey="Amaral A">AC Amaral</name></author><author><name sortKey="Vasconcelos, Nm" uniqKey="Vasconcelos N">NM Vasconcelos</name></author><author><name sortKey="Jeronimo, Ms" uniqKey="Jeronimo M">MS Jeronimo</name></author><author><name sortKey="Carneiro, Fp" uniqKey="Carneiro F">FP Carneiro</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Watson, Ds" uniqKey="Watson D">DS Watson</name></author><author><name sortKey="Endsley, An" uniqKey="Endsley A">AN Endsley</name></author><author><name sortKey="Huang, L" uniqKey="Huang L">L Huang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vyas, Sp" uniqKey="Vyas S">SP Vyas</name></author><author><name sortKey="Kannan, Me" uniqKey="Kannan M">ME Kannan</name></author><author><name sortKey="Jain, S" uniqKey="Jain S">S Jain</name></author><author><name sortKey="Mishra, V" uniqKey="Mishra V">V Mishra</name></author><author><name sortKey="Singh, P" uniqKey="Singh P">P Singh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vyas, S" uniqKey="Vyas S">S Vyas</name></author><author><name sortKey="Quraishi, S" uniqKey="Quraishi S">S Quraishi</name></author><author><name sortKey="Gupta, S" uniqKey="Gupta S">S Gupta</name></author><author><name sortKey="Jaganathan, K" uniqKey="Jaganathan K">K Jaganathan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joseph, A" uniqKey="Joseph A">A Joseph</name></author><author><name sortKey="Itskovitz Cooper, N" uniqKey="Itskovitz Cooper N">N Itskovitz-Cooper</name></author><author><name sortKey="Samira, S" uniqKey="Samira S">S Samira</name></author><author><name sortKey="Flasterstein, O" uniqKey="Flasterstein O">O Flasterstein</name></author><author><name sortKey="Eliyahu, H" uniqKey="Eliyahu H">H Eliyahu</name></author><author><name sortKey="Simberg, D" uniqKey="Simberg D">D Simberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Postma, Ns" uniqKey="Postma N">NS Postma</name></author><author><name sortKey="Hermsen, Cc" uniqKey="Hermsen C">CC Hermsen</name></author><author><name sortKey="Zuidema, J" uniqKey="Zuidema J">J Zuidema</name></author><author><name sortKey="Eling, Wm" uniqKey="Eling W">WM Eling</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Christensen, D" uniqKey="Christensen D">D Christensen</name></author><author><name sortKey="Korsholm, Ks" uniqKey="Korsholm K">KS Korsholm</name></author><author><name sortKey="Andersen, P" uniqKey="Andersen P">P Andersen</name></author><author><name sortKey="Agger, Em" uniqKey="Agger E">EM Agger</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mcneil, Se" uniqKey="Mcneil S">SE McNeil</name></author><author><name sortKey="Perrie, Y" uniqKey="Perrie Y">Y Perrie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Alving, Cr" uniqKey="Alving C">CR Alving</name></author><author><name sortKey="Beck, Z" uniqKey="Beck Z">Z Beck</name></author><author><name sortKey="Matyas, Gr" uniqKey="Matyas G">GR Matyas</name></author><author><name sortKey="Rao, M" uniqKey="Rao M">M Rao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kingsman, Sm" uniqKey="Kingsman S">SM Kingsman</name></author><author><name sortKey="Kingsman, Aj" uniqKey="Kingsman A">AJ Kingsman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Roldao, A" uniqKey="Roldao A">A Roldão</name></author><author><name sortKey="Mellado, Mcm" uniqKey="Mellado M">MCM Mellado</name></author><author><name sortKey="Castilho, Lr" uniqKey="Castilho L">LR Castilho</name></author><author><name sortKey="Carrondo, Mj" uniqKey="Carrondo M">MJ Carrondo</name></author><author><name sortKey="Alves, Pm" uniqKey="Alves P">PM Alves</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zeltins, A" uniqKey="Zeltins A">A Zeltins</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Grgacic, Evl" uniqKey="Grgacic E">EVL Grgacic</name></author><author><name sortKey="Anderson, Da" uniqKey="Anderson D">DA Anderson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Strable, E" uniqKey="Strable E">E Strable</name></author><author><name sortKey="Finn, Mg" uniqKey="Finn M">MG Finn</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Maurer, P" uniqKey="Maurer P">P Maurer</name></author><author><name sortKey="Jennings, Gt" uniqKey="Jennings G">GT Jennings</name></author><author><name sortKey="Willers, J" uniqKey="Willers J">J Willers</name></author><author><name sortKey="Rohner, F" uniqKey="Rohner F">F Rohner</name></author><author><name sortKey="Lindman, Y" uniqKey="Lindman Y">Y Lindman</name></author><author><name sortKey="Roubicek, K" uniqKey="Roubicek K">K Roubicek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Patel, Kg" uniqKey="Patel K">KG Patel</name></author><author><name sortKey="Swartz, Jr" uniqKey="Swartz J">JR Swartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawano, M" uniqKey="Kawano M">M Kawano</name></author><author><name sortKey="Matsui, M" uniqKey="Matsui M">M Matsui</name></author><author><name sortKey="Handa, H" uniqKey="Handa H">H Handa</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tissot, Ac" uniqKey="Tissot A">AC Tissot</name></author><author><name sortKey="Renhofa, R" uniqKey="Renhofa R">R Renhofa</name></author><author><name sortKey="Schmitz, N" uniqKey="Schmitz N">N Schmitz</name></author><author><name sortKey="Cielens, I" uniqKey="Cielens I">I Cielens</name></author><author><name sortKey="Meijerink, E" uniqKey="Meijerink E">E Meijerink</name></author><author><name sortKey="Ose, V" uniqKey="Ose V">V Ose</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gao, Y" uniqKey="Gao Y">Y Gao</name></author><author><name sortKey="Wijewardhana, C" uniqKey="Wijewardhana C">C Wijewardhana</name></author><author><name sortKey="Mann, Jfs" uniqKey="Mann J">JFS Mann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chahal, Js" uniqKey="Chahal J">JS Chahal</name></author><author><name sortKey="Khan, Of" uniqKey="Khan O">OF Khan</name></author><author><name sortKey="Cooper, Cl" uniqKey="Cooper C">CL Cooper</name></author><author><name sortKey="Mcpartlan, Js" uniqKey="Mcpartlan J">JS McPartlan</name></author><author><name sortKey="Tsosie, Jk" uniqKey="Tsosie J">JK Tsosie</name></author><author><name sortKey="Tilley, Ld" uniqKey="Tilley L">LD Tilley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bahadoran, A" uniqKey="Bahadoran A">A Bahadoran</name></author><author><name sortKey="Moeini, H" uniqKey="Moeini H">H Moeini</name></author><author><name sortKey="Bejo, Mh" uniqKey="Bejo M">MH Bejo</name></author><author><name sortKey="Hussein, Mz" uniqKey="Hussein M">MZ Hussein</name></author><author><name sortKey="Omar, Ar" uniqKey="Omar A">AR Omar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jaffer, U" uniqKey="Jaffer U">U Jaffer</name></author><author><name sortKey="Wade, Rg" uniqKey="Wade R">RG Wade</name></author><author><name sortKey="Gourlay, T" uniqKey="Gourlay T">T Gourlay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hora, Ms" uniqKey="Hora M">MS Hora</name></author><author><name sortKey="Rana, Rk" uniqKey="Rana R">RK Rana</name></author><author><name sortKey="Nunberg, Jh" uniqKey="Nunberg J">JH Nunberg</name></author><author><name sortKey="Tice, Tr" uniqKey="Tice T">TR Tice</name></author><author><name sortKey="Gilley, Rm" uniqKey="Gilley R">RM Gilley</name></author><author><name sortKey="Hudson, Me" uniqKey="Hudson M">ME Hudson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Melissen, Pm" uniqKey="Melissen P">PM Melissen</name></author><author><name sortKey="Van, Vianen W" uniqKey="Van V">Vianen W van</name></author><author><name sortKey="Bidjai, O" uniqKey="Bidjai O">O Bidjai</name></author><author><name sortKey="Van, Marion M" uniqKey="Van M">Marion M van</name></author><author><name sortKey="Bakker Woudenberg, Ia" uniqKey="Bakker Woudenberg I">IA Bakker-Woudenberg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ali, Oa" uniqKey="Ali O">OA Ali</name></author><author><name sortKey="Huebsch, N" uniqKey="Huebsch N">N Huebsch</name></author><author><name sortKey="Cao, L" uniqKey="Cao L">L Cao</name></author><author><name sortKey="Dranoff, G" uniqKey="Dranoff G">G Dranoff</name></author><author><name sortKey="Mooney, Dj" uniqKey="Mooney D">DJ Mooney</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Killion, Jj" uniqKey="Killion J">JJ Killion</name></author><author><name sortKey="Fishbeck, R" uniqKey="Fishbeck R">R Fishbeck</name></author><author><name sortKey="Bar Eli, M" uniqKey="Bar Eli M">M Bar-Eli</name></author><author><name sortKey="Chernajovsky, Y" uniqKey="Chernajovsky Y">Y Chernajovsky</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ha, Sj" uniqKey="Ha S">SJ Ha</name></author><author><name sortKey="Park, Sh" uniqKey="Park S">SH Park</name></author><author><name sortKey="Kim, Hj" uniqKey="Kim H">HJ Kim</name></author><author><name sortKey="Kim, Sc" uniqKey="Kim S">SC Kim</name></author><author><name sortKey="Kang, Hj" uniqKey="Kang H">HJ Kang</name></author><author><name sortKey="Lee, Eg" uniqKey="Lee E">EG Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kawai, T" uniqKey="Kawai T">T Kawai</name></author><author><name sortKey="Akira, S" uniqKey="Akira S">S Akira</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schenten, D" uniqKey="Schenten D">D Schenten</name></author><author><name sortKey="Medzhitov, R" uniqKey="Medzhitov R">R Medzhitov</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lynn, Gm" uniqKey="Lynn G">GM Lynn</name></author><author><name sortKey="Laga, R" uniqKey="Laga R">R Laga</name></author><author><name sortKey="Darrah, Pa" uniqKey="Darrah P">PA Darrah</name></author><author><name sortKey="Ishizuka, As" uniqKey="Ishizuka A">AS Ishizuka</name></author><author><name sortKey="Balaci, Aj" uniqKey="Balaci A">AJ Balaci</name></author><author><name sortKey="Dulcey, Ae" uniqKey="Dulcey A">AE Dulcey</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Goldinger, Sm" uniqKey="Goldinger S">SM Goldinger</name></author><author><name sortKey="Dummer, R" uniqKey="Dummer R">R Dummer</name></author><author><name sortKey="Baumgaertner, P" uniqKey="Baumgaertner P">P Baumgaertner</name></author><author><name sortKey="Mihic Probst, D" uniqKey="Mihic Probst D">D Mihic-Probst</name></author><author><name sortKey="Schwarz, K" uniqKey="Schwarz K">K Schwarz</name></author><author><name sortKey="Hammann Haenni, A" uniqKey="Hammann Haenni A">A Hammann-Haenni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dowling, Dj" uniqKey="Dowling D">DJ Dowling</name></author><author><name sortKey="Scott, Ea" uniqKey="Scott E">EA Scott</name></author><author><name sortKey="Scheid, A" uniqKey="Scheid A">A Scheid</name></author><author><name sortKey="Bergelson, I" uniqKey="Bergelson I">I Bergelson</name></author><author><name sortKey="Joshi, S" uniqKey="Joshi S">S Joshi</name></author><author><name sortKey="Pietrasanta, C" uniqKey="Pietrasanta C">C Pietrasanta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Moradi, B" uniqKey="Moradi B">B Moradi</name></author><author><name sortKey="Sankian, M" uniqKey="Sankian M">M Sankian</name></author><author><name sortKey="Amini, Y" uniqKey="Amini Y">Y Amini</name></author><author><name sortKey="Meshkat, Z" uniqKey="Meshkat Z">Z Meshkat</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xue, T" uniqKey="Xue T">T Xue</name></author><author><name sortKey="Stavropoulos, E" uniqKey="Stavropoulos E">E Stavropoulos</name></author><author><name sortKey="Yang, M" uniqKey="Yang M">M Yang</name></author><author><name sortKey="Ragno, S" uniqKey="Ragno S">S Ragno</name></author><author><name sortKey="Vordermeier, M" uniqKey="Vordermeier M">M Vordermeier</name></author><author><name sortKey="Chambers, M" uniqKey="Chambers M">M Chambers</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Romalde, Jl" uniqKey="Romalde J">JL Romalde</name></author><author><name sortKey="Luzardo Alvarez, A" uniqKey="Luzardo Alvarez A">A Luzardo-Alvárez</name></author><author><name sortKey="Ravelo, C" uniqKey="Ravelo C">C Ravelo</name></author><author><name sortKey="Toranzo, Ae" uniqKey="Toranzo A">AE Toranzo</name></author><author><name sortKey="Blanco Mendez, J" uniqKey="Blanco Mendez J">J Blanco-Méndez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wendorf, J" uniqKey="Wendorf J">J Wendorf</name></author><author><name sortKey="Singh, M" uniqKey="Singh M">M Singh</name></author><author><name sortKey="Chesko, J" uniqKey="Chesko J">J Chesko</name></author><author><name sortKey="Kazzaz, J" uniqKey="Kazzaz J">J Kazzaz</name></author><author><name sortKey="Soewanan, E" uniqKey="Soewanan E">E Soewanan</name></author><author><name sortKey="Ugozzoli, M" uniqKey="Ugozzoli M">M Ugozzoli</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stieneker, F" uniqKey="Stieneker F">F Stieneker</name></author><author><name sortKey="Kreuter, J" uniqKey="Kreuter J">J Kreuter</name></author><author><name sortKey="Lower, J" uniqKey="Lower J">J Löwer</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He, Q" uniqKey="He Q">Q He</name></author><author><name sortKey="Mitchell, Ar" uniqKey="Mitchell A">AR Mitchell</name></author><author><name sortKey="Johnson, Sl" uniqKey="Johnson S">SL Johnson</name></author><author><name sortKey="Wagner Bartak, C" uniqKey="Wagner Bartak C">C Wagner-Bartak</name></author><author><name sortKey="Morcol, T" uniqKey="Morcol T">T Morcol</name></author><author><name sortKey="Bell, Sj" uniqKey="Bell S">SJ Bell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oyewumi, Mo" uniqKey="Oyewumi M">MO Oyewumi</name></author><author><name sortKey="Kumar, A" uniqKey="Kumar A">A Kumar</name></author><author><name sortKey="Cui, Z" uniqKey="Cui Z">Z Cui</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Biabanikhankahdani, R" uniqKey="Biabanikhankahdani R">R Biabanikhankahdani</name></author><author><name sortKey="Alitheen, Nbm" uniqKey="Alitheen N">NBM Alitheen</name></author><author><name sortKey="Ho, Kl" uniqKey="Ho K">KL Ho</name></author><author><name sortKey="Tan, Ws" uniqKey="Tan W">WS Tan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Slutter, B" uniqKey="Slutter B">B Slütter</name></author><author><name sortKey="Soema, Pc" uniqKey="Soema P">PC Soema</name></author><author><name sortKey="Ding, Z" uniqKey="Ding Z">Z Ding</name></author><author><name sortKey="Verheul, R" uniqKey="Verheul R">R Verheul</name></author><author><name sortKey="Hennink, W" uniqKey="Hennink W">W Hennink</name></author><author><name sortKey="Jiskoot, W" uniqKey="Jiskoot W">W Jiskoot</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Giddam, Ak" uniqKey="Giddam A">AK Giddam</name></author><author><name sortKey="Giddam, Ak" uniqKey="Giddam A">AK Giddam</name></author><author><name sortKey="Zaman, M" uniqKey="Zaman M">M Zaman</name></author><author><name sortKey="Skwarczynski, M" uniqKey="Skwarczynski M">M Skwarczynski</name></author><author><name sortKey="Toth, I" uniqKey="Toth I">I Toth</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gluck, R" uniqKey="Gluck R">R Glück</name></author><author><name sortKey="Moser, C" uniqKey="Moser C">C Moser</name></author><author><name sortKey="Metcalfe, Ic" uniqKey="Metcalfe I">IC Metcalfe</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Morein, B" uniqKey="Morein B">B Morein</name></author><author><name sortKey="Sundquist, B" uniqKey="Sundquist B">B Sundquist</name></author><author><name sortKey="Hoglund, S" uniqKey="Hoglund S">S Höglund</name></author><author><name sortKey="Dalsgaard, K" uniqKey="Dalsgaard K">K Dalsgaard</name></author><author><name sortKey="Osterhaus, A" uniqKey="Osterhaus A">A Osterhaus</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Homhuan, A" uniqKey="Homhuan A">A Homhuan</name></author><author><name sortKey="Prakongpan, S" uniqKey="Prakongpan S">S Prakongpan</name></author><author><name sortKey="Poomvises, P" uniqKey="Poomvises P">P Poomvises</name></author><author><name sortKey="Maas, Ra" uniqKey="Maas R">RA Maas</name></author><author><name sortKey="Crommelin, Dja" uniqKey="Crommelin D">DJA Crommelin</name></author><author><name sortKey="Kersten, Gfa" uniqKey="Kersten G">GFA Kersten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Pedersen, Js" uniqKey="Pedersen J">JS Pedersen</name></author><author><name sortKey="Oliveira, Clp" uniqKey="Oliveira C">CLP Oliveira</name></author><author><name sortKey="Hubschmann, Hb" uniqKey="Hubschmann H">HB Hübschmann</name></author><author><name sortKey="Arleth, L" uniqKey="Arleth L">L Arleth</name></author><author><name sortKey="Manniche, S" uniqKey="Manniche S">S Manniche</name></author><author><name sortKey="Kirkby, N" uniqKey="Kirkby N">N Kirkby</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reid, G" uniqKey="Reid G">G Reid</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gregory, Ae" uniqKey="Gregory A">AE Gregory</name></author><author><name sortKey="Williamson, Ed" uniqKey="Williamson E">ED Williamson</name></author><author><name sortKey="Prior, Jl" uniqKey="Prior J">JL Prior</name></author><author><name sortKey="Butcher, Wa" uniqKey="Butcher W">WA Butcher</name></author><author><name sortKey="Thompson, Ij" uniqKey="Thompson I">IJ Thompson</name></author><author><name sortKey="Shaw, Am" uniqKey="Shaw A">AM Shaw</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reddy, St" uniqKey="Reddy S">ST Reddy</name></author><author><name sortKey="Rehor, A" uniqKey="Rehor A">A Rehor</name></author><author><name sortKey="Schmoekel, Hg" uniqKey="Schmoekel H">HG Schmoekel</name></author><author><name sortKey="Hubbell, Ja" uniqKey="Hubbell J">JA Hubbell</name></author><author><name sortKey="Swartz, Ma" uniqKey="Swartz M">MA Swartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sunshine, Jc" uniqKey="Sunshine J">JC Sunshine</name></author><author><name sortKey="Perica, K" uniqKey="Perica K">K Perica</name></author><author><name sortKey="Schneck, Jp" uniqKey="Schneck J">JP Schneck</name></author><author><name sortKey="Green, Jj" uniqKey="Green J">JJ Green</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yameen, B" uniqKey="Yameen B">B Yameen</name></author><author><name sortKey="Choi, W Il" uniqKey="Choi W">W Il Choi</name></author><author><name sortKey="Vilos, C" uniqKey="Vilos C">C Vilos</name></author><author><name sortKey="Swami, A" uniqKey="Swami A">A Swami</name></author><author><name sortKey="Shi, J" uniqKey="Shi J">J Shi</name></author><author><name sortKey="Farokhzad, Oc" uniqKey="Farokhzad O">OC Farokhzad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dobrovolskaia, Ma" uniqKey="Dobrovolskaia M">MA Dobrovolskaia</name></author><author><name sortKey="Aggarwal, P" uniqKey="Aggarwal P">P Aggarwal</name></author><author><name sortKey="Hall, Jb" uniqKey="Hall J">JB Hall</name></author><author><name sortKey="Mcneil, Se" uniqKey="Mcneil S">SE McNeil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zolnik, Bs" uniqKey="Zolnik B">BS Zolnik</name></author><author><name sortKey="Gonzalez Fernandez, A" uniqKey="Gonzalez Fernandez A">Á González-Fernández</name></author><author><name sortKey="Sadrieh, N" uniqKey="Sadrieh N">N Sadrieh</name></author><author><name sortKey="Dobrovolskaia, Ma" uniqKey="Dobrovolskaia M">MA Dobrovolskaia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joshi, Vb" uniqKey="Joshi V">VB Joshi</name></author><author><name sortKey="Geary, Sm" uniqKey="Geary S">SM Geary</name></author><author><name sortKey="Salem, Ak" uniqKey="Salem A">AK Salem</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Manolova, V" uniqKey="Manolova V">V Manolova</name></author><author><name sortKey="Flace, A" uniqKey="Flace A">A Flace</name></author><author><name sortKey="Bauer, M" uniqKey="Bauer M">M Bauer</name></author><author><name sortKey="Schwarz, K" uniqKey="Schwarz K">K Schwarz</name></author><author><name sortKey="Saudan, P" uniqKey="Saudan P">P Saudan</name></author><author><name sortKey="Bachmann, Mf" uniqKey="Bachmann M">MF Bachmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nishioka, Y" uniqKey="Nishioka Y">Y Nishioka</name></author><author><name sortKey="Yoshino, H" uniqKey="Yoshino H">H Yoshino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reddy, St" uniqKey="Reddy S">ST Reddy</name></author><author><name sortKey="Van, Der Vlies Aj" uniqKey="Van D">der Vlies AJ van</name></author><author><name sortKey="Simeoni, E" uniqKey="Simeoni E">E Simeoni</name></author><author><name sortKey="Angeli, V" uniqKey="Angeli V">V Angeli</name></author><author><name sortKey="Randolph, Gj" uniqKey="Randolph G">GJ Randolph</name></author><author><name sortKey="O Neil, Cp" uniqKey="O Neil C">CP O'Neil</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kostarelos, K" uniqKey="Kostarelos K">K Kostarelos</name></author><author><name sortKey="Lacerda, L" uniqKey="Lacerda L">L Lacerda</name></author><author><name sortKey="Pastorin, G" uniqKey="Pastorin G">G Pastorin</name></author><author><name sortKey="Wu, W" uniqKey="Wu W">W Wu</name></author><author><name sortKey="Wieckowski, S" uniqKey="Wieckowski S">S Wieckowski</name></author><author><name sortKey="Luangsivilay, J" uniqKey="Luangsivilay J">J Luangsivilay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Foged, C" uniqKey="Foged C">C Foged</name></author><author><name sortKey="Brodin, B" uniqKey="Brodin B">B Brodin</name></author><author><name sortKey="Frokjaer, S" uniqKey="Frokjaer S">S Frokjaer</name></author><author><name sortKey="Sundblad, A" uniqKey="Sundblad A">A Sundblad</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Thiele, L" uniqKey="Thiele L">L Thiele</name></author><author><name sortKey="Merkle, Hp" uniqKey="Merkle H">HP Merkle</name></author><author><name sortKey="Walter, E" uniqKey="Walter E">E Walter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Niikura, K" uniqKey="Niikura K">K Niikura</name></author><author><name sortKey="Matsunaga, T" uniqKey="Matsunaga T">T Matsunaga</name></author><author><name sortKey="Suzuki, T" uniqKey="Suzuki T">T Suzuki</name></author><author><name sortKey="Kobayashi, S" uniqKey="Kobayashi S">S Kobayashi</name></author><author><name sortKey="Yamaguchi, H" uniqKey="Yamaguchi H">H Yamaguchi</name></author><author><name sortKey="Orba, Y" uniqKey="Orba Y">Y Orba</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, St" uniqKey="Kim S">ST Kim</name></author><author><name sortKey="Saha, K" uniqKey="Saha K">K Saha</name></author><author><name sortKey="Kim, C" uniqKey="Kim C">C Kim</name></author><author><name sortKey="Rotello, Vm" uniqKey="Rotello V">VM Rotello</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hillaireau, H" uniqKey="Hillaireau H">H Hillaireau</name></author><author><name sortKey="Couvreur, P" uniqKey="Couvreur P">P Couvreur</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, A" uniqKey="Li A">A Li</name></author><author><name sortKey="Qin, L" uniqKey="Qin L">L Qin</name></author><author><name sortKey="Zhu, D" uniqKey="Zhu D">D Zhu</name></author><author><name sortKey="Zhu, R" uniqKey="Zhu R">R Zhu</name></author><author><name sortKey="Sun, J" uniqKey="Sun J">J Sun</name></author><author><name sortKey="Wang, S" uniqKey="Wang S">S Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu, R" uniqKey="Zhu R">R Zhu</name></author><author><name sortKey="Zhu, Y" uniqKey="Zhu Y">Y Zhu</name></author><author><name sortKey="Zhang, M" uniqKey="Zhang M">M Zhang</name></author><author><name sortKey="Xiao, Y" uniqKey="Xiao Y">Y Xiao</name></author><author><name sortKey="Du, X" uniqKey="Du X">X Du</name></author><author><name sortKey="Liu, H" uniqKey="Liu H">H Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nawwab, Al Deen Fm" uniqKey="Nawwab A">AL-Deen FM Nawwab</name></author><author><name sortKey="Selomulya, C" uniqKey="Selomulya C">C Selomulya</name></author><author><name sortKey="Kong, Yy" uniqKey="Kong Y">YY Kong</name></author><author><name sortKey="Xiang, Sd" uniqKey="Xiang S">SD Xiang</name></author><author><name sortKey="Ma, C" uniqKey="Ma C">C Ma</name></author><author><name sortKey="Coppel, Rl" uniqKey="Coppel R">RL Coppel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Toki, S" uniqKey="Toki S">S Toki</name></author><author><name sortKey="Omary, Ra" uniqKey="Omary R">RA Omary</name></author><author><name sortKey="Wilson, K" uniqKey="Wilson K">K Wilson</name></author><author><name sortKey="Gore, Jc" uniqKey="Gore J">JC Gore</name></author><author><name sortKey="Peebles, Rs" uniqKey="Peebles R">RS Peebles</name></author><author><name sortKey="Pham, W" uniqKey="Pham W">W Pham</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee, Yt" uniqKey="Lee Y">YT Lee</name></author><author><name sortKey="Ko, Ej" uniqKey="Ko E">EJ Ko</name></author><author><name sortKey="Hwang, Hs" uniqKey="Hwang H">HS Hwang</name></author><author><name sortKey="Lee, Js" uniqKey="Lee J">JS Lee</name></author><author><name sortKey="Kim, Kh" uniqKey="Kim K">KH Kim</name></author><author><name sortKey="Kwon, Ym" uniqKey="Kwon Y">YM Kwon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guo, Y" uniqKey="Guo Y">Y Guo</name></author><author><name sortKey="Wang, D" uniqKey="Wang D">D Wang</name></author><author><name sortKey="Song, Q" uniqKey="Song Q">Q Song</name></author><author><name sortKey="Wu, T" uniqKey="Wu T">T Wu</name></author><author><name sortKey="Zhuang, X" uniqKey="Zhuang X">X Zhuang</name></author><author><name sortKey="Bao, Y" uniqKey="Bao Y">Y Bao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li, M" uniqKey="Li M">M Li</name></author><author><name sortKey="Wang, B" uniqKey="Wang B">B Wang</name></author><author><name sortKey="Wu, Z" uniqKey="Wu Z">Z Wu</name></author><author><name sortKey="Shi, X" uniqKey="Shi X">X Shi</name></author><author><name sortKey="Zhang, J" uniqKey="Zhang J">J Zhang</name></author><author><name sortKey="Han, S" uniqKey="Han S">S Han</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Campbell, Df" uniqKey="Campbell D">DF Campbell</name></author><author><name sortKey="Saenz, R" uniqKey="Saenz R">R Saenz</name></author><author><name sortKey="Bharati, Is" uniqKey="Bharati I">IS Bharati</name></author><author><name sortKey="Seible, D" uniqKey="Seible D">D Seible</name></author><author><name sortKey="Zhang, L" uniqKey="Zhang L">L Zhang</name></author><author><name sortKey="Esener, S" uniqKey="Esener S">S Esener</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hernandez Gil, J" uniqKey="Hernandez Gil J">J Hernández-Gil</name></author><author><name sortKey="Cobaleda Siles, M" uniqKey="Cobaleda Siles M">M Cobaleda-Siles</name></author><author><name sortKey="Zabaleta, A" uniqKey="Zabaleta A">A Zabaleta</name></author><author><name sortKey="Salassa, L" uniqKey="Salassa L">L Salassa</name></author><author><name sortKey="Calvo, J" uniqKey="Calvo J">J Calvo</name></author><author><name sortKey="Mareque Rivas, Jc" uniqKey="Mareque Rivas J">JC Mareque-Rivas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lu, F" uniqKey="Lu F">F Lu</name></author><author><name sortKey="Mencia, A" uniqKey="Mencia A">A Mencia</name></author><author><name sortKey="Bi, L" uniqKey="Bi L">L Bi</name></author><author><name sortKey="Taylor, A" uniqKey="Taylor A">A Taylor</name></author><author><name sortKey="Yao, Y" uniqKey="Yao Y">Y Yao</name></author><author><name sortKey="Hogenesch, H" uniqKey="Hogenesch H">H HogenEsch</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sehgal, K" uniqKey="Sehgal K">K Sehgal</name></author><author><name sortKey="Ragheb, R" uniqKey="Ragheb R">R Ragheb</name></author><author><name sortKey="Fahmy, Tm" uniqKey="Fahmy T">TM Fahmy</name></author><author><name sortKey="Dhodapkar, M V" uniqKey="Dhodapkar M">M V Dhodapkar</name></author><author><name sortKey="Dhodapkar, Km" uniqKey="Dhodapkar K">KM Dhodapkar</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoang, Md" uniqKey="Hoang M">MD Hoang</name></author><author><name sortKey="Lee, Hj" uniqKey="Lee H">HJ Lee</name></author><author><name sortKey="Lee, Hj" uniqKey="Lee H">HJ Lee</name></author><author><name sortKey="Jung, Sh" uniqKey="Jung S">SH Jung</name></author><author><name sortKey="Choi, Nr" uniqKey="Choi N">NR Choi</name></author><author><name sortKey="Vo, Mc" uniqKey="Vo M">MC Vo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Mundayoor, S" uniqKey="Mundayoor S">S Mundayoor</name></author><author><name sortKey="Kumar, Ra" uniqKey="Kumar R">RA Kumar</name></author><author><name sortKey="Dhanasooraj, S" uniqKey="Dhanasooraj S">S Dhanasooraj</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amini, Y" uniqKey="Amini Y">Y Amini</name></author><author><name sortKey="Moradi, B" uniqKey="Moradi B">B Moradi</name></author><author><name sortKey="Tafaghodi, M" uniqKey="Tafaghodi M">M Tafaghodi</name></author><author><name sortKey="Meshkat, Z" uniqKey="Meshkat Z">Z Meshkat</name></author><author><name sortKey="Ghazvini, K" uniqKey="Ghazvini K">K Ghazvini</name></author><author><name sortKey="Fasihi Ramandi, M" uniqKey="Fasihi Ramandi M">M Fasihi-Ramandi</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Speth, Mt" uniqKey="Speth M">MT Speth</name></author><author><name sortKey="Repnik, U" uniqKey="Repnik U">U Repnik</name></author><author><name sortKey="Muller, E" uniqKey="Muller E">E Müller</name></author><author><name sortKey="Spanier, J" uniqKey="Spanier J">J Spanier</name></author><author><name sortKey="Kalinke, U" uniqKey="Kalinke U">U Kalinke</name></author><author><name sortKey="Corthay, A" uniqKey="Corthay A">A Corthay</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Poecheim, J" uniqKey="Poecheim J">J Poecheim</name></author><author><name sortKey="Barnier Quer, C" uniqKey="Barnier Quer C">C Barnier-Quer</name></author><author><name sortKey="Collin, N" uniqKey="Collin N">N Collin</name></author><author><name sortKey="Borchard, G" uniqKey="Borchard G">G Borchard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ballester, M" uniqKey="Ballester M">M Ballester</name></author><author><name sortKey="Nembrini, C" uniqKey="Nembrini C">C Nembrini</name></author><author><name sortKey="Dhar, N" uniqKey="Dhar N">N Dhar</name></author><author><name sortKey="De, Titta A" uniqKey="De T">Titta A de</name></author><author><name sortKey="De, Piano C" uniqKey="De P">Piano C de</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nel, Ae" uniqKey="Nel A">AE Nel</name></author><author><name sortKey="M Dler, L" uniqKey="M Dler L">L Mädler</name></author><author><name sortKey="Velegol, D" uniqKey="Velegol D">D Velegol</name></author><author><name sortKey="Xia, T" uniqKey="Xia T">T Xia</name></author><author><name sortKey="Hoek, Em V" uniqKey="Hoek E">EM V Hoek</name></author><author><name sortKey="Somasundaran, P" uniqKey="Somasundaran P">P Somasundaran</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lynch, I" uniqKey="Lynch I">I Lynch</name></author><author><name sortKey="Dawson, Ka" uniqKey="Dawson K">KA Dawson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vertegel, Aa" uniqKey="Vertegel A">AA Vertegel</name></author><author><name sortKey="Siegel, Rw" uniqKey="Siegel R">RW Siegel</name></author><author><name sortKey="Dordick, Js" uniqKey="Dordick J">JS Dordick</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Taylor, Pr" uniqKey="Taylor P">PR Taylor</name></author><author><name sortKey="Martinez Pomares, L" uniqKey="Martinez Pomares L">L Martinez-Pomares</name></author><author><name sortKey="Stacey, M" uniqKey="Stacey M">M Stacey</name></author><author><name sortKey="Lin, Hh" uniqKey="Lin H">HH Lin</name></author><author><name sortKey="Brown, Gd" uniqKey="Brown G">GD Brown</name></author><author><name sortKey="Gordon, S" uniqKey="Gordon S">S Gordon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Beduneau, A" uniqKey="Beduneau A">A Beduneau</name></author><author><name sortKey="Ma, Z" uniqKey="Ma Z">Z Ma</name></author><author><name sortKey="Grotepas, Cb" uniqKey="Grotepas C">CB Grotepas</name></author><author><name sortKey="Kabanov, A" uniqKey="Kabanov A">A Kabanov</name></author><author><name sortKey="Rabinow, Be" uniqKey="Rabinow B">BE Rabinow</name></author><author><name sortKey="Gong, N" uniqKey="Gong N">N Gong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Laroui, H" uniqKey="Laroui H">H Laroui</name></author><author><name sortKey="Viennois, E" uniqKey="Viennois E">E Viennois</name></author><author><name sortKey="Xiao, B" uniqKey="Xiao B">B Xiao</name></author><author><name sortKey="Canup, Bsb" uniqKey="Canup B">BSB Canup</name></author><author><name sortKey="Geem, D" uniqKey="Geem D">D Geem</name></author><author><name sortKey="Denning, Tl" uniqKey="Denning T">TL Denning</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Verma, A" uniqKey="Verma A">A Verma</name></author><author><name sortKey="Stellacci, F" uniqKey="Stellacci F">F Stellacci</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kolaczkowska, E" uniqKey="Kolaczkowska E">E Kolaczkowska</name></author><author><name sortKey="Kubes, P" uniqKey="Kubes P">P Kubes</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kamaly, N" uniqKey="Kamaly N">N Kamaly</name></author><author><name sortKey="Fredman, G" uniqKey="Fredman G">G Fredman</name></author><author><name sortKey="Subramanian, M" uniqKey="Subramanian M">M Subramanian</name></author><author><name sortKey="Gadde, S" uniqKey="Gadde S">S Gadde</name></author><author><name sortKey="Pesic, A" uniqKey="Pesic A">A Pesic</name></author><author><name sortKey="Cheung, L" uniqKey="Cheung L">L Cheung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chu, D" uniqKey="Chu D">D Chu</name></author><author><name sortKey="Gao, J" uniqKey="Gao J">J Gao</name></author><author><name sortKey="Wang, Z" uniqKey="Wang Z">Z Wang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Endsley, An" uniqKey="Endsley A">AN Endsley</name></author><author><name sortKey="Ho, Rjy" uniqKey="Ho R">RJY Ho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Perise Barrios, Aj" uniqKey="Perise Barrios A">AJ Perisé-Barrios</name></author><author><name sortKey="Jimenez, Jl" uniqKey="Jimenez J">JL Jiménez</name></author><author><name sortKey="Dominguez Soto, A" uniqKey="Dominguez Soto A">A Domínguez-Soto</name></author><author><name sortKey="De, La Mata Fj" uniqKey="De L">la Mata FJ de</name></author><author><name sortKey="Corbi, Al" uniqKey="Corbi A">AL Corbí</name></author><author><name sortKey="Gomez, R" uniqKey="Gomez R">R Gomez</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harding, C V" uniqKey="Harding C">C V Harding</name></author><author><name sortKey="Collins, Ds" uniqKey="Collins D">DS Collins</name></author><author><name sortKey="Slot, Jw" uniqKey="Slot J">JW Slot</name></author><author><name sortKey="Geuze, Hj" uniqKey="Geuze H">HJ Geuze</name></author><author><name sortKey="Unanue, Er" uniqKey="Unanue E">ER Unanue</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stano, A" uniqKey="Stano A">A Stano</name></author><author><name sortKey="Nembrini, C" uniqKey="Nembrini C">C Nembrini</name></author><author><name sortKey="Swartz, Ma" uniqKey="Swartz M">MA Swartz</name></author><author><name sortKey="Hubbell, Ja" uniqKey="Hubbell J">JA Hubbell</name></author><author><name sortKey="Simeoni, E" uniqKey="Simeoni E">E Simeoni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kim, Ym" uniqKey="Kim Y">YM Kim</name></author><author><name sortKey="Pan, Jyj" uniqKey="Pan J">JYJ Pan</name></author><author><name sortKey="Korbel, Ga" uniqKey="Korbel G">GA Korbel</name></author><author><name sortKey="Peperzak, V" uniqKey="Peperzak V">V Peperzak</name></author><author><name sortKey="Boes, M" uniqKey="Boes M">M Boes</name></author><author><name sortKey="Ploegh, Hl" uniqKey="Ploegh H">HL Ploegh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chackerian, B" uniqKey="Chackerian B">B Chackerian</name></author><author><name sortKey="Lowy, Dr" uniqKey="Lowy D">DR Lowy</name></author><author><name sortKey="Schiller, Jt" uniqKey="Schiller J">JT Schiller</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Friede, M" uniqKey="Friede M">M Friede</name></author><author><name sortKey="Muller, S" uniqKey="Muller S">S Muller</name></author><author><name sortKey="Briand, Jp" uniqKey="Briand J">JP Briand</name></author><author><name sortKey="Van, Regenmortel Mh" uniqKey="Van R">Regenmortel MH Van</name></author><author><name sortKey="Schuber, F" uniqKey="Schuber F">F Schuber</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bershteyn, A" uniqKey="Bershteyn A">A Bershteyn</name></author><author><name sortKey="Hanson, Mc" uniqKey="Hanson M">MC Hanson</name></author><author><name sortKey="Crespo, Mp" uniqKey="Crespo M">MP Crespo</name></author><author><name sortKey="Moon, Jj" uniqKey="Moon J">JJ Moon</name></author><author><name sortKey="Li, A V" uniqKey="Li A">A V Li</name></author><author><name sortKey="Suh, H" uniqKey="Suh H">H Suh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Temchura, Vv" uniqKey="Temchura V">VV Temchura</name></author><author><name sortKey="Kozlova, D" uniqKey="Kozlova D">D Kozlova</name></author><author><name sortKey="Sokolova, V" uniqKey="Sokolova V">V Sokolova</name></author><author><name sortKey="Uberla, K" uniqKey="Uberla K">K Uberla</name></author><author><name sortKey="Epple, M" uniqKey="Epple M">M Epple</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Joffre, Op" uniqKey="Joffre O">OP Joffre</name></author><author><name sortKey="Segura, E" uniqKey="Segura E">E Segura</name></author><author><name sortKey="Savina, A" uniqKey="Savina A">A Savina</name></author><author><name sortKey="Amigorena, S" uniqKey="Amigorena S">S Amigorena</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brode, S" uniqKey="Brode S">S Brode</name></author><author><name sortKey="Macary, Pa" uniqKey="Macary P">PA Macary</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Amigorena, S" uniqKey="Amigorena S">S Amigorena</name></author><author><name sortKey="Savina, A" uniqKey="Savina A">A Savina</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kovacsovics Bankowski, M" uniqKey="Kovacsovics Bankowski M">M Kovacsovics-Bankowski</name></author><author><name sortKey="Clark, K" uniqKey="Clark K">K Clark</name></author><author><name sortKey="Benacerraf, B" uniqKey="Benacerraf B">B Benacerraf</name></author><author><name sortKey="Rock, Kl" uniqKey="Rock K">KL Rock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kovacsovics Bankowski, M" uniqKey="Kovacsovics Bankowski M">M Kovacsovics-Bankowski</name></author><author><name sortKey="Rock, Kl" uniqKey="Rock K">KL Rock</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Reis, E Sousa C" uniqKey="Reis E">e Sousa C Reis</name></author><author><name sortKey="Germain, Rn" uniqKey="Germain R">RN Germain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Harding, C V" uniqKey="Harding C">C V Harding</name></author><author><name sortKey="Song, R" uniqKey="Song R">R Song</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jain, S" uniqKey="Jain S">S Jain</name></author><author><name sortKey="Yap, Wt" uniqKey="Yap W">WT Yap</name></author><author><name sortKey="Irvine, Dj" uniqKey="Irvine D">DJ Irvine</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hamdy, S" uniqKey="Hamdy S">S Hamdy</name></author><author><name sortKey="Elamanchili, P" uniqKey="Elamanchili P">P Elamanchili</name></author><author><name sortKey="Alshamsan, A" uniqKey="Alshamsan A">A Alshamsan</name></author><author><name sortKey="Molavi, O" uniqKey="Molavi O">O Molavi</name></author><author><name sortKey="Satou, T" uniqKey="Satou T">T Satou</name></author><author><name sortKey="Samuel, J" uniqKey="Samuel J">J Samuel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanaka, Y" uniqKey="Tanaka Y">Y Tanaka</name></author><author><name sortKey="Taneichi, M" uniqKey="Taneichi M">M Taneichi</name></author><author><name sortKey="Kasai, M" uniqKey="Kasai M">M Kasai</name></author><author><name sortKey="Kakiuchi, T" uniqKey="Kakiuchi T">T Kakiuchi</name></author><author><name sortKey="Uchida, T" uniqKey="Uchida T">T Uchida</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Brandtzaeg, P" uniqKey="Brandtzaeg P">P Brandtzaeg</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Macho, Fernandez E" uniqKey="Macho F">Fernandez E Macho</name></author><author><name sortKey="Chang, J" uniqKey="Chang J">J Chang</name></author><author><name sortKey="Fontaine, J" uniqKey="Fontaine J">J Fontaine</name></author><author><name sortKey="Bialecki, E" uniqKey="Bialecki E">E Bialecki</name></author><author><name sortKey="Rodriguez, F" uniqKey="Rodriguez F">F Rodriguez</name></author><author><name sortKey="Werkmeister, E" uniqKey="Werkmeister E">E Werkmeister</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van, Der Vlies Aj" uniqKey="Van D">der Vlies AJ van</name></author><author><name sortKey="O Neil, Cp" uniqKey="O Neil C">CP O'Neil</name></author><author><name sortKey="Hasegawa, U" uniqKey="Hasegawa U">U Hasegawa</name></author><author><name sortKey="Hammond, N" uniqKey="Hammond N">N Hammond</name></author><author><name sortKey="Hubbell, Ja" uniqKey="Hubbell J">JA Hubbell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hirosue, S" uniqKey="Hirosue S">S Hirosue</name></author><author><name sortKey="Kourtis, Ic" uniqKey="Kourtis I">IC Kourtis</name></author><author><name sortKey="Van, Der Vlies Aj" uniqKey="Van D">der Vlies AJ van</name></author><author><name sortKey="Hubbell, Ja" uniqKey="Hubbell J">JA Hubbell</name></author><author><name sortKey="Swartz, Ma" uniqKey="Swartz M">MA Swartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Nembrini, C" uniqKey="Nembrini C">C Nembrini</name></author><author><name sortKey="Stano, A" uniqKey="Stano A">A Stano</name></author><author><name sortKey="Dane, Ky" uniqKey="Dane K">KY Dane</name></author><author><name sortKey="Ballester, M" uniqKey="Ballester M">M Ballester</name></author><author><name sortKey="Van, Der Vlies Aj" uniqKey="Van D">der Vlies AJ van</name></author><author><name sortKey="Marsland, Bj" uniqKey="Marsland B">BJ Marsland</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Swartz, Ma" uniqKey="Swartz M">MA Swartz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cubas, R" uniqKey="Cubas R">R Cubas</name></author><author><name sortKey="Zhang, S" uniqKey="Zhang S">S Zhang</name></author><author><name sortKey="Kwon, S" uniqKey="Kwon S">S Kwon</name></author><author><name sortKey="Sevick Muraca, Em" uniqKey="Sevick Muraca E">EM Sevick-Muraca</name></author><author><name sortKey="Li, M" uniqKey="Li M">M Li</name></author><author><name sortKey="Chen, C" uniqKey="Chen C">C Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Dane, Ky" uniqKey="Dane K">KY Dane</name></author><author><name sortKey="Nembrini, C" uniqKey="Nembrini C">C Nembrini</name></author><author><name sortKey="Tomei, Aa" uniqKey="Tomei A">AA Tomei</name></author><author><name sortKey="Eby, Jk" uniqKey="Eby J">JK Eby</name></author><author><name sortKey="O Neil, Cp" uniqKey="O Neil C">CP O'Neil</name></author><author><name sortKey="Velluto, D" uniqKey="Velluto D">D Velluto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Allen, Tm" uniqKey="Allen T">TM Allen</name></author><author><name sortKey="Hansen, Cb" uniqKey="Hansen C">CB Hansen</name></author><author><name sortKey="Guo, Ls" uniqKey="Guo L">LS Guo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vetro, M" uniqKey="Vetro M">M Vetro</name></author><author><name sortKey="Safari, D" uniqKey="Safari D">D Safari</name></author><author><name sortKey="Fallarini, S" uniqKey="Fallarini S">S Fallarini</name></author><author><name sortKey="Salsabila, K" uniqKey="Salsabila K">K Salsabila</name></author><author><name sortKey="Lahmann, M" uniqKey="Lahmann M">M Lahmann</name></author><author><name sortKey="Penades, S" uniqKey="Penades S">S Penadés</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Margaroni, M" uniqKey="Margaroni M">M Margaroni</name></author><author><name sortKey="Agallou, M" uniqKey="Agallou M">M Agallou</name></author><author><name sortKey="Athanasiou, E" uniqKey="Athanasiou E">E Athanasiou</name></author><author><name sortKey="Kammona, O" uniqKey="Kammona O">O Kammona</name></author><author><name sortKey="Kiparissides, C" uniqKey="Kiparissides C">C Kiparissides</name></author><author><name sortKey="Gaitanaki, C" uniqKey="Gaitanaki C">C Gaitanaki</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Qi, M" uniqKey="Qi M">M Qi</name></author><author><name sortKey="Zhang, Xe" uniqKey="Zhang X">XE Zhang</name></author><author><name sortKey="Sun, X" uniqKey="Sun X">X Sun</name></author><author><name sortKey="Zhang, X" uniqKey="Zhang X">X Zhang</name></author><author><name sortKey="Yao, Y" uniqKey="Yao Y">Y Yao</name></author><author><name sortKey="Liu, S" uniqKey="Liu S">S Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sawaengsak, C" uniqKey="Sawaengsak C">C Sawaengsak</name></author><author><name sortKey="Mori, Y" uniqKey="Mori Y">Y Mori</name></author><author><name sortKey="Yamanishi, K" uniqKey="Yamanishi K">K Yamanishi</name></author><author><name sortKey="Mitrevej, A" uniqKey="Mitrevej A">A Mitrevej</name></author><author><name sortKey="Sinchaipanid, N" uniqKey="Sinchaipanid N">N Sinchaipanid</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Figueiredo, L" uniqKey="Figueiredo L">L Figueiredo</name></author><author><name sortKey="Cadete, A" uniqKey="Cadete A">A Cadete</name></author><author><name sortKey="Goncalves, L" uniqKey="Goncalves L">L Gonçalves</name></author><author><name sortKey="Corvo, M" uniqKey="Corvo M">M Corvo</name></author><author><name sortKey="Almeida, Aj" uniqKey="Almeida A">AJ Almeida</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Khatri, K" uniqKey="Khatri K">K Khatri</name></author><author><name sortKey="Goyal, Ak" uniqKey="Goyal A">AK Goyal</name></author><author><name sortKey="Gupta, Pn" uniqKey="Gupta P">PN Gupta</name></author><author><name sortKey="Mishra, N" uniqKey="Mishra N">N Mishra</name></author><author><name sortKey="Vyas, Sp" uniqKey="Vyas S">SP Vyas</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ai, W" uniqKey="Ai W">W Ai</name></author><author><name sortKey="Yue, Y" uniqKey="Yue Y">Y Yue</name></author><author><name sortKey="Xiong, S" uniqKey="Xiong S">S Xiong</name></author><author><name sortKey="Xu, W" uniqKey="Xu W">W Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Meerak, J" uniqKey="Meerak J">J Meerak</name></author><author><name sortKey="Wanichwecharungruang, Sp" uniqKey="Wanichwecharungruang S">SP Wanichwecharungruang</name></author><author><name sortKey="Palaga, T" uniqKey="Palaga T">T Palaga</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="review-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30337923</article-id><article-id pub-id-type="pmc">6180194</article-id><article-id pub-id-type="doi">10.3389/fimmu.2018.02224</article-id><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Nanoparticle Vaccines Against Infectious Diseases</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pati</surname><given-names>Rashmirekha</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shevtsov</surname><given-names>Maxim</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/313340/overview"></uri></contrib><contrib contrib-type="author"><name><surname>Sonawane</surname><given-names>Avinash</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/547997/overview"></uri></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>School of Biotechnology, KIIT University</institution>,<addr-line>Bhubaneswar</addr-line>,<country>India</country></aff><aff id="aff2"><sup>2</sup><institution>Institute of Cytology of the Russian Academy of Sciences (RAS)</institution>,<addr-line>St. Petersburg</addr-line>,<country>Russia</country></aff><aff id="aff3"><sup>3</sup><institution>Klinikum Rechts der Isar, Technical University of Munich</institution>,<addr-line>Munich</addr-line>,<country>Germany</country></aff><aff id="aff4"><sup>4</sup><institution>First Pavlov State Medical University of St.Petersburg</institution>,<addr-line>St. Petersburg</addr-line>,<country>Russia</country></aff><aff id="aff5"><sup>5</sup><institution>Discipline of Biosciences and Biomedical Engineering, Indian Institute of Technology Indore</institution>,<addr-line>Indore</addr-line>,<country>India</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Nahid Ali, Indian Institute of Chemical Biology, India</p></fn><fn fn-type="edited-by"><p>Reviewed by: Randy A. Albrecht, Icahn School of Medicine at Mount Sinai, United States; Michael Schotsaert, Icahn School of Medicine at Mount Sinai, United States; Katie Louise Flanagan, RMIT University, Australia</p></fn><corresp id="c001">*Correspondence: Avinash Sonawane <email>asonawane@iiti.ac.in</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>04</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>2224</elocation-id><history><date date-type="received"><day>13</day><month>4</month><year>2018</year></date><date date-type="accepted"><day>07</day><month>9</month><year>2018</year></date></history><permissions><copyright-statement>Copyright © 2018 Pati, Shevtsov and Sonawane.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Pati, Shevtsov and Sonawane</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Due to emergence of new variants of pathogenic micro-organisms the treatment and immunization of infectious diseases have become a great challenge in the past few years. In the context of vaccine development remarkable efforts have been made to develop new vaccines and also to improve the efficacy of existing vaccines against specific diseases. To date, some vaccines are developed from protein subunits or killed pathogens, whilst several vaccines are based on live-attenuated organisms, which carry the risk of regaining their pathogenicity under certain immunocompromised conditions. To avoid this, the development of risk-free effective vaccines in conjunction with adequate delivery systems are considered as an imperative need to obtain desired humoral and cell-mediated immunity against infectious diseases. In the last several years, the use of nanoparticle-based vaccines has received a great attention to improve vaccine efficacy, immunization strategies, and targeted delivery to achieve desired immune responses at the cellular level. To improve vaccine efficacy, these nanocarriers should protect the antigens from premature proteolytic degradation, facilitate antigen uptake and processing by antigen presenting cells, control release, and should be safe for human use. Nanocarriers composed of lipids, proteins, metals or polymers have already been used to attain some of these attributes. In this context, several physico-chemical properties of nanoparticles play an important role in the determination of vaccine efficacy. This review article focuses on the applications of nanocarrier-based vaccine formulations and the strategies used for the functionalization of nanoparticles to accomplish efficient delivery of vaccines in order to induce desired host immunity against infectious diseases.</p></abstract><kwd-group><kwd>nanoparticles</kwd><kwd>vaccine development</kwd><kwd>human diseases</kwd><kwd>targeted vaccine delivery</kwd><kwd>antigens</kwd></kwd-group><funding-group><award-group><funding-source id="cn001">Department of Scientific and Industrial Research, Ministry of Science and Technology<named-content content-type="fundref-id">10.13039/501100001408</named-content></funding-source><award-id rid="cn001">SR/NM/NS-1159/2016</award-id></award-group><award-group><funding-source id="cn002">Alexander von Humboldt-Stiftung<named-content content-type="fundref-id">10.13039/100005156</named-content></funding-source></award-group></funding-group><counts><fig-count count="2"></fig-count><table-count count="1"></table-count><equation-count count="0"></equation-count><ref-count count="228"></ref-count><page-count count="16"></page-count><word-count count="14090"></word-count></counts></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>In twenty-first Century, infectious diseases have emerged as a serious threat to the health of millions of people across the globe (<xref rid="B1" ref-type="bibr">1</xref>). According to the World Health Organization (WHO) report for 2016, ~3.2 million deaths have occurred due to lower respiratory infections and 1.4 million from tuberculosis alone worldwide (<xref rid="B2" ref-type="bibr">2</xref>). Over the past few decades, many new infectious diseases have emerged and few old diseases re-emerged, which were once considered to be no longer a threat to the human being (<xref rid="B3" ref-type="bibr">3</xref>–<xref rid="B5" ref-type="bibr">5</xref>). Collectively, these diseases account for millions of deaths that cause enormous impact on the global socio-economical and health-care sectors. The major challenges to combat such diseases are that for many of them, there are no effective drugs available. One of the plausible approaches could be based on the application of nanocarrier based vaccination (<xref rid="B6" ref-type="bibr">6</xref>). However, there are still no effective vaccines available against some of the most prevalent diseases including immune deficiency syndrome (AIDS) and tuberculosis. This underlines an urgent need for the development of desired vaccines against these diseases. Some of the important aspects of any optimal vaccine includes (i) safety, (ii) stability, and (iii) the ability to elicit durable and adequate immune response with a minimum number of doses (<xref rid="B7" ref-type="bibr">7</xref>–<xref rid="B9" ref-type="bibr">9</xref>). Presently, different generation vaccines such as attenuated or killed whole organisms (<italic>first generation</italic>), subunit (<italic>second generation</italic>) and RNA or DNA vaccines (<italic>third generation</italic>) are used to elicit protective immunity against diseases (<xref rid="B10" ref-type="bibr">10</xref>–<xref rid="B12" ref-type="bibr">12</xref>). Despite several advantages of RNA or DNA vaccines such as minimal risk of infection, ability to elicit immune response against specific pathogen and cost effective (<xref rid="B13" ref-type="bibr">13</xref>); there are a number of challenges associated with the efficient delivery of these vaccine molecules to the target sites and the requirement of the prime-boost vaccination regimens with other immunogenic agents. These includes premature degradation of molecules and the inability to translate into a functional immunogen (<xref rid="B14" ref-type="bibr">14</xref>). Similarly, protein based vaccines are used successfully against several infectious diseases such as <italic>Haemophilus influenza</italic> type b, diphtheria, tetanus, acellular pertusis, meningococcus and pneumococcus (<xref rid="B15" ref-type="bibr">15</xref>), however they require an adjuvant to potentiate their immunogenicity, and also encounter early degradation after exposure to hostile milieu. Introduced recombinant protein-based vaccines (e.g., recombinant hemagglutinin vaccine for influenza) further enhance the immunity toward infection indicating the applicability of the recombinant technology for the vaccine production (<xref rid="B16" ref-type="bibr">16</xref>). To overcome these hurdles, an efficient vaccine delivery system is required which not only delivers the vaccine molecules to the target site to evoke enduring immune responses but also has minimal side effects and requires less doses. Moreover, there is an increasing need to develop new generation composite vaccine molecules that will act as immunogen as well as an adjuvant. Nanotechnology based formulations offer numerous advantages for the development of new generation vaccines. Nanocarrier based delivery system can protect the vaccines from premature degradation, improve stability, has good adjuvant properties, and also assists in targeted delivery of an immunogen to the antigen presenting cells (APCs). There are several mechanisms by which vaccines can be delivered to the specific sites using nanocarriers. Vaccine antigens can be encapsulated within the nanocarriers or decorated on their surface (Figure <xref ref-type="fig" rid="F1">1</xref>). Encapsulation within the nanoparticles (NPs) can protect the antigen from premature protease degradation and elicit sustainable release, whereas the surface adsorption facilitates their interaction with cognate surface receptors such as toll like receptors (TLRs) of APCs (<xref rid="B17" ref-type="bibr">17</xref>). Nanocarrier based delivery systems provide a suitable route of administration of vaccine molecules and enhance cellular uptake thereby resulting in robust innate, humoral, cellular as well as mucosal immune responses when compared with unconjugated antigens. This review mainly focuses on the potential use of nano delivery systems as novel vaccine strategies for the induction of innate as well as adaptive immune responses against infectious diseases.</p><fig id="F1" position="float"><label>Figure 1</label><caption><p>Schematic representation of the nanocarriers. Antigen can be conjugated to the nanoparticles surface or incapsulated into core of the particles. Decoration of the nanoparticles surface with targeting molecules (e.g., antibodies, Fab-fragments, peptides, etc) could further increase the delivery of particles into the antigen presenting cells (APCs) to induce innate and adaptive immune responses.</p></caption><graphic xlink:href="fimmu-09-02224-g0001"></graphic></fig></sec><sec id="s2"><title>Key cellular components of the immune system</title><p>The immune system is composed of a collection of mobile cells that traffic throughout the body as well as reside at the site of entry (i.e., skin, respiratory, gastrointestinal, and genital tracts) in search of invading pathogens. These cells belong to two major types of innate and adaptive immune system. The innate immune cells like macrophages and neutrophils rapidly respond to the pathogens by recognizing pathogen surface moieties, phagocytosis, and the elimination of pathogens through activation of different antibacterial effector functions. Similarly, two major components of the adaptive immunity i.e., T and B-cells are important for the generation of cell mediated and humoral immune responses, respectively. T cells including CD4<sup>+</sup> helper T cells secrete different cytokines to modulate the functions of B cells, whereas CD8<sup>+</sup> T cells recognize and destroy virally infected cells. Antibodies produced by the B cells can further neutralize the invading microbes or clear infected cell or opsonized pathogens through cell-mediated systems. APCs, in particular dendritic cells (DCs) and macrophages, migrate through the body to sample, process and present the antigens to T-cells to activate cellular immune responses. These cells express various surface receptors to recognize cognate ligands and danger signals to trigger activation of different signaling pathways that eventually lead to the activation of T-cells (<xref rid="B18" ref-type="bibr">18</xref>). After sampling the antigens, DCs migrate from the peripheral tissues into the draining lymph nodes to activate naive T-cells (<xref rid="B19" ref-type="bibr">19</xref>), whereas macrophages after ingestion of antigens increase their lysosomal degradative machinery to enhance the antigen presentation to activate helper T cells.</p></sec><sec id="s3"><title>Types of nano-immuno activators</title><p>Some NPs are themselves able to stimulate different immune cells to boost the host immunity. The size, shape and surface chemistry of NPs (described below in more detail) are important factors that determine their potential to activate immune responses. In general, NPs are able to stimulate immune reactions by increasing the synthesis of defense genes and inflammatory reactions (<xref rid="B20" ref-type="bibr">20</xref>). Various types of NPs like gold, carbon, dendrimers, polymers and liposomes have the capability to induce cytokine and antibody responses (<xref rid="B21" ref-type="bibr">21</xref>–<xref rid="B26" ref-type="bibr">26</xref>). This was observed in the case of administration of empty PEGylated liposomes, which were able to elicit IgM response in an <italic>in-vivo</italic> model. (<xref rid="B27" ref-type="bibr">27</xref>, <xref rid="B28" ref-type="bibr">28</xref>). Besides their potential to deliver various immune stimulators to the specific sites as well as into the deep tissues where vaccine molecules alone may not able to reach, these NPs have also been exploited as adjuvants to augment immunogenicity of vaccine candidates. Nano-immuno stimulators are the nano scale (20–100 nm) vaccine particles that can improve the vaccine efficacy <italic>in vivo</italic> better than bulk molecules (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B29" ref-type="bibr">29</xref>). Some of the known nano-immuno stimulators that have been used for this specific purpose are inorganic NPs (iron and silica) (<xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B31" ref-type="bibr">31</xref>), polymeric NPs (chitosan, PLGA, PVPONAlk, γ-PGA) (<xref rid="B32" ref-type="bibr">32</xref>–<xref rid="B37" ref-type="bibr">37</xref>), liposomes (cholesterol and lipids) (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B38" ref-type="bibr">38</xref>) and virus like particles (VLPs) (<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>). Different types of NPs used to deliver antigens to give protection against different diseases have been listed in Table <xref rid="T1" ref-type="table">1</xref>.</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>List of antigens delivered by using different nanocarriers for the treatment of different diseases.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><bold>Antigen</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Nanocarrier used</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>Disease</bold></th><th valign="top" align="left" rowspan="1" colspan="1"><bold>References</bold></th></tr></thead><tbody><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>AGAINST BACTERIAL INFECTION</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antigenic protein</td><td valign="top" align="left" rowspan="1" colspan="1">Poly(D,L-lactic-co-glycolic acid) nanospheres</td><td valign="top" align="left" rowspan="1" colspan="1">Anthrax</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">41</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">DNA encoding T cell epitopes of Esat-6 and FL</td><td valign="top" align="left" rowspan="1" colspan="1">Chitosan Nanoparticle</td><td valign="top" align="left" rowspan="1" colspan="1">Tuberculosis</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B42" ref-type="bibr">42</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mycobacterium lipids</td><td valign="top" align="left" rowspan="1" colspan="1">Chitosan Nanoparticle</td><td valign="top" align="left" rowspan="1" colspan="1">Tuberculosis</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B43" ref-type="bibr">43</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Polysaccharides</td><td valign="top" align="left" rowspan="1" colspan="1">Liposomes</td><td valign="top" align="left" rowspan="1" colspan="1">Pneumonia</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B44" ref-type="bibr">44</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Bacterial toxic and parasitic protein</td><td valign="top" align="left" rowspan="1" colspan="1">Liposomes</td><td valign="top" align="left" rowspan="1" colspan="1">Cholera and Malaria</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">45</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fusion protein</td><td valign="top" align="left" rowspan="1" colspan="1">Liposomes</td><td valign="top" align="left" rowspan="1" colspan="1"><italic>Helicobacter pylori</italic> infection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B46" ref-type="bibr">46</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antigenic protein</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoemulsion</td><td valign="top" align="left" rowspan="1" colspan="1">Cystic fibrosis</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B47" ref-type="bibr">47</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antigenic protein</td><td valign="top" align="left" rowspan="1" colspan="1">Nanoemulsion</td><td valign="top" align="left" rowspan="1" colspan="1">Anthrax</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B48" ref-type="bibr">48</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mycobacterium fusion protein</td><td valign="top" align="left" rowspan="1" colspan="1">Liposome</td><td valign="top" align="left" rowspan="1" colspan="1">Tuberculosis</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B49" ref-type="bibr">49</xref>)</td></tr><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>AGAINST VIRAL INFECTION</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Antigenic protein</td><td valign="top" align="left" rowspan="1" colspan="1">Chitosan Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis B</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B33" ref-type="bibr">33</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Viral protein</td><td valign="top" align="left" rowspan="1" colspan="1">Gold Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Foot and mouth disease</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B50" ref-type="bibr">50</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Membrane protein</td><td valign="top" align="left" rowspan="1" colspan="1">Gold Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B51" ref-type="bibr">51</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Viral plasmid DNA</td><td valign="top" align="left" rowspan="1" colspan="1">Gold Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">HIV</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B52" ref-type="bibr">52</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tetanus toxoid</td><td valign="top" align="left" rowspan="1" colspan="1">Poly(D,L-lactic-co-glycolic acid) nanospheres</td><td valign="top" align="left" rowspan="1" colspan="1">Tetanus</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B53" ref-type="bibr">53</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis B surface antigen</td><td valign="top" align="left" rowspan="1" colspan="1">Poly(D,L-lactic-co-glycolic acid) nanospheres</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis B</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B54" ref-type="bibr">54</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis B surface antigen</td><td valign="top" align="left" rowspan="1" colspan="1">Alginate coated chitosan Nanoparticle</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis B</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B55" ref-type="bibr">55</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Live virus vaccine</td><td valign="top" align="left" rowspan="1" colspan="1">Chitosan Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Newcastle disease</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B56" ref-type="bibr">56</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Capsid protein</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Norwalk virus infection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B57" ref-type="bibr">57</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Capsid protein</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Norwalk virus infection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B58" ref-type="bibr">58</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Influenza virus structural protein</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Influenza</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B59" ref-type="bibr">59</xref>, <xref rid="B60" ref-type="bibr">60</xref>, <xref rid="B61" ref-type="bibr">61</xref>, <xref rid="B62" ref-type="bibr">62</xref>, <xref rid="B63" ref-type="bibr">63</xref>, <xref rid="B64" ref-type="bibr">64</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nucleocapsid protein</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Hepatitis</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B65" ref-type="bibr">65</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fusion protein</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Human papilloma virus</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>, <xref rid="B66" ref-type="bibr">66</xref>, <xref rid="B67" ref-type="bibr">67</xref>, <xref rid="B68" ref-type="bibr">68</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Multiple proteins</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Rotavirus</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B69" ref-type="bibr">69</xref>, <xref rid="B70" ref-type="bibr">70</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Virus proteins</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">Blue tongue virus</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B71" ref-type="bibr">71</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Enveloped single protein</td><td valign="top" align="left" rowspan="1" colspan="1">VLPs</td><td valign="top" align="left" rowspan="1" colspan="1">HIV</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B72" ref-type="bibr">72</xref>, <xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>, <xref rid="B75" ref-type="bibr">75</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Viral protein</td><td valign="top" align="left" rowspan="1" colspan="1">Polypeptide Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Corona virus for Severe acute respiratory syndrome (SARS)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B76" ref-type="bibr">76</xref>)</td></tr><tr><td valign="top" align="left" colspan="4" style="background-color:#bbbdc0" rowspan="1"><bold>AGAINST PARASITIC INFECTION</bold></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Merozoite surface protein</td><td valign="top" align="left" rowspan="1" colspan="1">Iron oxide Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Malaria</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Epitope of <italic>Plasmodium berghei</italic> circumsporozoite protein.</td><td valign="top" align="left" rowspan="1" colspan="1">Polypeptide Nanoparticles</td><td valign="top" align="left" rowspan="1" colspan="1">Rhodent mamarial parasitic infection</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B77" ref-type="bibr">77</xref>)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Surface protein from <italic>Eimeria falciformis</italic> sporozoites</td><td valign="top" align="left" rowspan="1" colspan="1">ISCOMs</td><td valign="top" align="left" rowspan="1" colspan="1">Diarrhea</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B78" ref-type="bibr">78</xref>)</td></tr></tbody></table></table-wrap><sec><title>Inorganic NPs</title><p>Some biocompatible inorganic NPs such as gold, carbon and silica have been exploited in the vaccine delivery studies (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B79" ref-type="bibr">79</xref>–<xref rid="B81" ref-type="bibr">81</xref>). These NPs can be synthesized in various shapes, size and surface modified forms. Some of the viral antigens were successfully delivered using inorganic NPs as carriers. This caused increase in antigen stability by protecting them from premature degradation by proteolytic enzymes. Delivery of viral and bacterial antigens using gold NPs was also found to induce quite robust host immune responses against influenza, immunodeficiency virus, foot and mouth, and tuberculosis diseases in mice (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B82" ref-type="bibr">82</xref>, <xref rid="B83" ref-type="bibr">83</xref>). Encapsulation of plasmid DNA that encode mycobacterial hsp65 antigen in gold NPs exhibited significant reduction in the <italic>Mycobacterium tuberculosis</italic>, causative agent of human tuberculosis, burden in infected mice (<xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B82" ref-type="bibr">82</xref>). Few studies have used hollow mesosporous silica, nanotube and spherical forms of carbon NPs as adjuvants to improve the immunogenicity and delivery of protein and peptide antigens against viral infections (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B83" ref-type="bibr">83</xref>, <xref rid="B84" ref-type="bibr">84</xref>). Silica based NPs contain abundant silanol groups that can be utilized to introduce specific functional groups on their surface to gain access for vaccine molecules into target cells (<xref rid="B84" ref-type="bibr">84</xref>–<xref rid="B86" ref-type="bibr">86</xref>). The major advantages of inorganic NPs include low production cost, reproducibility and safety in application.</p><sec><title>Polymeric NPs</title><p>In recent years, polymeric NPs have received great attention for their applications in the delivery of a number of vaccines. This is primarily due to their ease in preparation, biodegradability, biocompatibility, reduced cytotoxicity, and the possibility to fine-tune surface properties as needed (<xref rid="B87" ref-type="bibr">87</xref>). Moreover, it is relatively easy to control the rate of vaccine release by altering the composition or ratio of co-polymers during the NP synthesis process (<xref rid="B87" ref-type="bibr">87</xref>). The most commonly used polymeric NPs for vaccine delivery are poly (lactic-<italic>co</italic>-glycolic acid; PLGA) or poly (lactic acid; PLA). PLGA NPs have already been tried in the delivery of a broad range of antigens, including hydrophobic antigens (<xref rid="B34" ref-type="bibr">34</xref>, <xref rid="B35" ref-type="bibr">35</xref>), hepatitis-B virus antigens (<xref rid="B54" ref-type="bibr">54</xref>), <italic>Bacillus anthracis</italic> (<xref rid="B41" ref-type="bibr">41</xref>), tetanus toxoid (<xref rid="B35" ref-type="bibr">35</xref>), and ovalbumin (<xref rid="B88" ref-type="bibr">88</xref>). The use of PLGA conjugated antigens exhibited strong immuno-stimulatory property by inducing cytokine and nitric oxide production against mycobacteria infection (<xref rid="B89" ref-type="bibr">89</xref>). In addition to synthetic polymers, some natural biopolymers such as alginate, pullans, inulins, and chitosan have been used as adjuvants (<xref rid="B90" ref-type="bibr">90</xref>–<xref rid="B93" ref-type="bibr">93</xref>). Inulin, a known activator of the complement cascade (<xref rid="B94" ref-type="bibr">94</xref>), conferred better protection against hepatitis B and influenza viruses (<xref rid="B92" ref-type="bibr">92</xref>, <xref rid="B93" ref-type="bibr">93</xref>). Similarly, chitosan NPs were demonstrated as nanocarrier molecules for HBV antigens (<xref rid="B55" ref-type="bibr">55</xref>), DNA vaccine (<xref rid="B56" ref-type="bibr">56</xref>), and Newcastle disease vaccine (<xref rid="B42" ref-type="bibr">42</xref>). The delivery of PLGA and chitosan NP conjugated vaccine molecules enhanced the immune responses at the mucosal site (<xref rid="B95" ref-type="bibr">95</xref>, <xref rid="B96" ref-type="bibr">96</xref>). Our recent study also showed that delivery of <italic>M. tuberculosis</italic> lipids using biocompatible chitosan NPs was able to induce significant humoral as well as cellular immune responses when compared to lipids alone in mice (<xref rid="B43" ref-type="bibr">43</xref>). We also found that intraperitoneal administration of these conjugates showed better activation of splenic T-cells. Another study by de Titta et al. has shown that intradermal administration of CpG conjugated polymeric NPs increased dendritic cell activation by several fold, exhibited comparable vaccine efficacy at ~400 times lower dose, and also caused enduring cellular immunity in comparison to free CpG (<xref rid="B97" ref-type="bibr">97</xref>). These desired properties along with already known reduced toxicity and biocompatibility under both <italic>in vitro</italic> and <italic>in vivo</italic> conditions make polymeric NPs plausible candidates for further preclinical pharmacokinetics and therapeutic applications (<xref rid="B98" ref-type="bibr">98</xref>).</p></sec><sec><title>Liposomes</title><p>In addition to polymeric NPs, liposomes are the second most widely explored vaccine and drug delivery vehicle in the nanomedicine field. The synthesis of liposomes is a spontaneous process, where hydration of lipids enables the lipid bilayer formation around an aqueous core (<xref rid="B99" ref-type="bibr">99</xref>). So far, different types of liposomes, including unilamellar or multilamellar vesicles composed of biodegradable phospholipids (e.g., phosphatidylserine, phosphatidylcholin and cholesterol) were included in the vaccine studies (<xref rid="B100" ref-type="bibr">100</xref>). Liposomes deliver vaccines by fusion with the target cell membrane (<xref rid="B101" ref-type="bibr">101</xref>).The structurally flexible and versatile liposomes are able to encapsulate both hydrophilic and hydrophobic substances. The hydrophilic molecules can be incorporated into the aqueous core, while hydrophobic molecules are encased within the phospholipid bilayer. Earlier reports have shown that delivery of antigenic proteins entrapped in multilamellar lipid vesicles elicit strong T and B-cell responses (<xref rid="B102" ref-type="bibr">102</xref>). Similarly antigenic peptides conjugated to phosphatidylserine (PS)-liposomes were readily internalized by APCs to potentiate T-helper cell mediated immune responses (<xref rid="B103" ref-type="bibr">103</xref>) and delivery of heat shock protein encoding vaccine DNA using liposomes elicited strong protective immunity against fungal infection (<xref rid="B104" ref-type="bibr">104</xref>). Because of their foreseen applications, several liposome based vaccine nano-formulations have been approved for clinical trials against intracellular pathogens, including viruses and <italic>M. tuberculosis</italic> (<xref rid="B105" ref-type="bibr">105</xref>). One such study already demonstrated the potency of liposomal aerosol carriers in the generation of protective immunity against <italic>M. tuberculosis</italic> infection (<xref rid="B106" ref-type="bibr">106</xref>, <xref rid="B107" ref-type="bibr">107</xref>). Other studies have tried a combination of dimethyl dioctadecyl ammonium (DDA) lipid based liposomes and various immunomodulators to enhance immunity against influenza, chlamydia, erythrocytic-stage malaria, and tuberculosis infections (<xref rid="B108" ref-type="bibr">108</xref>–<xref rid="B112" ref-type="bibr">112</xref>). In the context of DNA vaccines, lipid-DNA complexes have been successfully delivered to the lungs of monkeys (<xref rid="B101" ref-type="bibr">101</xref>).</p></sec><sec><title>VLPs (virus like particles)</title><p>There are several reports that adequately proved applications of VLPs as a vaccine carrier, and also their ability to stimulate the host immune responses (<xref rid="B113" ref-type="bibr">113</xref>–<xref rid="B115" ref-type="bibr">115</xref>). VLPs are composed of self-assembled viral membrane that forms a monomeric complex displaying a high density of epitopes (<xref rid="B115" ref-type="bibr">115</xref>, <xref rid="B116" ref-type="bibr">116</xref>). Interestingly, VLPs can also be engineered to express additional proteins either by fusion of proteins with the particles or by endogenous expression of multiple antigens (<xref rid="B113" ref-type="bibr">113</xref>, <xref rid="B117" ref-type="bibr">117</xref>). It is also possible to chemically couple non-protein antigens and small organic molecules onto the viral surface to produce bioconjugates with VLPs (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>). Due to these distinct features, VLPs can provide protection not only against virus, but also against heterologous antigens (<xref rid="B116" ref-type="bibr">116</xref>). A specific immune response was successfully generated after the delivery of an antigen using virus capsid protein SV40 in mammalian cells (<xref rid="B120" ref-type="bibr">120</xref>). VLPs were also found to increase the immunogenicity of weak antigens. For example <italic>Salmonella typhi</italic> membrane antigen, influenza A M2 protein and H1V1 Nef gonadotropin releasing hormone (GnRH) assembled VLPs produced strong antigen specific humoral as well as cellular immune responses (<xref rid="B121" ref-type="bibr">121</xref>, <xref rid="B122" ref-type="bibr">122</xref>). It is presumed that the use of VLP based nanoformulations could enable the antigens to achieve conformations resembling to native antigen structure, thus it may result in better stimulation of the host immune response (<xref rid="B122" ref-type="bibr">122</xref>).</p></sec><sec><title>Dendrimers</title><p>Dendrimers are three dimensional, mono-dispersed and hyperbranched nano structures that are made up of a mixture of amines and amides. Few studies have explored the application of dendrimers in the delivery of different antigenic molecules. The most commonly used dendrimers for vaccine delivery are polypropyleneimine (PPI) and polyamido amine (PAMAM) dendrimers. A single dose of dendrimer encapsulated multiple antigens was found to produce strong antibody and T-cell responses against Ebola virus, H1N1 influenza, and <italic>Toxoplasma gondii</italic> (<xref rid="B123" ref-type="bibr">123</xref>). This generation of robust immune response was found to be due to efficient uptake of dendrimers by the host cells. Similarly a significant increase in the vaccine efficacy of HIV transactivator of transcription (TAT) based DNA vaccine was observed due to enhanced cellular uptake of PMAM dendrimer (<xref rid="B124" ref-type="bibr">124</xref>). Hence, the possibility to tailor the dendrimers to attain certain biological and physico-chemical properties, and also the feasibility to conjugate several ligands to the single molecule have made dendrimers promising candidates for the development of new generation vaccines with enhanced immunogenic properties.</p></sec></sec></sec><sec id="s4"><title>Delivery of immune stimulators using nanocarriers</title><sec><title>Cytokines</title><p>Cytokines are known as important signaling molecules secreted by different cells in response to external stimuli. Some of the cytokines are able to activate immune cells to generate protective immunity against several diseases. However, cytokines are mostly susceptible to early degradation that subdue their participation in the generation of host immunity. Moreover, uncontrolled release of cytokines as immune responders may sometimes lead to harmful side effects (<xref rid="B125" ref-type="bibr">125</xref>). To overcome these limitations, several studies have attempted to synthesize engineered nanocarriers to achieve effective and controlled delivery of cytokines to the target sites. This approach was found to reduce their toxicity, improve circulation time and antigen specific T-cell responses in comparison to free cytokines (<xref rid="B126" ref-type="bibr">126</xref>, <xref rid="B127" ref-type="bibr">127</xref>). Incorporation of granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha (IFN-α) into nano-carriers exhibited great application in cancer therapy (<xref rid="B128" ref-type="bibr">128</xref>, <xref rid="B129" ref-type="bibr">129</xref>). Nano-carrier conjugated cytokines also showed great potential in the treatment of infectious diseases. For example, IL-12 encapsulated microspheres induced strong protective immunity against tuberculosis (<xref rid="B130" ref-type="bibr">130</xref>). This effect was due to production of high antibody titers as a result of sustained and controlled release of IL-12 from the microspheres in immunized mice (<xref rid="B130" ref-type="bibr">130</xref>).</p></sec><sec><title>Toll like receptor agonists</title><p>Like cytokines, several toll-like receptor (TLR) agonists were also explored as immune activators to augment immune surveillance mechanisms. Different immune effector cells such as macrophages, B-cells and DCs express different types of TLRs, which are known to interact with specific pathogen associated molecular patterns (PAMPs). These specific interactions eventually initiate downstream signaling cascades to ensure the elimination or generation of immunity against pathogens (<xref rid="B131" ref-type="bibr">131</xref>, <xref rid="B132" ref-type="bibr">132</xref>). Conjugation of TLR specific agonists on nanocarriers helps to target the molecules to specific immune cells and therefore reduce the possibility of systemic biodistribution. One such study has shown that conjugation of TLR-7/8 agonist on nano polymers caused efficient internalization by APCs and also prolonged the T cell responses (<xref rid="B133" ref-type="bibr">133</xref>). Administration of NPs loaded with vaccine peptide antigen and TLR-7 and 9 ligands were also found to induce strong memory and effector CD8<sup>+</sup> T-cell response (<xref rid="B134" ref-type="bibr">134</xref>). Another study has shown that conjugation of TLR-8 agonist to a polymer nanocarrier increased activation and maturation of naive DCs due to selective endocytosis and prolonged release of an immunogen by the nanocarrier inside DCs (<xref rid="B135" ref-type="bibr">135</xref>). Moreover, intradermal injection of CpG and antigen encapsulated polymeric NPs were rapidly drained into the lymph nodes to activate DCs (<xref rid="B97" ref-type="bibr">97</xref>). These studies indicate that NPs can be used as a tool to appropriately target presentation of antigens to T and B-cell rich lymphoid organs.</p></sec><sec><title>Nucleic acids</title><p>The genetic molecules such as DNA, plasmids and RNA can also act as immuno-stimulants. Due to these characteristics, in addition to less risk to cause disease particularly in immunocompromised individuals, these genetic materials are considered as promising candidates for the development of next generation vaccines. After administration, the plasmid vector translocates to the nucleus to initiate transcription of recombinant genes using the host cellular machinery. A recombinant DNA segment encoding HspX-PPE44-esxV fusion antigen of <italic>M. tuberculosis</italic> showed great potential as a new tuberculosis DNA vaccine candidate (<xref rid="B136" ref-type="bibr">136</xref>). A similar type of study has been conducted in the past where the vaccination of DNA or RNA constructs expressing mycobacterium antigens were capable of inducing humoral as well as cellular immune responses (<xref rid="B137" ref-type="bibr">137</xref>). Likewise, plasmids harboring genes encoding for viral antigen have been encapsulated into alginate nanocarriers and targeted against viral infections (<xref rid="B138" ref-type="bibr">138</xref>).</p></sec></sec><sec id="s5"><title>Importance of physicochemical properties in designing nano-immuno formulations</title><p>In order to improve their delivery and vaccine characteristics, different approaches have been practiced to conjugate vaccine molecules to different nanocarriers. Vaccine molecules can be surface conjugated, encapsulated or surface adsorbed with the nanocarriers. Antigen adsorption on the nanocarrier is simply based on the presence of a charge or hydrophobic interactions between NPs and the candidate molecule (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B140" ref-type="bibr">140</xref>). This type of interaction is usually non-covalent, which may lead to rapid dissociation of antigens from nanocarriers depending upon the external milieu such as pH, ionic strength, temperature, and the antigen hydrophobicity. On the other hand, encapsulation and chemical conjugation of antigen to nanocarriers is more stable due to strong interactions and chemical bond formation between the target molecule and the nanocarrier. Further, antigens can also be encapsulated into nanocarriers by simple mixing reaction during the synthesis. In this case, the antigens are released only after partial or complete dissociation of the nanocarrier (<xref rid="B141" ref-type="bibr">141</xref>). These processes have already been used with silica and gold NPs (<xref rid="B142" ref-type="bibr">142</xref>). Similarly, chitosan and dextran sulfate NPs were used for the preparation of cationic and anionic antigenic formulations. Some viral antigens are known to bind to both positive as well as negative charged NPs through immobilization process and hydrogen bonds (<xref rid="B143" ref-type="bibr">143</xref>). The immobilization process depends on the charge, pH, ratio of NPs and antigens, and the protein partition coefficient between the solution and the colloid (<xref rid="B143" ref-type="bibr">143</xref>). Several antigens were successfully delivered to the target sites by chemical conjugation, adsorption and encapsulation to soft nanocarriers like VLPs, liposomes and immune stimulating complexes (ISCOM) (<xref rid="B144" ref-type="bibr">144</xref>–<xref rid="B147" ref-type="bibr">147</xref>). ISCOMs are a class of adjuvant formulations that consist of saponins, cholesterol and phospholipids in specific ratios. Antigens can be formulated into ISCOMs directly (<xref rid="B148" ref-type="bibr">148</xref>) or after the surface modification (<xref rid="B149" ref-type="bibr">149</xref>, <xref rid="B150" ref-type="bibr">150</xref>). Since ISCOM particles are negatively charged, direct conjugation of most of the soluble proteins is a limiting factor. Nanocarriers can augment immunogenicity of a molecule. For example, influenza antigen H1N1 conjugated chitosan NPs and <italic>Yersinia pestis</italic> F1-antigen coated gold NPs (AuNPs) produced higher levels of antibody and cytokine responses in comparison to mice administered with unconjugated antigens (<xref rid="B151" ref-type="bibr">151</xref>).This was found to be due to stabilization and increased immunogenicity of vaccine antigens due to conjugation with NPs.</p><p>Another important aspect in the development of nano-immuno formulations is that they improve antigen delivery and presentation (<xref rid="B152" ref-type="bibr">152</xref>). In this context, NP shape, size and surface charge are key factors that affect NP circulation, biodistribution, bioavailability and specificity by crossing biological barriers. Besides these factors, particle geometry such as surface to volume ratio plays an important role in the determination of immunogen release and degradation kinetics (<xref rid="B153" ref-type="bibr">153</xref>, <xref rid="B154" ref-type="bibr">154</xref>). Here, the importance of different physicochemical parameters such as size, shape, surface area, porosity, hydrophobicity, hydrophilicity and crystallinity in the interaction between NPs and the target cell is discussed.</p><sec><title>Size</title><p>The size of NPs determines the mode of cellular uptake and specificity (<xref rid="B155" ref-type="bibr">155</xref>, <xref rid="B156" ref-type="bibr">156</xref>). PLGA NPs of large size (1, 7 and 17 μm) showed reduced internalization rate in comparison to smaller NPs (300 nm) (<xref rid="B157" ref-type="bibr">157</xref>). The size of NPs also determines the cellular specificity and migration. Smaller NPs (20–200 nm) were readily endocytosed by the resident DCs, whereas larger size (500–2,000 nm) NPs were effectively taken up by the migratory DCs (<xref rid="B158" ref-type="bibr">158</xref>). NPs of less than 200 nm size were drained into the lymph nodes (<xref rid="B159" ref-type="bibr">159</xref>), while particles up to 20 nm range were suitably transported to the APCs (<xref rid="B152" ref-type="bibr">152</xref>, <xref rid="B160" ref-type="bibr">160</xref>). Notably, NP curvature also affects the cellular interaction and phagocytosis rate (<xref rid="B161" ref-type="bibr">161</xref>). NPs of 150 nm diameter and 450 nm height showed more cellular uptake as compared to the particles having 1,200 × 200 nm size. Of note the size of NPs was also found to influence the activation of signaling pathways. A study has demonstrated that smaller NPs are able to alter the cell signaling processes more efficaciously than the large NPs (<xref rid="B31" ref-type="bibr">31</xref>).</p></sec><sec><title>Surface charge</title><p>Vaccine loaded NPs can also be targeted to specific sites by modifying the NP surface charge. Delivery of such NPs at appropriate sites elicit strong immune responses against antigens. NP surface charge is responsible for the interaction with congnate surface molecules present on the target cells. This was exemplified from the observation that cationic polysterene NPs were efficiently internalized by the APCs in comparison to neutral surface charged NPs. This may be due to electrostatic interactions between the cationic NPs with anionic cell membranes (<xref rid="B162" ref-type="bibr">162</xref>, <xref rid="B163" ref-type="bibr">163</xref>). Interestingly, pulmonary instillation of cationic and anionic NPs showed similar endocytosis rate in macrophages and draining lymph nodes, however cationic formulations showed more expression of <italic>Ccl2</italic> and <italic>Cxc10</italic> chemokines that caused more recruitment and maturation of CD11b DCs in comparison to anionic NPs in the lung (<xref rid="B125" ref-type="bibr">125</xref>, <xref rid="B156" ref-type="bibr">156</xref>). Similarly, neutral silica-silane shell polymer NPs were less effective in the activation of innate immune cells (<xref rid="B128" ref-type="bibr">128</xref>). These studies clearly indicate appropriate surface modifications of NPs may help to generate stronger immunological responses against specific infection.</p></sec><sec><title>Shape</title><p>Beside size and surface charge, NP shape is also a critical determinant in the cellular interaction, intracellular trafficking and the rate of antigen release inside the host cells (<xref rid="B79" ref-type="bibr">79</xref>, <xref rid="B141" ref-type="bibr">141</xref>). Spherical gold NPs were actively internalized by bone marrow derived dendritic cells in comparison to rod shaped particles of similar dimensions (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>), and that spherical NPs were able to induce strong immune response than cube or rod shaped NPs (<xref rid="B164" ref-type="bibr">164</xref>). Another study reported that worm-like particles were impaired in phagocytosis as compared to spherical NPs (<xref rid="B151" ref-type="bibr">151</xref>). These distinctions were ascribed to the differences in contact area between NPs and the target cell membrane. The shape of NPs also determines the localization of NPs inside the host cells. This was demonstrated by the fact that although nano rods and nano sheets were internalized via clathrin mediated endocytosis, nano rods were particularly delivered to the nucleus while nano-sheet were retained in the cytoplasm (<xref rid="B146" ref-type="bibr">146</xref>, <xref rid="B147" ref-type="bibr">147</xref>, <xref rid="B155" ref-type="bibr">155</xref>). This is an important aspect in the context of improving antigen processing and presentation to T-cells. It is well established that enhanced antigen processing and presentation can be achieved if the candidate molecules are delivered to the lysosomal compartment of the cells.</p></sec><sec><title>Hydrophobicity</title><p>Hydrophobicity of NPs plays a significant role in the interaction with soluble proteins and immune cells through recognition of hydrophobic moieties (<xref rid="B165" ref-type="bibr">165</xref>). Previous studies have shown that hydrophobic polymeric NPs are strong inducers of cytokines and co-stimulatory molecules than hydrophilic polymeric NPs (<xref rid="B53" ref-type="bibr">53</xref>, <xref rid="B105" ref-type="bibr">105</xref>, <xref rid="B166" ref-type="bibr">166</xref>). Exposure to hydrophobic NPs showed enhanced activation of DCs by inducing the expression of CD86 co-stimulatory molecules when compared with hydrophilic ones. Similar observations were reported in other innate immune cells, in which hydrophobic NPs were able to activate these cells by up-regulating the expression of proinflammatory cytokine encoding genes (<xref rid="B102" ref-type="bibr">102</xref>), and also facilitated opsonization process by increasing the adsorption of immunoglobulins on the cell surfaces (<xref rid="B103" ref-type="bibr">103</xref>). However, other studies have reported that polyethylene glycol coating (PEGylation) reduced the interaction of NPs with immune receptors (<xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B80" ref-type="bibr">80</xref>). This property is considered useful in the prevention of non-specific adsorption of proteins on NPs and thereby prevent their up-take by APCs (<xref rid="B50" ref-type="bibr">50</xref>). Such non-specific adsorption of proteins and their uptake by phagocytic cells can also be preventing by the incorporation of an alkyl linker between the PEG and thiol moieties on NPs (<xref rid="B80" ref-type="bibr">80</xref>).</p></sec><sec><title>Surface modification</title><p>Surface modification of NPs alters ligand specificity and interaction with APCs (<xref rid="B160" ref-type="bibr">160</xref>). Conjugation of CD47 molecules on the surface of NPs modulated the down-stream signaling cascades and also reduced NP internalization by phagocytic cells (<xref rid="B131" ref-type="bibr">131</xref>). Functionalization of NPs with TLR-7, TLR-8, and TLR-9 agonists increased cytokine production and the expression of immunoregulatory genes (<xref rid="B132" ref-type="bibr">132</xref>–<xref rid="B134" ref-type="bibr">134</xref>). Similarly, conjugation of poly (methyl vinyl ether-co-maleic anhydride; PVMA), TLR2, and TLR4 agonists, and galactose polymer to NPs were shown to activate the complement pathway as a result of stable binding to C3b complement factor (<xref rid="B139" ref-type="bibr">139</xref>, <xref rid="B142" ref-type="bibr">142</xref>). Further, lipoprotein-like NPs showed LPS scavenging activity, thereby resulting in the inhibition of TLR-4 dependent inflammatory responses (<xref rid="B140" ref-type="bibr">140</xref>). Overall, these studies strongly demonstrated that tuning of physico-chemical properties of NPs could be used as a fundamental tool to target vaccine molecules to specific sites to induce desired immune responses.</p></sec></sec><sec id="s6"><title>Implications of the nanocarriers in the vaccine development</title><p>Emerging studies have proved that nanocarriers can be useful mediators in the development of vaccines against various diseases. In this context, it is important to develop NP formulations that can deliver immunogens to APCs especially DCs to induce effective antigen-specific T-cell responses (Figure <xref ref-type="fig" rid="F2">2</xref>). Several nanocarriers have been shown to specifically activate DCs to effectuate anti-tumor or anti-viral immune responses (<xref rid="B167" ref-type="bibr">167</xref>–<xref rid="B170" ref-type="bibr">170</xref>). Zhu et al. proposed that nano-TiO<sub>2</sub> and Fe<sub>3</sub>O<sub>4</sub>-TiO<sub>2</sub> particles could function as a useful vector to promote vaccine delivery in immune cells (<xref rid="B168" ref-type="bibr">168</xref>). Co-incubation of nano-TiO<sub>2</sub> and Fe<sub>3</sub>O<sub>4</sub>-TiO<sub>2</sub> with DCs resulted in an increased production of TNF-α, and also upregulated the expression of CD80, CD86 and MHC class II molecules through the NF-κB signaling pathway (<xref rid="B163" ref-type="bibr">163</xref>). In this way, immunization efficacy of various NP formulations such as erythrocyte membrane-enveloped poly(D,L-lactide-co-glycolide) (PLGA) NPs for antigenic peptide (hgp10025-33) and TLR-4 agonist, VLPs expressing RSV glycoproteins, chitosan-coated EphrinA1-PE38/GM-CSF, and several others have been improved (<xref rid="B171" ref-type="bibr">171</xref>–<xref rid="B177" ref-type="bibr">177</xref>). NPs can also control cell polarization and differentiation. Branched polyethylenimine-superparamagnetic iron oxide NPs (bPEI-SPIONs) promoted Th1 polarization of DCs (<xref rid="B178" ref-type="bibr">178</xref>). Another study by Sehgal et al. showed that NPs can also be used to target subsets of particular immune cells. They have shown that simultaneous targeting of DC subsets (i.e., DC-SIGN+ and BDCA3+DC) by NPs synergistically stimulated the activation of T cell-mediated immunity when compared with targeting of each DC subset separately (<xref rid="B170" ref-type="bibr">170</xref>).</p><fig id="F2" position="float"><label>Figure 2</label><caption><p>Targeted delivery of antigenic molecules using surface engineered nanoparticles into the antigen presenting cells (APCs). Endogenously generated antigens are presented in complex with class I major histocompatibility complex (MHC I) on the membrane of APCs to CD8+ T lymphocytes. Following the interaction between MHC I and T-cell receptor (TCR) in presence of co-stimulatory molecules and cytokines the activated CD8+ cells kill the infected cells by inducing cytotoxicity. Also the antigens are presented on the APC surface by class II MHC molecules to the helper (CD4+) T cells. Subsequently, CD4+ cells activate B-cells that produce anti-microbial antibodies. Upon stimulation the adaptor proteins MyD88 (myeloid differentiation marker 88) and TIRAP (TIR domain containing adaptor protein) colocalize with TLR (toll-like receptor) allowing for activation of the NF-κB pathway and leading to the production of pro-inflammatory cytokines.</p></caption><graphic xlink:href="fimmu-09-02224-g0002"></graphic></fig><p>Preclinical studies by different research groups have successfully demonstrated the efficacy of NP based vaccines in the induction of specific immune responses against tuberculosis (<xref rid="B42" ref-type="bibr">42</xref>, <xref rid="B179" ref-type="bibr">179</xref>–<xref rid="B182" ref-type="bibr">182</xref>). Feng et al. developed a NP-based recombinant DNA vaccine that consists of Esat-6 and fms-like tyrosine kinase 3 ligand enveloped with chitosan NPs (<xref rid="B42" ref-type="bibr">42</xref>). Intramuscular prime vaccination followed by nasal boost of this recombinant DNA vaccine remarkably enhanced T cell responses in <italic>Mycobacterium tuberculosis</italic> challenged mice (<xref rid="B42" ref-type="bibr">42</xref>). Another study has shown that pulmonary administration of <italic>M. tuberculosis</italic> Ag85B antigen and CpG adjuvant conjugated polypropylene sulfide NPs (NP-Ag85B) induced <italic>M. tuberculosis</italic> specific polyfunctional Th1 responses and also reduced the lung bacterial burden (<xref rid="B183" ref-type="bibr">183</xref>).</p></sec><sec id="s7"><title>Targeted delivery of nanoparticles can activate innate and adaptive immune responses</title><sec><title>Innate immunity</title><p>Macrophages and monocytes are highly heterologous cells that are distributed throughout the body. Macrophages process and present the antigens to elicit adaptive immune response. Due to their intrinsic phagocytic nature, macrophages can be easily targeted by surface engineered NPs, in which cognate ligands agonist to macrophage receptors can be conjugated on the NP surface (Figure <xref ref-type="fig" rid="F1">1</xref>). As discussed above several physico-chemical parameters of NPs such as size, surface charge, hydrophobicity, surface topography, and material composition can be optimized to facilitate the interactions between NPs and macrophage receptors (<xref rid="B184" ref-type="bibr">184</xref>–<xref rid="B186" ref-type="bibr">186</xref>). The rate of NP endocytosis also depends upon the type of cell surface receptors and the ligand conjugated to the NP surface. For example, NPs targeted via mannose and Fc receptors were rapidly internalized as compared to scavenger receptors (<xref rid="B187" ref-type="bibr">187</xref>). Endocytosis of IgG and anti-F4/80 antibody coated NPs showed more uptake rate and retention time inside the macrophages without affecting the cell viability (<xref rid="B188" ref-type="bibr">188</xref>, <xref rid="B189" ref-type="bibr">189</xref>). Also, positively charged NPs interact more strongly with negatively charged phospholipid components of the cell membrane (<xref rid="B190" ref-type="bibr">190</xref>). Hyperactivation of some inflammatory cells can also be restricted through controlled release of stimulants using NPs. Upon activation, neutrophils can secrete variety of cytokines and hydrolytic enzymes in response to infection (<xref rid="B191" ref-type="bibr">191</xref>). Prolonged neutrophil activation often leads to acute inflammation and tissue damage at the localized site. Therefore, controlled release of molecules is necessary to prevent the hyperactivation and massive recruitment of neutrophils. It has been reported that bovine serum albumin (BSA) NPs were able to modulate the functions of neutrophils following their internalization. Intravenous injection of anti-inflammatory peptide encapsulated polymeric NPs reduced neutrophil recruitment and subsequently hyperinflammation to prevent further tissue damage (<xref rid="B192" ref-type="bibr">192</xref>). The use of NPs to deliver vaccine/drugs in a controlled fashion is now considered as an attractive approach to develop therapeutic strategies against a range of acute and chronic inflammatory diseases (<xref rid="B193" ref-type="bibr">193</xref>).</p></sec><sec><title>Adpative immunity</title><p>T and B-cells of the adaptive immune system express a repertoire of receptors to recognize a range of antigens. Activation or suppression of T-cell immunity can determine the fate of a disease. A number of NP based therapeutic strategies have been developed to regulate T-cell activity against viral, bacterial, or fungal infections. For example, antiviral siRNA or retroviral drug encapsulated lipid NPs or dendrimers were effectively delivered to CD4<sup>+</sup> T-cells to block HIV replication. This caused a significant reduction in HIV titer when compared with the use of non-encapsulated retroviral drugs (<xref rid="B191" ref-type="bibr">191</xref>, <xref rid="B194" ref-type="bibr">194</xref>). T-cell activation also depends up on the type and size of NP used for the delivery of antigen. Liposome encapsulated antigens were better presented to CD4<sup>+</sup> T cells by APCs (<xref rid="B195" ref-type="bibr">195</xref>, <xref rid="B196" ref-type="bibr">196</xref>) and delivery of 200 nm ova conjugated NPs increased MHC class I and II expression and also produced a higher percentage of antigen specific CD4<sup>+</sup>T cells as compared to 30 nm ova conjugated particles (<xref rid="B197" ref-type="bibr">197</xref>).</p><p>B cells are able to recognize and respond to the microbial surface antigens through B-cell receptors (<xref rid="B198" ref-type="bibr">198</xref>). Activation and clonal expansion of antigen specific B-cells using engineered NPs have been exploited for the development of vaccines against different diseases (Figure <xref ref-type="fig" rid="F2">2</xref>). Encapsulation of antigen in virus like particles (VLPs) was able to induce strong and durable humoral responses when compared with the administration of exposed vaccine molecules (<xref rid="B199" ref-type="bibr">199</xref>). The potency of immune responses also depends upon the mode of antigen presentation to the target cells. Surface conjugated immunogenic proteins and peptides were able to activate B cells much stronger than encapsulated antigens (<xref rid="B200" ref-type="bibr">200</xref>). A single dose of PLGA NPs with surface displayed ovalbumin (OVA) elicited strong antibody responses <italic>in vivo</italic> as compared to free OVA (<xref rid="B201" ref-type="bibr">201</xref>, <xref rid="B202" ref-type="bibr">202</xref>). NPs can also be used to activate specific immune responses. A study has shown that peptide conjugated carbon nanotubes showed significant antigen specific IgG response in comparison to peptide or adjuvant alone (<xref rid="B83" ref-type="bibr">83</xref>).</p></sec></sec><sec id="s8"><title>Nanoparticles can be used to increase cross antigen presentation</title><p>In general, antigens captured by APCs from the extracellular environment are targeted to the endo-lysosomal compartments, where they are first processed into peptides and then loaded onto class II MHC molecules before presentation to CD4<sup>+</sup> helper T cells. However, cytosolic antigens are loaded on MHC class I molecules and presented to CD8<sup>+</sup> T-cells, which are crucial for the clearance of viral and intracellular infections (<xref rid="B203" ref-type="bibr">203</xref>). It is reported that some fraction of antigens delivered through NPs are trafficked to cytosolic vacuoles of APCs and presented by MHC class I molecules (<xref rid="B203" ref-type="bibr">203</xref>–<xref rid="B205" ref-type="bibr">205</xref>). The NP mediated cross antigen presentation was first demonstrated in antigens conjugated to iron oxide polymer NPs (<xref rid="B206" ref-type="bibr">206</xref>–<xref rid="B209" ref-type="bibr">209</xref>). In addition, inorganic and polymeric NPs have also been used for antigen delivery to cytosol (<xref rid="B210" ref-type="bibr">210</xref>,–<xref rid="B212" ref-type="bibr">212</xref>). In this context, lipid NPs were shown to induce CD8<sup>+</sup> T cell expansion by efficient antigen cross presentation against viral infection in <italic>in-vivo</italic> models (<xref rid="B102" ref-type="bibr">102</xref>, <xref rid="B213" ref-type="bibr">213</xref>). Similarly, invariant natural killer T cells (iNKT), which are a special subset of T-cells, recognize lipid antigens presented by CD1d cells. PLGA NPs conjugated with α-galactosylceramide glycolipid, an iNKT cell stimulant, increased cytokine release as well as expansion of antigen specific CD8+ T cells (<xref rid="B214" ref-type="bibr">214</xref>). The cross antigen presentation also depends upon the particle-antigen linkages. It has been shown that disulfide bonding between NP and antigens caused release of antigens into the endosomal compartment and also enhanced CD8<sup>+</sup> T cell formation as compared to non-degradable linkers (<xref rid="B215" ref-type="bibr">215</xref>, <xref rid="B216" ref-type="bibr">216</xref>). Similarly, pulmonary administration of NPs efficiently enhanced cross antigen presentation, which resulted in at least 10-fold more effector CD8<sup>+</sup>T cells in lungs (<xref rid="B217" ref-type="bibr">217</xref>).</p></sec><sec id="s9"><title>Nanoparticles as adjuvants to generate immune responses in lymphoid organs</title><p>Adjuvants are known to enhance and prolong the immune responses against antigens. Delivery of adjuvants and antigens using NPs have been found useful to prolong their exposure in the lymphoid organs such as lymph nodes to generate robust immune responses. This is especially important for small adjuvant molecules, which are rapidly cleared from the bloodstream. NPs with a size ranging from 10–100 nm can penetrate the extracellular matrix and travel to the lymph nodes where they can be internalized by the resident macrophages to activate T-cell responses (<xref rid="B218" ref-type="bibr">218</xref>–<xref rid="B220" ref-type="bibr">220</xref>). The bio-distribution of NPs also depends upon the route of administration and size. It was observed that larger particles accumulated near the site of NPs and were subsequently endocytosed by the local APCs (<xref rid="B160" ref-type="bibr">160</xref>), whereas the smaller NPs drained to the blood capillaries (<xref rid="B158" ref-type="bibr">158</xref>, <xref rid="B218" ref-type="bibr">218</xref>). PEG coated liposomes of 80–90 nm diameter showed higher accumulation in lymph nodes after subcutaneous administration as compared to intravenous and intraperitoneal administration (<xref rid="B221" ref-type="bibr">221</xref>).</p></sec><sec sec-type="conclusions" id="s10"><title>Conclusions</title><p>The nano-immuno formulations can improve the antigen stability, targeted delivery and also enhance their immunogenicity properties. Most soluble antigens cannot be efficiently endocytosed by the APCs and hence are poorly effective in inducing protective immunity. The immunogenicity of such soluble vaccine antigens can be improved by conjugating them with nanocarriers that can facilitate the recognition and uptake by APCs. This strategy has already been proved effective for inducing/increasing the immunogenicity of poorly immunogenic antigens, such as polysaccharides of pneumococcal vaccines (<xref rid="B222" ref-type="bibr">222</xref>). In the last few years, the application of nanotechnology in the field of immune engineering is growing rapidly with a number of new carrier synthesis strategies. Furthermore, novel nano formulations also contain immunostimulatory molecules to enhance the adjuvant properties of the nanoparticles. Co-encapsulation of the TLR agonists [e.g., CpG, poly(I:C)] (<xref rid="B77" ref-type="bibr">77</xref>) or imiquimoid (<xref rid="B78" ref-type="bibr">78</xref>) into dextran or chitosan NPs, respectively enhanced receptor-based recognition of the nanovaccines with subsequent cell activation. The recent study by Margaroni et al. showed that vaccination with poly(D,L-lactide-co-glycolide; PLGA) nanoparticles with <italic>Leishmania infantum</italic> antigens (sLiAg) and surface-modified with a TNFα-mimicking eight-amino-acid peptide (p8) induced significant protection against parasite infection in BALB/c mice accompanied by activation of CD8+ T cells and increase in IFNγ production (<xref rid="B223" ref-type="bibr">223</xref>).</p><p>Additionally, NPs can be tailored for non-invasive administration and prolonged delivery of the vaccine antigens to a specific location, thus providing the possibility for formulation of the single dose vaccine. Several studies clearly demonstrated the efficacy of the non-invasively administered vaccines such as intranasal application of influenza nano vaccine (<xref rid="B224" ref-type="bibr">224</xref>), chitosan NPs with hemagglutinin protein of H1N1 influenza virus (<xref rid="B225" ref-type="bibr">225</xref>), <italic>Streptococcus equi</italic> proteins (<xref rid="B226" ref-type="bibr">226</xref>), hepatitis B surface antigen (pRc/CMV-HBs) (<xref rid="B227" ref-type="bibr">227</xref>) and plasmid encoding a multi-epitope protein against <italic>M. tuberculosis</italic> (pHSP65pep) (<xref rid="B228" ref-type="bibr">228</xref>) or antigen 85B (<xref rid="B229" ref-type="bibr">229</xref>) were used to provide protective immunity against infections. These considerations can improve the progress of ongoing strategies in the development of nanoparticle-based vaccines. In future, development of nanovaccines will address not only the possibility to induce the immune response but also the anti-infective therapeutic activity of NPs thus representing the feasibility to apply multifunctional particles for the treatment of diseases.</p></sec><sec id="s11"><title>Author contributions</title><p>AS and RP wrote the manuscript. AS supervised the process. MS wrote the part on Use of nanocarriers in vaccine delivery to dendritic cells.</p><sec><title>Conflict of interest statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></sec></body><back><ack><p>The authors thank Nan-Jong Lee for figures preparation.</p></ack><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> For financial support, we thank Department of Science and Technology (SR/NM/NS-1159/2016), Govt of India and Alexander von Humboldt Fellowship to AS. MS was supported by the Alexander von Humboldt Fellowship and by a grant of the Russian Science Foundation 14-50-00068 and by the Federal Agency of Scientific Organizations, Russia.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dye</surname><given-names>C</given-names></name></person-group>. <article-title>After 2015: infectious diseases in a new era of health and development</article-title>. <source>Philos Trans R Soc Lond B Biol Sci.</source> (<year>2014</year>) <volume>369</volume>:<fpage>20130426</fpage>. <pub-id pub-id-type="doi">10.1098/rstb.2013.0426</pub-id><pub-id pub-id-type="pmid">24821913</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Global Tuberculosis Report</source>. World Health Organization (<year>2016</year>).</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kahn</surname><given-names>RE</given-names></name><name><surname>Ma</surname><given-names>W</given-names></name><name><surname>Richt</surname><given-names>JA</given-names></name></person-group>. <article-title>Swine and influenza: a challenge to one health research</article-title>, in <source>Curr Top Microbiol Immunol.</source> (<year>2014</year>) <volume>385</volume>:<fpage>205</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1007/82_2014_392</pub-id><pub-id pub-id-type="pmid">25005926</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braden</surname><given-names>CR</given-names></name><name><surname>Dowell</surname><given-names>SF</given-names></name><name><surname>Jernigan</surname><given-names>DB</given-names></name><name><surname>Hughes</surname><given-names>JM</given-names></name></person-group>. <article-title>Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome</article-title>. <source>Emerg Infect Dis.</source> (<year>2013</year>) <volume>19</volume>:<fpage>864</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.3201/eid1906.130192</pub-id><pub-id pub-id-type="pmid">23731871</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wejse</surname><given-names>C</given-names></name><name><surname>Patsche</surname><given-names>CB</given-names></name><name><surname>Kühle</surname><given-names>A</given-names></name><name><surname>Bamba</surname><given-names>FJV</given-names></name><name><surname>Mendes</surname><given-names>MS</given-names></name><name><surname>Lemvik</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Impact of HIV-1, HIV-2, and HIV-1+2 dual infection on the outcome of tuberculosis</article-title>. <source>Int J Infect Dis.</source> (<year>2015</year>) <volume>32</volume>:<fpage>128</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2014.12.015</pub-id><pub-id pub-id-type="pmid">25499041</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenwood</surname><given-names>B</given-names></name></person-group>. <article-title>The contribution of vaccination to global health: past, present and future</article-title>. <source>Philos Trans R Soc B Biol Sci</source>. (<year>2014</year>) <volume>369</volume>:<fpage>20130433</fpage>. <pub-id pub-id-type="doi">10.1098/rstb.2013.0433</pub-id><pub-id pub-id-type="pmid">24821919</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ada</surname><given-names>GL</given-names></name></person-group>. <article-title>The ideal vaccine</article-title>. <source>World J Microbiol Biotechnol</source>. (<year>1991</year>) <volume>7</volume>:<fpage>105</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/BF00328978</pub-id><pub-id pub-id-type="pmid">24424920</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atkins</surname><given-names>HS</given-names></name><name><surname>Morton</surname><given-names>M</given-names></name><name><surname>Griffin</surname><given-names>KF</given-names></name><name><surname>Stokes</surname><given-names>MGM</given-names></name><name><surname>Nataro</surname><given-names>JP</given-names></name><name><surname>Titball</surname><given-names>RW</given-names></name></person-group>. <article-title>Recombinant Salmonella vaccines for biodefence</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>2710</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.046</pub-id><pub-id pub-id-type="pmid">16434131</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beverley</surname><given-names>PCL</given-names></name></person-group>. <article-title>Immunology of vaccination</article-title>. <source>Br Med Bull</source>. (<year>2002</year>) <volume>62</volume>:<fpage>15</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1093/bmb/62.1.15</pub-id><pub-id pub-id-type="pmid">12176847</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulmer</surname><given-names>JB</given-names></name><name><surname>Donnelly</surname><given-names>JJ</given-names></name><name><surname>Parker</surname><given-names>SE</given-names></name><name><surname>Rhodes</surname><given-names>GH</given-names></name><name><surname>Felgner</surname><given-names>PL</given-names></name><name><surname>Dwarki</surname><given-names>VJ</given-names></name><etal></etal></person-group>. <article-title>Heterologous protection against influenza by injection of DNA encoding a viral protein</article-title>. <source>Science</source> (<year>1993</year>) <volume>259</volume>:<fpage>1745</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1126/science.8456302</pub-id><pub-id pub-id-type="pmid">8456302</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scallan</surname><given-names>CD</given-names></name><name><surname>Tingley</surname><given-names>DW</given-names></name><name><surname>Lindbloom</surname><given-names>JD</given-names></name><name><surname>Toomey</surname><given-names>JS</given-names></name><name><surname>Tucker</surname><given-names>SN</given-names></name></person-group>. <article-title>An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models</article-title>. <source>Clin Vaccine Immunol</source>. (<year>2013</year>) <volume>20</volume>:<fpage>85</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00552-12</pub-id><pub-id pub-id-type="pmid">23155123</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altenburg</surname><given-names>AF</given-names></name><name><surname>Kreijtz</surname><given-names>JH</given-names></name><name><surname>de</surname><given-names>Vries RD</given-names></name><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Fux</surname><given-names>R</given-names></name><name><surname>Rimmelzwaan</surname><given-names>GF</given-names></name><etal></etal></person-group>. <article-title>Modified vaccinia virus ankara (MVA) as production platform forvaccines against influenza and other viral respiratory diseases</article-title>. <source>Viruses</source> (<year>2014</year>) <volume>6</volume>:<fpage>2735</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.3390/v6072735</pub-id><pub-id pub-id-type="pmid">25036462</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nascimento</surname><given-names>IP</given-names></name><name><surname>Leite</surname><given-names>LCC</given-names></name></person-group>. <article-title>Recombinant vaccines and the development of new vaccine strategies</article-title>. <source>Braz J Med Biol Res.</source> (<year>2012</year>) <volume>45</volume>:<fpage>1102</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1590/S0100-879X2012007500142</pub-id><pub-id pub-id-type="pmid">22948379</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donnelly</surname><given-names>JJ</given-names></name><name><surname>Wahren</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>MA</given-names></name></person-group>. <article-title>DNA vaccines: progress and challenges</article-title>. <source>J Immunol</source>. (<year>2005</year>) <volume>175</volume>:<fpage>633</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.175.2.633</pub-id><pub-id pub-id-type="pmid">16002657</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skibinski</surname><given-names>DA</given-names></name><name><surname>Baudner</surname><given-names>BC</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>O'Hagan</surname><given-names>DT</given-names></name></person-group>. <article-title>Combination vaccines</article-title>. <source>J Glob Infect Dis</source>. (<year>2011</year>) <volume>3</volume>:<fpage>63</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.4103/0974-777X.77298</pub-id><pub-id pub-id-type="pmid">21572611</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>VC</given-names></name></person-group>. <article-title>Influenza vaccines: from whole virus preparations to recombinant protein technology</article-title>. <source>Expert Rev Vaccines</source>. (<year>2014</year>) <volume>13</volume>:<fpage>31</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1586/14760584.2014.852476</pub-id><pub-id pub-id-type="pmid">24192014</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Means</surname><given-names>TK</given-names></name><name><surname>Hayashi</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>KD</given-names></name><name><surname>Aderem</surname><given-names>A</given-names></name><name><surname>Luster</surname><given-names>AD</given-names></name></person-group>. <article-title>The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells</article-title>. <source>J Immunol</source>. (<year>2003</year>) <volume>170</volume>:<fpage>5165</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.170.10.5165</pub-id><pub-id pub-id-type="pmid">12734364</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mogensen</surname><given-names>TH</given-names></name></person-group>. <article-title>Pathogen recognition and inflammatory signaling in innate immune defenses</article-title>. <source>Clin Microbiol Rev.</source> (<year>2009</year>) <volume>22</volume>:<fpage>240</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00046-08</pub-id><pub-id pub-id-type="pmid">19366914</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>Ochando</surname><given-names>J</given-names></name><name><surname>Partida-Sánchez</surname><given-names>S</given-names></name></person-group>. <article-title>Migration of dendritic cell subsets and their precursors</article-title>. <source>Annu Rev Immunol.</source> (<year>2008</year>) <volume>26</volume>:<fpage>293</fpage>–<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.26.021607.090254</pub-id><pub-id pub-id-type="pmid">18045026</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>DM</given-names></name><name><surname>Simon</surname><given-names>JK</given-names></name><name><surname>Baker</surname><given-names>JR</given-names></name></person-group>. <article-title>Applications of nanotechnology for immunology</article-title>. <source>Nat Rev Immunol</source>. (<year>2013</year>) <volume>13</volume>:<fpage>592</fpage>–<lpage>605</lpage>. <pub-id pub-id-type="doi">10.1038/nri3488</pub-id><pub-id pub-id-type="pmid">23883969</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fifis</surname><given-names>T</given-names></name><name><surname>Gamvrellis</surname><given-names>A</given-names></name><name><surname>Crimeen-Irwin</surname><given-names>B</given-names></name><name><surname>Pietersz</surname><given-names>GA</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Mottram</surname><given-names>PL</given-names></name><etal></etal></person-group>. <article-title>Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors</article-title>. <source>J Immunol</source>. (<year>2004</year>) <volume>173</volume>:<fpage>3148</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.173.5.3148</pub-id><pub-id pub-id-type="pmid">15322175</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mottram</surname><given-names>PL</given-names></name><name><surname>Leong</surname><given-names>D</given-names></name><name><surname>Crimeen-Irwin</surname><given-names>B</given-names></name><name><surname>Gloster</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>SD</given-names></name><name><surname>Meanger</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus</article-title>. <source>Mol Pharm</source>. (<year>2007</year>) <volume>4</volume>:<fpage>73</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1021/mp060096p</pub-id><pub-id pub-id-type="pmid">17274665</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schöler</surname><given-names>N</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Müller</surname><given-names>RH</given-names></name><name><surname>Liesenfeld</surname><given-names>O</given-names></name></person-group>. <article-title>Effect of lipid matrix and size of solid lipid nanoparticles (SLN) on the viability and cytokine production of macrophages</article-title>. <source>Int J Pharm</source>. (<year>2002</year>) <volume>231</volume>:<fpage>167</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-5173(01)00882-1</pub-id><pub-id pub-id-type="pmid">11755269</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schöler</surname><given-names>N</given-names></name><name><surname>Olbrich</surname><given-names>C</given-names></name><name><surname>Tabatt</surname><given-names>K</given-names></name><name><surname>Müller</surname><given-names>RH</given-names></name><name><surname>Hahn</surname><given-names>H</given-names></name><name><surname>Liesenfeld</surname><given-names>O</given-names></name></person-group><article-title>Surfactant, but not the size of solid lipid nanoparticles (SLN) influences viability and cytokine production of macrophages</article-title>. <source>Int J Pharm</source>. (<year>2001</year>) <volume>221</volume>:<fpage>57</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-5173(01)00660-3</pub-id><pub-id pub-id-type="pmid">11397567</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vallhov</surname><given-names>H</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Johansson</surname><given-names>SM</given-names></name><name><surname>Ahlborg</surname><given-names>N</given-names></name><name><surname>Muhammed</surname><given-names>MA</given-names></name><name><surname>Scheynius</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications</article-title>. <source>Nano Lett</source>. (<year>2006</year>) <volume>6</volume>:<fpage>1682</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1021/nl060860z</pub-id><pub-id pub-id-type="pmid">16895356</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shvedova</surname><given-names>AA</given-names></name><name><surname>Kisin</surname><given-names>ER</given-names></name><name><surname>Mercer</surname><given-names>R</given-names></name><name><surname>Murray</surname><given-names>AR</given-names></name><name><surname>Johnson</surname><given-names>VJ</given-names></name><name><surname>Potapovich</surname><given-names>AI</given-names></name><etal></etal></person-group>. <article-title>Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice</article-title>. <source>Am J Physiol Cell Mol Physiol</source>. (<year>2005</year>) <volume>289</volume>:<fpage>L698</fpage>–<lpage>708</lpage>. <pub-id pub-id-type="doi">10.1152/ajplung.00084.2005</pub-id><pub-id pub-id-type="pmid">15951334</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Kiwada</surname><given-names>H</given-names></name></person-group>. <article-title>Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes</article-title>. <source>J Control Release</source> (<year>2007</year>) <volume>119</volume>:<fpage>236</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2007.02.010</pub-id><pub-id pub-id-type="pmid">17399838</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishida</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Nawata</surname><given-names>K</given-names></name><name><surname>Kiwada</surname><given-names>H</given-names></name></person-group>. <article-title>PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner</article-title>. <source>J Control Release</source> (<year>2007</year>) <volume>122</volume>:<fpage>349</fpage>–<lpage>55</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2007.05.015</pub-id><pub-id pub-id-type="pmid">17610982</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irvine</surname><given-names>DJ</given-names></name><name><surname>Swartz</surname><given-names>MA</given-names></name><name><surname>Szeto</surname><given-names>GL</given-names></name></person-group>. <article-title>Engineering synthetic vaccines using cues from natural immunity</article-title>. <source>Nat Mater</source>. (<year>2013</year>) <volume>12</volume>:<fpage>978</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1038/nmat3775</pub-id><pub-id pub-id-type="pmid">24150416</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pusic</surname><given-names>K</given-names></name><name><surname>Aguilar</surname><given-names>Z</given-names></name><name><surname>McLoughlin</surname><given-names>J</given-names></name><name><surname>Kobuch</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Tsang</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood-stage human malaria vaccine</article-title>. <source>FASEB J</source>. (<year>2013</year>) <volume>27</volume>:<fpage>1153</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1096/fj.12-218362</pub-id><pub-id pub-id-type="pmid">23195035</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>JS</given-names></name><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>JN</given-names></name><name><surname>Hwang</surname><given-names>YK</given-names></name><name><surname>Yun</surname><given-names>MY</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><etal></etal></person-group>. <article-title>Intracellular protein delivery by hollow mesoporous silica capsules with a large surface hole</article-title>. <source>Nanotechnology</source> (<year>2012</year>) <volume>23</volume>:<fpage>85101</fpage>. <pub-id pub-id-type="doi">10.1088/0957-4484/23/8/085101</pub-id><pub-id pub-id-type="pmid">22293239</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akagi</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Uto</surname><given-names>T</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name><name><surname>Akashi</surname><given-names>M</given-names></name></person-group>. <article-title>Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives</article-title>. <source>Biomaterials</source> (<year>2007</year>) <volume>28</volume>:<fpage>3427</fpage>–<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2007.04.023</pub-id><pub-id pub-id-type="pmid">17482261</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prego</surname><given-names>C</given-names></name><name><surname>Paolicelli</surname><given-names>P</given-names></name><name><surname>Díaz</surname><given-names>B</given-names></name><name><surname>Vicente</surname><given-names>S</given-names></name><name><surname>Sánchez</surname><given-names>A</given-names></name><name><surname>González-Fernández</surname><given-names>Á</given-names></name><etal></etal></person-group>. <article-title>Chitosan-based nanoparticles for improving immunization against hepatitis B infection</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>:<fpage>2607</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.011</pub-id><pub-id pub-id-type="pmid">20096389</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Ackerman</surname><given-names>AL</given-names></name><name><surname>Cody</surname><given-names>V</given-names></name><name><surname>Giodini</surname><given-names>A</given-names></name><name><surname>Hinson</surname><given-names>ER</given-names></name><name><surname>Cresswell</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles</article-title>. <source>Immunology</source> (<year>2006</year>) <volume>117</volume>:<fpage>78</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2005.02268.x</pub-id><pub-id pub-id-type="pmid">16423043</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diwan</surname><given-names>M</given-names></name><name><surname>Tafaghodi</surname><given-names>M</given-names></name><name><surname>Samuel</surname><given-names>J</given-names></name></person-group>. <article-title>Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres</article-title>. <source>J Control Release</source> (<year>2002</year>) <volume>85</volume>:<fpage>247</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/S0168-3659(02)00275-4</pub-id><pub-id pub-id-type="pmid">12480329</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mintern</surname><given-names>JD</given-names></name><name><surname>Percival</surname><given-names>C</given-names></name><name><surname>Kamphuis</surname><given-names>MMJ</given-names></name><name><surname>Chin</surname><given-names>WJ</given-names></name><name><surname>Caruso</surname><given-names>F</given-names></name><name><surname>Johnston</surname><given-names>APR</given-names></name></person-group>. <article-title>Targeting dendritic cells: the role of specific receptors in the internalization of polymer capsules</article-title>. <source>Adv Healthc Mater</source>. (<year>2013</year>) <volume>2</volume>:<fpage>940</fpage>–<lpage>4</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201200441</pub-id><pub-id pub-id-type="pmid">23335448</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Uto</surname><given-names>T</given-names></name><name><surname>Akagi</surname><given-names>T</given-names></name><name><surname>Akashi</surname><given-names>M</given-names></name><name><surname>Baba</surname><given-names>M</given-names></name></person-group>. <article-title>Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120</article-title>. <source>J Virol</source>. (<year>2007</year>) <volume>81</volume>:<fpage>10009</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00489-07</pub-id><pub-id pub-id-type="pmid">17609261</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richards</surname><given-names>RL</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name><name><surname>Wassef</surname><given-names>NM</given-names></name><name><surname>Glenn</surname><given-names>GM</given-names></name><name><surname>Rothwell</surname><given-names>SW</given-names></name><name><surname>Alving</surname><given-names>CR</given-names></name></person-group>. <article-title>Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen</article-title>. <source>Infect Immun</source>. (<year>1998</year>) <volume>66</volume>:<fpage>2859</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="pmid">9596760</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyler</surname><given-names>M</given-names></name><name><surname>Tumban</surname><given-names>E</given-names></name><name><surname>Peabody</surname><given-names>DS</given-names></name><name><surname>Chackerian</surname><given-names>B</given-names></name></person-group>. <article-title>The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine</article-title>. <source>Biotechnol Bioeng</source>. (<year>2014</year>) <volume>111</volume>:<fpage>2398</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1002/bit.25311</pub-id><pub-id pub-id-type="pmid">24917327</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slupetzky</surname><given-names>K</given-names></name><name><surname>Gambhira</surname><given-names>R</given-names></name><name><surname>Culp</surname><given-names>TD</given-names></name><name><surname>Shafti-Keramat</surname><given-names>S</given-names></name><name><surname>Schellenbacher</surname><given-names>C</given-names></name><name><surname>Christensen</surname><given-names>ND</given-names></name><etal></etal></person-group>. <article-title>A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<fpage>2001</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.11.049</pub-id><pub-id pub-id-type="pmid">17239496</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manish</surname><given-names>M</given-names></name><name><surname>Rahi</surname><given-names>A</given-names></name><name><surname>Kaur</surname><given-names>M</given-names></name><name><surname>Bhatnagar</surname><given-names>R</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name></person-group>. <article-title>A single-dose PLGA encapsulated protective antigen domain 4 nanoformulation protects mice against <italic>Bacillus anthracis</italic> spore challenge</article-title>. <source>PLoS ONE</source> (<year>2013</year>) <volume>8</volume>:<fpage>e61885</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061885</pub-id><pub-id pub-id-type="pmid">23637922</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>Q</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Enhanced immune response and protective effects of nano-chitosan-based DNA vaccine encoding T cell epitopes of Esat-6 and FL against <italic>Mycobacterium Tuberculosis</italic> infection</article-title>. <source>PLoS ONE</source> (<year>2013</year>) <volume>8</volume>:<fpage>e61135</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0061135</pub-id><pub-id pub-id-type="pmid">23637790</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>I</given-names></name><name><surname>Padhi</surname><given-names>A</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Dash</surname><given-names>DP</given-names></name><name><surname>Kar</surname><given-names>S</given-names></name><name><surname>Sonawane</surname><given-names>A</given-names></name></person-group>. <article-title>Biocompatible chitosan nanoparticles as an efficient delivery vehicle for <italic>Mycobacterium tuberculosis</italic> lipids to induce potent cytokines and antibody response through activation of γ<italic>δ</italic> T cells in mice</article-title>. <source>Nanotechnology</source> (<year>2017</year>) <volume>28</volume>:<fpage>165101</fpage>. <pub-id pub-id-type="doi">10.1088/1361-6528/aa60fd</pub-id><pub-id pub-id-type="pmid">28206982</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>E</given-names></name></person-group>. <article-title>Intranasal immunization with bacterial polysaccharide containing liposomes enhances antigen-specific pulmonary secretory antibody response</article-title>. <source>Vaccine</source> (<year>1992</year>) <volume>10</volume>:<fpage>461</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(92)90395-Z</pub-id><pub-id pub-id-type="pmid">1609549</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alving</surname><given-names>CR</given-names></name><name><surname>Richards</surname><given-names>RL</given-names></name><name><surname>Moss</surname><given-names>J</given-names></name><name><surname>Alving</surname><given-names>LI</given-names></name><name><surname>Clements</surname><given-names>JD</given-names></name><name><surname>Shiba</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen</article-title>. <source>Vaccine</source> (<year>1986</year>) <volume>4</volume>:<fpage>166</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(86)90005-8</pub-id><pub-id pub-id-type="pmid">3532603</pub-id></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name></person-group>. <article-title>Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<fpage>7664</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.08.034</pub-id><pub-id pub-id-type="pmid">17913305</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Makidon</surname><given-names>PE</given-names></name><name><surname>Knowlton</surname><given-names>J</given-names></name><name><surname>Groom</surname><given-names>J V</given-names></name><name><surname>Blanco</surname><given-names>LP</given-names></name><name><surname>LiPuma</surname><given-names>JJ</given-names></name><name><surname>Bielinska</surname><given-names>AU</given-names></name><etal></etal></person-group>. <article-title>Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine</article-title>. <source>Med Microbiol Immunol</source>. (<year>2010</year>) <volume>199</volume>:<fpage>81</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1007/s00430-009-0137-2</pub-id><pub-id pub-id-type="pmid">19967396</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bielinska</surname><given-names>AU</given-names></name><name><surname>Janczak</surname><given-names>KW</given-names></name><name><surname>Landers</surname><given-names>JJ</given-names></name><name><surname>Makidon</surname><given-names>P</given-names></name><name><surname>Sower</surname><given-names>LE</given-names></name><name><surname>Peterson</surname><given-names>JW</given-names></name><etal></etal></person-group>. <article-title>Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against <italic>Bacillus anthracis</italic> spore challenge</article-title>. <source>Infect Immun</source>. (<year>2007</year>) <volume>75</volume>:<fpage>4020</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00070-07</pub-id><pub-id pub-id-type="pmid">17502384</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamath</surname><given-names>AT</given-names></name><name><surname>Rochat</surname><given-names>AF</given-names></name><name><surname>Christensen</surname><given-names>D</given-names></name><name><surname>Agger</surname><given-names>EM</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Lambert</surname><given-names>PH</given-names></name><etal></etal></person-group>. <article-title>A liposome-based mycobacterial vaccine induces potent adult and neonatal multifunctional T cells through the exquisite targeting of dendritic cells</article-title>. <source>PLoS ONE</source> (<year>2009</year>) <volume>4</volume>:<fpage>e5771</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0005771</pub-id><pub-id pub-id-type="pmid">19492047</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YS</given-names></name><name><surname>Hung</surname><given-names>YC</given-names></name><name><surname>Lin</surname><given-names>WH</given-names></name><name><surname>Huang</surname><given-names>GS</given-names></name></person-group>. <article-title>Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide</article-title>. <source>Nanotechnology</source> (<year>2010</year>) <volume>21</volume>:<fpage>195101</fpage>. <pub-id pub-id-type="doi">10.1088/0957-4484/21/19/195101</pub-id><pub-id pub-id-type="pmid">20400818</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tao</surname><given-names>W</given-names></name><name><surname>Gill</surname><given-names>HS</given-names></name></person-group>. <article-title>M2e-immobilized gold nanoparticles as influenza A vaccine: role of soluble M2e and longevity of protection</article-title>. <source>Vaccine</source> (<year>2015</year>) <volume>33</volume>:<fpage>2307</fpage>–<lpage>2315</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2015.03.063</pub-id><pub-id pub-id-type="pmid">25842219</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment</article-title>. <source>Nano Lett</source>. (<year>2012</year>) <volume>12</volume>:<fpage>2003</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1021/nl300027p</pub-id><pub-id pub-id-type="pmid">22372996</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuvanshi</surname><given-names>RS</given-names></name><name><surname>Katare</surname><given-names>YK</given-names></name><name><surname>Lalwani</surname><given-names>K</given-names></name><name><surname>Ali</surname><given-names>MM</given-names></name><name><surname>Singh</surname><given-names>O</given-names></name><name><surname>Panda</surname><given-names>AK</given-names></name></person-group>. <article-title>Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants</article-title>. <source>Int J Pharm</source>. (<year>2002</year>) <volume>245</volume>:<fpage>109</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-5173(02)00342-3</pub-id><pub-id pub-id-type="pmid">12270248</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>C</given-names></name><name><surname>Rawat</surname><given-names>A</given-names></name><name><surname>Hope-Weeks</surname><given-names>L</given-names></name><name><surname>Ahsan</surname><given-names>F</given-names></name></person-group>. <article-title>Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine</article-title>. <source>Mol Pharm</source>. (<year>2011</year>) <volume>8</volume>:<fpage>405</fpage>–<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1021/mp100255c</pub-id><pub-id pub-id-type="pmid">21189035</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borges</surname><given-names>O</given-names></name><name><surname>Cordeiro-da-Silva</surname><given-names>A</given-names></name><name><surname>Tavares</surname><given-names>J</given-names></name><name><surname>Santarém</surname><given-names>N</given-names></name><name><surname>de</surname><given-names>Sousa A</given-names></name><name><surname>Borchard</surname><given-names>G</given-names></name><etal></etal></person-group>. <article-title>Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles</article-title>. <source>Eur J Pharm Biopharm</source>. (<year>2008</year>) <volume>69</volume>:<fpage>405</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2008.01.019</pub-id><pub-id pub-id-type="pmid">18364251</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Preparation and efficacy of a live newcastle disease virus vaccine encapsulated in chitosan nanoparticles</article-title>. <source>PLoS ONE</source> (<year>2012</year>) 7:e53314. <pub-id pub-id-type="doi">10.1371/journal.pone.0053314</pub-id><pub-id pub-id-type="pmid">23285276</pub-id></mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>JM</given-names></name><name><surname>Hardy</surname><given-names>ME</given-names></name><name><surname>Atmar</surname><given-names>RL</given-names></name><name><surname>Conner</surname><given-names>ME</given-names></name><name><surname>Estes</surname><given-names>MK</given-names></name></person-group>. <article-title>Oral immunization with recombinant Norwalk virus-like particles induces a systemic and mucosal immune response in mice</article-title>. <source>J Virol</source>. (<year>1998</year>) <volume>72</volume>:<fpage>1345</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="pmid">9445035</pub-id></mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ball</surname><given-names>JM</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Opekun</surname><given-names>AR</given-names></name><name><surname>Gilger</surname><given-names>MA</given-names></name><name><surname>Guerrero</surname><given-names>RA</given-names></name><name><surname>Estes</surname><given-names>MK</given-names></name></person-group>. <article-title>Recombinant Norwalk virus-like particles given orally to volunteers: phase I study</article-title>. <source>Gastroenterology</source> (<year>1999</year>) <volume>117</volume>:<fpage>40</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/S0016-5085(99)70548-2</pub-id><pub-id pub-id-type="pmid">10381908</pub-id></mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bright</surname><given-names>RA</given-names></name><name><surname>Carter</surname><given-names>DM</given-names></name><name><surname>Daniluk</surname><given-names>S</given-names></name><name><surname>Toapanta</surname><given-names>FR</given-names></name><name><surname>Ahmad</surname><given-names>A</given-names></name><name><surname>Gavrilov</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<fpage>3871</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.106</pub-id><pub-id pub-id-type="pmid">17337102</pub-id></mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>FS</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name></person-group>. <article-title>Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus</article-title>. <source>J Virol</source>. (<year>2007</year>) <volume>81</volume>:<fpage>3514</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.02052-06</pub-id><pub-id pub-id-type="pmid">17251294</pub-id></mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matassov</surname><given-names>D</given-names></name><name><surname>Cupo</surname><given-names>A</given-names></name><name><surname>Galarza</surname><given-names>JM</given-names></name></person-group>. <article-title>A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1)</article-title>. <source>Viral Immunol</source>. (<year>2007</year>) <volume>20</volume>:<fpage>441</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1089/vim.2007.0027</pub-id><pub-id pub-id-type="pmid">17931114</pub-id></mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bright</surname><given-names>RA</given-names></name><name><surname>Carter</surname><given-names>DM</given-names></name><name><surname>Crevar</surname><given-names>CJ</given-names></name><name><surname>Toapanta</surname><given-names>FR</given-names></name><name><surname>Steckbeck</surname><given-names>JD</given-names></name><name><surname>Cole</surname><given-names>KS</given-names></name><etal></etal></person-group>. <article-title>Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle</article-title>. <source>PLoS ONE</source> (<year>2008</year>) <volume>3</volume>:<fpage>e1501</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0001501</pub-id><pub-id pub-id-type="pmid">18231588</pub-id></mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahmood</surname><given-names>K</given-names></name><name><surname>Bright</surname><given-names>RA</given-names></name><name><surname>Mytle</surname><given-names>N</given-names></name><name><surname>Carter</surname><given-names>DM</given-names></name><name><surname>Crevar</surname><given-names>CJ</given-names></name><name><surname>Achenbach</surname><given-names>JE</given-names></name><etal></etal></person-group>. <article-title>H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses</article-title>. <source>Vaccine</source> (<year>2008</year>) <volume>26</volume>:<fpage>5393</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.084</pub-id><pub-id pub-id-type="pmid">18706956</pub-id></mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Compans</surname><given-names>RW</given-names></name><name><surname>Yao</surname><given-names>Q</given-names></name></person-group>. <article-title>Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles</article-title>. <source>Virology</source> (<year>2003</year>) <volume>313</volume>:<fpage>502</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/S0042-6822(03)00372-6</pub-id><pub-id pub-id-type="pmid">12954217</pub-id></mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geldmacher</surname><given-names>A</given-names></name><name><surname>Skrastina</surname><given-names>D</given-names></name><name><surname>Borisova</surname><given-names>G</given-names></name><name><surname>Petrovskis</surname><given-names>I</given-names></name><name><surname>Krüger</surname><given-names>DH</given-names></name><name><surname>Pumpens</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies</article-title>. <source>Vaccine</source> (<year>2005</year>) <volume>23</volume>:<fpage>3973</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.02.025</pub-id><pub-id pub-id-type="pmid">15917119</pub-id></mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeyen</surname><given-names>JR</given-names></name><name><surname>Tourne</surname><given-names>S</given-names></name><name><surname>Shkreli</surname><given-names>M</given-names></name><name><surname>Sizaret</surname><given-names>PY</given-names></name><name><surname>Coursaget</surname><given-names>P</given-names></name></person-group>. <article-title>Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope</article-title>. <source>Virology</source> (<year>2003</year>) <volume>309</volume>:<fpage>32</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/S0042-6822(02)00134-4</pub-id><pub-id pub-id-type="pmid">12726724</pub-id></mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paz</surname><given-names>De la Rosa G</given-names></name><name><surname>Monroy-García</surname><given-names>A</given-names></name><name><surname>Mora-García</surname><given-names>M de L</given-names></name><name><surname>Peña</surname><given-names>CGR</given-names></name><name><surname>Hernández-Montes</surname><given-names>J</given-names></name><name><surname>Weiss-Steider</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice</article-title>. <source>Virol J</source>. (<year>2009</year>) <volume>6</volume>:<fpage>2</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-6-2</pub-id><pub-id pub-id-type="pmid">19126233</pub-id></mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>YK</given-names></name><name><surname>Sohn</surname><given-names>T</given-names></name><name><surname>Park</surname><given-names>JS</given-names></name><name><surname>Kang</surname><given-names>MJ</given-names></name><name><surname>Choi</surname><given-names>HG</given-names></name><name><surname>Kim</surname><given-names>JA</given-names></name><etal></etal></person-group>. <article-title>Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant</article-title>. <source>Virology</source> (<year>2004</year>) <volume>328</volume>:<fpage>266</fpage>–<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2004.06.047</pub-id><pub-id pub-id-type="pmid">15464846</pub-id></mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neal</surname><given-names>CM</given-names></name><name><surname>Crawford</surname><given-names>SE</given-names></name><name><surname>Estes</surname><given-names>MK</given-names></name><name><surname>Conner</surname><given-names>ME</given-names></name></person-group>. <article-title>Rotavirus virus-like particles administered mucosally induce protective immunity</article-title>. <source>J Virol</source>. (<year>1997</year>) <volume>71</volume>:<fpage>8707</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="pmid">9343229</pub-id></mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parez</surname><given-names>N</given-names></name><name><surname>Fourgeux</surname><given-names>C</given-names></name><name><surname>Mohamed</surname><given-names>A</given-names></name><name><surname>Dubuquoy</surname><given-names>C</given-names></name><name><surname>Pillot</surname><given-names>M</given-names></name><name><surname>Dehee</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Rectal immunization with rotavirus virus-like particles induces systemic and mucosal humoral immune responses and protects mice against rotavirus infection</article-title>. <source>J Virol</source>. (<year>2006</year>) <volume>80</volume>:<fpage>1752</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.80.4.1752-1761.2006</pub-id><pub-id pub-id-type="pmid">16439532</pub-id></mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roy</surname><given-names>P</given-names></name><name><surname>Bishop</surname><given-names>DH</given-names></name><name><surname>LeBlois</surname><given-names>H</given-names></name><name><surname>Erasmus</surname><given-names>BJ</given-names></name></person-group>. <article-title>Long-lasting protection of sheep against bluetongue challenge after vaccination with virus-like particles: evidence for homologous and partial heterologous protection</article-title>. <source>Vaccine</source> (<year>1994</year>) <volume>12</volume>:<fpage>805</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(94)90289-5</pub-id><pub-id pub-id-type="pmid">7975859</pub-id></mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deml</surname><given-names>L</given-names></name><name><surname>Kratochwil</surname><given-names>G</given-names></name><name><surname>Osterrieder</surname><given-names>N</given-names></name><name><surname>Knüchel</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>H</given-names></name><name><surname>Wagner</surname><given-names>R</given-names></name></person-group>. <article-title>Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain</article-title>. <source>Virology</source> (<year>1997</year>) <volume>235</volume>:<fpage>10</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1006/viro.1997.8669</pub-id><pub-id pub-id-type="pmid">9300033</pub-id></mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crooks</surname><given-names>ET</given-names></name><name><surname>Moore</surname><given-names>PL</given-names></name><name><surname>Franti</surname><given-names>M</given-names></name><name><surname>Cayanan</surname><given-names>CS</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120</article-title>. <source>Virology</source> (<year>2007</year>) <volume>366</volume>:<fpage>245</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.virol.2007.04.033</pub-id><pub-id pub-id-type="pmid">17580087</pub-id></mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buonaguro</surname><given-names>L</given-names></name><name><surname>Visciano</surname><given-names>ML</given-names></name><name><surname>Tornesello</surname><given-names>ML</given-names></name><name><surname>Tagliamonte</surname><given-names>M</given-names></name><name><surname>Biryahwaho</surname><given-names>B</given-names></name><name><surname>Buonaguro</surname><given-names>FM</given-names></name></person-group>. <article-title>Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation</article-title>. <source>J Virol</source>. (<year>2005</year>) <volume>79</volume>:<fpage>7059</fpage>–<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.79.11.7059-7067.2005</pub-id><pub-id pub-id-type="pmid">15890945</pub-id></mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BZ</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Kang</surname><given-names>SM</given-names></name><name><surname>Alam</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles</article-title>. <source>J Virol</source>. (<year>2007</year>) <volume>81</volume>:<fpage>10869</fpage>–<lpage>78</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.00542-07</pub-id><pub-id pub-id-type="pmid">17670815</pub-id></mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimentel</surname><given-names>TAPF</given-names></name><name><surname>Yan</surname><given-names>Z</given-names></name><name><surname>Jeffers</surname><given-names>SA</given-names></name><name><surname>Holmes</surname><given-names>K V</given-names></name></person-group>, Hodges RS, Burkhard P. Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. <source>Chem Biol Drug Des</source>. (<year>2009</year>) <volume>73</volume>:<fpage>53</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1111/j.1747-0285.2008.00746.x</pub-id><pub-id pub-id-type="pmid">19152635</pub-id></mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaba</surname><given-names>SA</given-names></name><name><surname>Brando</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Mittelholzer</surname><given-names>C</given-names></name><name><surname>Raman</surname><given-names>S</given-names></name><name><surname>Tropel</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria</article-title>. <source>J Immunol</source>. (<year>2009</year>) <volume>183</volume>:<fpage>7268</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0901957</pub-id><pub-id pub-id-type="pmid">19915055</pub-id></mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kazanji</surname><given-names>M</given-names></name><name><surname>Laurent</surname><given-names>F</given-names></name><name><surname>Péry</surname><given-names>P</given-names></name></person-group>. <article-title>Immune responses and protective effect in mice vaccinated orally with surface sporozoite protein of <italic>Eimeria</italic> falciformis in ISCOMs</article-title>. <source>Vaccine</source> (<year>1994</year>) <volume>12</volume>:<fpage>798</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(94)90288-7</pub-id><pub-id pub-id-type="pmid">7975858</pub-id></mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zou</surname><given-names>M</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Ji</surname><given-names>Z</given-names></name><name><surname>Gao</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>G</given-names></name></person-group>. <article-title>Synthesis of a novel kind of carbon nanoparticle with large mesopores and macropores and its application as an oral vaccine adjuvant</article-title>. <source>Eur J Pharm Sci</source>. (<year>2011</year>) <volume>44</volume>:<fpage>653</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2011.10.012</pub-id><pub-id pub-id-type="pmid">22064451</pub-id></mixed-citation></ref><ref id="B80"><label>80.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Zha</surname><given-names>X</given-names></name><name><surname>Fu</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>The effect of conjugation to gold nanoparticles on the ability of low molecular weight chitosan to transfer DNA vaccine</article-title>. <source>Biomaterials</source> (<year>2008</year>) <volume>29</volume>:<fpage>111</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2007.09.007</pub-id><pub-id pub-id-type="pmid">17905427</pub-id></mixed-citation></ref><ref id="B81"><label>81.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turkevich</surname><given-names>J</given-names></name><name><surname>Stevenson</surname><given-names>PC</given-names></name><name><surname>Hillier</surname><given-names>J</given-names></name></person-group><article-title>A study of the nucleation and growth processes in the synthesis of colloidal gold</article-title>. <source>Discuss Faraday Soc</source>. (<year>1951</year>) <volume>11</volume>:<fpage>55</fpage><pub-id pub-id-type="doi">10.1039/df9511100055</pub-id></mixed-citation></ref><ref id="B82"><label>82.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>CL</given-names></name><name><surname>Bonato</surname><given-names>VLD</given-names></name><name><surname>Coelho-Castelo</surname><given-names>AAM</given-names></name><name><surname>De</surname><given-names>Souza AO</given-names></name><name><surname>Santos</surname><given-names>SA</given-names></name><name><surname>Lima</surname><given-names>KM</given-names></name><etal></etal></person-group>. <article-title>Immunotherapy with plasmid DNA encoding mycobacterial hsp65 in association with chemotherapy is a more rapid and efficient form of treatment for tuberculosis in mice</article-title>. <source>Gene Ther</source>. (<year>2005</year>) <volume>12</volume>:<fpage>281</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/sj.gt.3302418</pub-id><pub-id pub-id-type="pmid">15526006</pub-id></mixed-citation></ref><ref id="B83"><label>83.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>CH</given-names></name><name><surname>Dao</surname><given-names>T</given-names></name><name><surname>Ahearn</surname><given-names>I</given-names></name><name><surname>Fehrenbacher</surname><given-names>N</given-names></name><name><surname>Casey</surname><given-names>E</given-names></name><name><surname>Rey</surname><given-names>DA</given-names></name><etal></etal></person-group>. <article-title>Single-walled carbon nanotubes deliver peptide antigen into dendritic cells and enhance IgG responses to tumor-associated antigens</article-title>. <source>ACS Nano</source>. (<year>2011</year>) <volume>5</volume>:<fpage>5300</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1021/nn200182x</pub-id><pub-id pub-id-type="pmid">21682329</pub-id></mixed-citation></ref><ref id="B84"><label>84.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M</given-names></name><name><surname>Jambhrunkar</surname><given-names>S</given-names></name><name><surname>Thorn</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Hyaluronic acid modified mesoporous silica nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells</article-title>. <source>Nanoscale</source> (<year>2013</year>) <volume>5</volume>:<fpage>178</fpage>–<lpage>83</lpage>. <pub-id pub-id-type="doi">10.1039/C2NR32145A</pub-id><pub-id pub-id-type="pmid">23076766</pub-id></mixed-citation></ref><ref id="B85"><label>85.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Kovochich</surname><given-names>M</given-names></name><name><surname>Liong</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>H</given-names></name><name><surname>Kabehie</surname><given-names>S</given-names></name><name><surname>George</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs</article-title>. <source>ACS Nano</source> (<year>2009</year>) <volume>3</volume>:<fpage>3273</fpage>–<lpage>86</lpage>. <pub-id pub-id-type="doi">10.1021/nn900918w</pub-id><pub-id pub-id-type="pmid">19739605</pub-id></mixed-citation></ref><ref id="B86"><label>86.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><etal></etal></person-group>. <article-title>Bioconjugated nanoparticles for DNA protection from cleavage</article-title>. <source>J Am Chem Soc</source>. (<year>2003</year>) <volume>125</volume>:<fpage>7168</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/ja034450d</pub-id><pub-id pub-id-type="pmid">12797777</pub-id></mixed-citation></ref><ref id="B87"><label>87.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name></person-group>. <article-title><italic>In vitro</italic> protein release and degradation of poly-dl-lactide-poly(ethylene glycol) microspheres with entrapped human serum albumin: quantitative evaluation of the factors involved in protein release phases</article-title>. <source>Pharm Res</source>. (<year>2001</year>) <volume>18</volume>:<fpage>117</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1023/A:1011043230573</pub-id><pub-id pub-id-type="pmid">11336346</pub-id></mixed-citation></ref><ref id="B88"><label>88.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demento</surname><given-names>SL</given-names></name><name><surname>Cui</surname><given-names>W</given-names></name><name><surname>Criscione</surname><given-names>JM</given-names></name><name><surname>Stern</surname><given-names>E</given-names></name><name><surname>Tulipan</surname><given-names>J</given-names></name><name><surname>Kaech</surname><given-names>SM</given-names></name><etal></etal></person-group>. <article-title>Role of sustained antigen release from nanoparticle vaccines in shaping the T cell memory phenotype</article-title>. <source>Biomaterials</source> (<year>2012</year>) <volume>33</volume>:<fpage>4957</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2012.03.041</pub-id><pub-id pub-id-type="pmid">22484047</pub-id></mixed-citation></ref><ref id="B89"><label>89.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lima</surname><given-names>VM</given-names></name><name><surname>Bonato</surname><given-names>VL</given-names></name><name><surname>Lima</surname><given-names>KM</given-names></name><name><surname>Dos</surname><given-names>Santos SA</given-names></name><name><surname>Dos</surname><given-names>Santos RR</given-names></name><name><surname>Gonçalves</surname><given-names>ED</given-names></name><etal></etal></person-group>. <article-title>Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis</article-title>. <source>Infect Immun</source>. (<year>2001</year>) <volume>69</volume>:<fpage>5305</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.69.9.5305-5312.2001</pub-id><pub-id pub-id-type="pmid">11500399</pub-id></mixed-citation></ref><ref id="B90"><label>90.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Noguchi</surname><given-names>Y</given-names></name><name><surname>Koizumi</surname><given-names>F</given-names></name><name><surname>Uenaka</surname><given-names>A</given-names></name><name><surname>Tanaka</surname><given-names>M</given-names></name><name><surname>Shimono</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title><italic>In vitro</italic> stimulation of CD8 and CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: identification of a new HLA-DR15-binding CD4 T-cell epitope</article-title>. <source>Clin Cancer Res</source>. (<year>2006</year>) <volume>12</volume>:<fpage>1921</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1900</pub-id><pub-id pub-id-type="pmid">16551878</pub-id></mixed-citation></ref><ref id="B91"><label>91.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Gao</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Pan</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Bioreducible alginate-poly(ethylenimine) nanogels as an antigen-delivery system robustly enhance vaccine-elicited humoral and cellular immune responses</article-title>. <source>J Control Release</source> (<year>2013</year>) <volume>168</volume>:<fpage>271</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2013.03.025</pub-id><pub-id pub-id-type="pmid">23562637</pub-id></mixed-citation></ref><ref id="B92"><label>92.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name><surname>Saade</surname><given-names>F</given-names></name><name><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>Advax<sup>TM</sup>, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>5373</fpage>–<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.06.021</pub-id><pub-id pub-id-type="pmid">22728225</pub-id></mixed-citation></ref><ref id="B93"><label>93.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saade</surname><given-names>F</given-names></name><name><surname>Honda-Okubo</surname><given-names>Y</given-names></name><name><surname>Trec</surname><given-names>S</given-names></name><name><surname>Petrovsky</surname><given-names>N</given-names></name></person-group>. <article-title>A novel hepatitis B vaccine containing Advax<sup>TM</sup>, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<fpage>1999</fpage>–<lpage>2007</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.077</pub-id><pub-id pub-id-type="pmid">23306367</pub-id></mixed-citation></ref><ref id="B94"><label>94.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Götze</surname><given-names>O</given-names></name><name><surname>Müller-Eberhard</surname><given-names>HJ</given-names></name></person-group><article-title>The C3-activator system: an alternate pathway of complement activation</article-title>. <source>J Exp Med</source>. (<year>1971</year>) <volume>134</volume>:<fpage>90</fpage>s−108s.<pub-id pub-id-type="pmid">19867385</pub-id></mixed-citation></ref><ref id="B95"><label>95.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pawar</surname><given-names>D</given-names></name><name><surname>Mangal</surname><given-names>S</given-names></name><name><surname>Goswami</surname><given-names>R</given-names></name><name><surname>Jaganathan</surname><given-names>KS</given-names></name></person-group>. <article-title>Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity</article-title>. <source>Eur J Pharm Biopharm</source>. (<year>2013</year>) <volume>85</volume>:<fpage>550</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejpb.2013.06.017</pub-id><pub-id pub-id-type="pmid">23831265</pub-id></mixed-citation></ref><ref id="B96"><label>96.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sonaje</surname><given-names>K</given-names></name><name><surname>Chuang</surname><given-names>EY</given-names></name><name><surname>Lin</surname><given-names>KJ</given-names></name><name><surname>Yen</surname><given-names>TC</given-names></name><name><surname>Su</surname><given-names>FY</given-names></name><etal></etal></person-group>. <article-title>Opening of epithelial tight junctions and enhancement of paracellular permeation by chitosan: microscopic, ultrastructural, and computed-tomographic observations</article-title>. <source>Mol Pharm</source>. (<year>2012</year>) <volume>9</volume>:<fpage>1271</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1021/mp200572t</pub-id><pub-id pub-id-type="pmid">22462641</pub-id></mixed-citation></ref><ref id="B97"><label>97.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de</surname><given-names>Titta A</given-names></name><name><surname>Ballester</surname><given-names>M</given-names></name><name><surname>Julier</surname><given-names>Z</given-names></name><name><surname>Nembrini</surname><given-names>C</given-names></name><name><surname>Jeanbart</surname><given-names>L</given-names></name><name><surname>van</surname><given-names>der Vlies AJ</given-names></name><etal></etal></person-group><article-title>Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2013</year>) <volume>110</volume>:<fpage>19902</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1313152110</pub-id><pub-id pub-id-type="pmid">24248387</pub-id></mixed-citation></ref><ref id="B98"><label>98.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammed</surname><given-names>MA</given-names></name><name><surname>Syeda</surname><given-names>JTM</given-names></name><name><surname>Wasan</surname><given-names>KM</given-names></name><name><surname>Wasan</surname><given-names>EK</given-names></name></person-group>. <article-title>An overview of chitosan nanoparticles and its application in non-parenteral drug delivery</article-title>. <source>Pharmaceutics</source> (<year>2017</year>) <volume>9</volume>:<fpage>53</fpage>. <pub-id pub-id-type="doi">10.3390/pharmaceutics9040053</pub-id><pub-id pub-id-type="pmid">29156634</pub-id></mixed-citation></ref><ref id="B99"><label>99.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>Liposomes in drug delivery: Progress and limitations</article-title>. <source>Int J Pharm</source>. (<year>1997</year>) <volume>154</volume>:<fpage>123</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/S0378-5173(97)00135-X</pub-id></mixed-citation></ref><ref id="B100"><label>100.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Storm</surname><given-names>G</given-names></name><name><surname>Crommelin</surname><given-names>DJ</given-names></name></person-group><article-title>Liposomes: quo vadis?</article-title><source>Pharm Sci Technolo Today</source> (<year>1998</year>) <volume>1</volume>:<fpage>19</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/S1461-5347(98)00007-8</pub-id></mixed-citation></ref><ref id="B101"><label>101.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tyagi</surname><given-names>RK</given-names></name><name><surname>Garg</surname><given-names>NK</given-names></name><name><surname>Sahu</surname><given-names>T</given-names></name></person-group>. <article-title>Vaccination strategies against malaria: novel carrier(s) more than a tour de force</article-title>. <source>J Control Release</source> (<year>2012</year>) <volume>162</volume>:<fpage>242</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2012.04.037</pub-id><pub-id pub-id-type="pmid">22564369</pub-id></mixed-citation></ref><ref id="B102"><label>102.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>JJ</given-names></name><name><surname>Suh</surname><given-names>H</given-names></name><name><surname>Bershteyn</surname><given-names>A</given-names></name><name><surname>Stephan</surname><given-names>MT</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses</article-title>. <source>Nat Mater</source>. (<year>2011</year>) <volume>10</volume>:<fpage>243</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1038/nmat2960</pub-id><pub-id pub-id-type="pmid">21336265</pub-id></mixed-citation></ref><ref id="B103"><label>103.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ichihashi</surname><given-names>T</given-names></name><name><surname>Satoh</surname><given-names>T</given-names></name><name><surname>Sugimoto</surname><given-names>C</given-names></name><name><surname>Kajino</surname><given-names>K</given-names></name></person-group>. <article-title>Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope-specific T cell responses</article-title>. <source>PLoS ONE</source> (<year>2013</year>) 8:e60068. <pub-id pub-id-type="doi">10.1371/journal.pone.0060068</pub-id><pub-id pub-id-type="pmid">23533665</pub-id></mixed-citation></ref><ref id="B104"><label>104.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>AM</given-names></name><name><surname>Souza</surname><given-names>ACO</given-names></name><name><surname>Amaral</surname><given-names>AC</given-names></name><name><surname>Vasconcelos</surname><given-names>NM</given-names></name><name><surname>Jeronimo</surname><given-names>MS</given-names></name><name><surname>Carneiro</surname><given-names>FP</given-names></name><etal></etal></person-group>. <article-title>Nanobiotechnological approaches to delivery of DNA vaccine against fungal infection</article-title>. <source>J Biomed Nanotechnol</source>. (<year>2013</year>) <volume>9</volume>:<fpage>221</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1166/jbn.2013.1491</pub-id><pub-id pub-id-type="pmid">23627048</pub-id></mixed-citation></ref><ref id="B105"><label>105.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>DS</given-names></name><name><surname>Endsley</surname><given-names>AN</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group>. <article-title>Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>2256</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.01.070</pub-id><pub-id pub-id-type="pmid">22306376</pub-id></mixed-citation></ref><ref id="B106"><label>106.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyas</surname><given-names>SP</given-names></name><name><surname>Kannan</surname><given-names>ME</given-names></name><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Mishra</surname><given-names>V</given-names></name><name><surname>Singh</surname><given-names>P</given-names></name></person-group>. <article-title>Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages</article-title>. <source>Int J Pharm</source>. (<year>2004</year>) <volume>269</volume>:<fpage>37</fpage>–<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2003.08.017</pub-id><pub-id pub-id-type="pmid">14698575</pub-id></mixed-citation></ref><ref id="B107"><label>107.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vyas</surname><given-names>S</given-names></name><name><surname>Quraishi</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Jaganathan</surname><given-names>K</given-names></name></person-group>. <article-title>Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages</article-title>. <source>Int J Pharm</source>. (<year>2005</year>) <volume>296</volume>:<fpage>12</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2005.02.003</pub-id><pub-id pub-id-type="pmid">15885451</pub-id></mixed-citation></ref><ref id="B108"><label>108.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>A</given-names></name><name><surname>Itskovitz-Cooper</surname><given-names>N</given-names></name><name><surname>Samira</surname><given-names>S</given-names></name><name><surname>Flasterstein</surname><given-names>O</given-names></name><name><surname>Eliyahu</surname><given-names>H</given-names></name><name><surname>Simberg</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>A new intranasal influenza vaccine based on a novel polycationic lipid–ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice</article-title>. <source>Vaccine</source> (<year>2006</year>) <volume>24</volume>:<fpage>3990</fpage>–<lpage>4006</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.12.017</pub-id><pub-id pub-id-type="pmid">16516356</pub-id></mixed-citation></ref><ref id="B109"><label>109.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Postma</surname><given-names>NS</given-names></name><name><surname>Hermsen</surname><given-names>CC</given-names></name><name><surname>Zuidema</surname><given-names>J</given-names></name><name><surname>Eling</surname><given-names>WM</given-names></name></person-group>. <article-title>Plasmodium vinckei: optimization of desferrioxamine B delivery in the treatment of murine malaria</article-title>. <source>Exp Parasitol</source>. (<year>1998</year>) <volume>89</volume>:<fpage>323</fpage>–<lpage>30</lpage>. <pub-id pub-id-type="doi">10.1006/expr.1998.4282</pub-id><pub-id pub-id-type="pmid">9676710</pub-id></mixed-citation></ref><ref id="B110"><label>110.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christensen</surname><given-names>D</given-names></name><name><surname>Korsholm</surname><given-names>KS</given-names></name><name><surname>Andersen</surname><given-names>P</given-names></name><name><surname>Agger</surname><given-names>EM</given-names></name></person-group>. <article-title>Cationic liposomes as vaccine adjuvants</article-title>. <source>Expert Rev Vaccines</source> (<year>2011</year>) <volume>10</volume>:<fpage>513</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1586/erv.11.17</pub-id><pub-id pub-id-type="pmid">21506648</pub-id></mixed-citation></ref><ref id="B111"><label>111.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McNeil</surname><given-names>SE</given-names></name><name><surname>Perrie</surname><given-names>Y</given-names></name></person-group><article-title>Gene delivery using cationic liposomes</article-title>. <source>Expert Opin Ther Pat</source>. (<year>2006</year>) <volume>16</volume>:<fpage>1371</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1517/13543776.16.10.1371</pub-id></mixed-citation></ref><ref id="B112"><label>112.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alving</surname><given-names>CR</given-names></name><name><surname>Beck</surname><given-names>Z</given-names></name><name><surname>Matyas</surname><given-names>GR</given-names></name><name><surname>Rao</surname><given-names>M</given-names></name></person-group>. <article-title>Liposomal adjuvants for human vaccines</article-title>. <source>Expert Opin Drug Deliv</source>. (<year>2016</year>) <volume>13</volume>:<fpage>807</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1517/17425247.2016.1151871</pub-id><pub-id pub-id-type="pmid">26866300</pub-id></mixed-citation></ref><ref id="B113"><label>113.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kingsman</surname><given-names>SM</given-names></name><name><surname>Kingsman</surname><given-names>AJ</given-names></name></person-group>. <article-title>Polyvalent recombinant antigens: a new vaccine strategy</article-title>. <source>Vaccine</source> (<year>1988</year>) <volume>6</volume>:<fpage>304</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(88)90174-0</pub-id><pub-id pub-id-type="pmid">2847436</pub-id></mixed-citation></ref><ref id="B114"><label>114.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roldão</surname><given-names>A</given-names></name><name><surname>Mellado</surname><given-names>MCM</given-names></name><name><surname>Castilho</surname><given-names>LR</given-names></name><name><surname>Carrondo</surname><given-names>MJ</given-names></name><name><surname>Alves</surname><given-names>PM</given-names></name></person-group>. <article-title>Virus-like particles in vaccine development</article-title>. <source>Expert Rev Vaccines</source> (<year>2010</year>) <volume>9</volume>:<fpage>1149</fpage>–<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1586/erv.10.115</pub-id><pub-id pub-id-type="pmid">20923267</pub-id></mixed-citation></ref><ref id="B115"><label>115.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeltins</surname><given-names>A</given-names></name></person-group>. <article-title>Construction and characterization of virus-like particles: a review</article-title>. <source>Mol Biotechnol</source>. (<year>2013</year>) <volume>53</volume>:<fpage>92</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1007/s12033-012-9598-4</pub-id><pub-id pub-id-type="pmid">23001867</pub-id></mixed-citation></ref><ref id="B116"><label>116.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grgacic</surname><given-names>EVL</given-names></name><name><surname>Anderson</surname><given-names>DA</given-names></name></person-group>. <article-title>Virus-like particles: passport to immune recognition</article-title>. <source>Methods</source> (<year>2006</year>) <volume>40</volume>:<fpage>60</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.ymeth.2006.07.018</pub-id><pub-id pub-id-type="pmid">16997714</pub-id></mixed-citation></ref><ref id="B117"><label>117.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strable</surname><given-names>E</given-names></name><name><surname>Finn</surname><given-names>MG</given-names></name></person-group>. <article-title>Chemical modification of viruses and virus-like particles</article-title>. <source>Curr Top Microbiol Immunol</source>. (<year>2009</year>) <volume>327</volume>:<fpage>1</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1007/978-3-540-69379-6_1</pub-id><pub-id pub-id-type="pmid">19198568</pub-id></mixed-citation></ref><ref id="B118"><label>118.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>P</given-names></name><name><surname>Jennings</surname><given-names>GT</given-names></name><name><surname>Willers</surname><given-names>J</given-names></name><name><surname>Rohner</surname><given-names>F</given-names></name><name><surname>Lindman</surname><given-names>Y</given-names></name><name><surname>Roubicek</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity</article-title>. <source>Eur J Immunol.</source> (<year>2005</year>) <volume>35</volume>:<fpage>2031</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200526285</pub-id><pub-id pub-id-type="pmid">15971275</pub-id></mixed-citation></ref><ref id="B119"><label>119.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KG</given-names></name><name><surname>Swartz</surname><given-names>JR</given-names></name></person-group>. <article-title>Surface functionalization of virus-like particles by direct conjugation using azide–alkyne click chemistry</article-title>. <source>Bioconjug Chem</source>. (<year>2011</year>) <volume>22</volume>:<fpage>376</fpage>–<lpage>87</lpage>. <pub-id pub-id-type="doi">10.1021/bc100367u</pub-id><pub-id pub-id-type="pmid">21355575</pub-id></mixed-citation></ref><ref id="B120"><label>120.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawano</surname><given-names>M</given-names></name><name><surname>Matsui</surname><given-names>M</given-names></name><name><surname>Handa</surname><given-names>H</given-names></name></person-group>. <article-title>SV40 virus-like particles as an effective delivery system and its application to a vaccine carrier</article-title>. <source>Expert Rev Vaccines</source> (<year>2013</year>) <volume>12</volume>:<fpage>199</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1586/erv.12.149</pub-id><pub-id pub-id-type="pmid">23414410</pub-id></mixed-citation></ref><ref id="B121"><label>121.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tissot</surname><given-names>AC</given-names></name><name><surname>Renhofa</surname><given-names>R</given-names></name><name><surname>Schmitz</surname><given-names>N</given-names></name><name><surname>Cielens</surname><given-names>I</given-names></name><name><surname>Meijerink</surname><given-names>E</given-names></name><name><surname>Ose</surname><given-names>V</given-names></name><etal></etal></person-group>. <article-title>Versatile virus-like particle carrier for epitope based vaccines</article-title>. <source>PLoS ONE</source> (<year>2010</year>) <volume>5</volume>:<fpage>e9809</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0009809</pub-id><pub-id pub-id-type="pmid">20352110</pub-id></mixed-citation></ref><ref id="B122"><label>122.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wijewardhana</surname><given-names>C</given-names></name><name><surname>Mann</surname><given-names>JFS</given-names></name></person-group>. <article-title>Virus-like particle, liposome, and polymeric particle-based vaccines against HIV-1</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<fpage>345</fpage>. <pub-id pub-id-type="doi">10.3389/fimmu.2018.00345</pub-id><pub-id pub-id-type="pmid">29541072</pub-id></mixed-citation></ref><ref id="B123"><label>123.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chahal</surname><given-names>JS</given-names></name><name><surname>Khan</surname><given-names>OF</given-names></name><name><surname>Cooper</surname><given-names>CL</given-names></name><name><surname>McPartlan</surname><given-names>JS</given-names></name><name><surname>Tsosie</surname><given-names>JK</given-names></name><name><surname>Tilley</surname><given-names>LD</given-names></name><etal></etal></person-group>. <article-title>Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and <italic>Toxoplasma gondii</italic> challenges with a single dose</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2016</year>) <volume>113</volume>:<fpage>E4133</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1600299113</pub-id><pub-id pub-id-type="pmid">27382155</pub-id></mixed-citation></ref><ref id="B124"><label>124.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahadoran</surname><given-names>A</given-names></name><name><surname>Moeini</surname><given-names>H</given-names></name><name><surname>Bejo</surname><given-names>MH</given-names></name><name><surname>Hussein</surname><given-names>MZ</given-names></name><name><surname>Omar</surname><given-names>AR</given-names></name></person-group>. <article-title>Development of Tat-conjugated dendrimer for transdermal DNA vaccine delivery</article-title>. <source>J Pharm Pharm Sci.</source> (<year>2016</year>) <volume>19</volume>:<fpage>325</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.18433/J3G31Q</pub-id><pub-id pub-id-type="pmid">27806247</pub-id></mixed-citation></ref><ref id="B125"><label>125.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaffer</surname><given-names>U</given-names></name><name><surname>Wade</surname><given-names>RG</given-names></name><name><surname>Gourlay</surname><given-names>T</given-names></name></person-group>. <article-title>Cytokines in the systemic inflammatory response syndrome: a review</article-title>. <source>HSR Proc Intensive Care Cardiovasc Anesth</source>. (<year>2010</year>) <volume>2</volume>:<fpage>161</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="pmid">23441054</pub-id></mixed-citation></ref><ref id="B126"><label>126.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hora</surname><given-names>MS</given-names></name><name><surname>Rana</surname><given-names>RK</given-names></name><name><surname>Nunberg</surname><given-names>JH</given-names></name><name><surname>Tice</surname><given-names>TR</given-names></name><name><surname>Gilley</surname><given-names>RM</given-names></name><name><surname>Hudson</surname><given-names>ME</given-names></name></person-group>. <article-title>Controlled release of interleukin-2 from biodegradable microspheres</article-title>. <source>Biotechnology</source> (<year>1990</year>) <volume>8</volume>:<fpage>755</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="pmid">1366902</pub-id></mixed-citation></ref><ref id="B127"><label>127.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melissen</surname><given-names>PM</given-names></name><name><surname>van</surname><given-names>Vianen W</given-names></name><name><surname>Bidjai</surname><given-names>O</given-names></name><name><surname>van</surname><given-names>Marion M</given-names></name><name><surname>Bakker-Woudenberg</surname><given-names>IA</given-names></name></person-group>. <article-title>Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria monocytogenes</article-title>. <source>Biotherapy</source> (<year>1993</year>) <volume>6</volume>:<fpage>113</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1007/BF01877424</pub-id><pub-id pub-id-type="pmid">8398570</pub-id></mixed-citation></ref><ref id="B128"><label>128.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>OA</given-names></name><name><surname>Huebsch</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Dranoff</surname><given-names>G</given-names></name><name><surname>Mooney</surname><given-names>DJ</given-names></name></person-group>. <article-title>Infection-mimicking materials to program dendritic cells in situ</article-title>. <source>Nat Mater</source>. (<year>2009</year>) <volume>8</volume>:<fpage>151</fpage>–<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1038/nmat2357</pub-id><pub-id pub-id-type="pmid">19136947</pub-id></mixed-citation></ref><ref id="B129"><label>129.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Killion</surname><given-names>JJ</given-names></name><name><surname>Fishbeck</surname><given-names>R</given-names></name><name><surname>Bar-Eli</surname><given-names>M</given-names></name><name><surname>Chernajovsky</surname><given-names>Y</given-names></name></person-group>. <article-title>Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors</article-title>. <source>Cytokine</source> (<year>1994</year>) <volume>6</volume>:<fpage>443</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/1043-4666(94)90069-8</pub-id><pub-id pub-id-type="pmid">7948753</pub-id></mixed-citation></ref><ref id="B130"><label>130.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ha</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Kang</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>EG</given-names></name><etal></etal></person-group>. <article-title>Enhanced immunogenicity and protective efficacy with the use of interleukin-12-encapsulated microspheres plus AS01B in tuberculosis subunit vaccination</article-title>. <source>Infect Immun</source>. (<year>2006</year>) <volume>74</volume>:<fpage>4954</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.01781-05</pub-id><pub-id pub-id-type="pmid">16861689</pub-id></mixed-citation></ref><ref id="B131"><label>131.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawai</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group>. <article-title>Toll-like receptors and their crosstalk with other innate receptors in infection and immunity</article-title>. <source>Immunity</source> (<year>2011</year>) <volume>34</volume>:<fpage>637</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><pub-id pub-id-type="pmid">21616434</pub-id></mixed-citation></ref><ref id="B132"><label>132.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schenten</surname><given-names>D</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group>. <article-title>The control of adaptive immune responses by the innate immune system</article-title>. <source>Adv Immunol.</source> (<year>2011</year>) <volume>109</volume>:<fpage>87</fpage>–<lpage>124</lpage>. <pub-id pub-id-type="doi">10.1016/B978-0-12-387664-5.00003-0</pub-id><pub-id pub-id-type="pmid">21569913</pub-id></mixed-citation></ref><ref id="B133"><label>133.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynn</surname><given-names>GM</given-names></name><name><surname>Laga</surname><given-names>R</given-names></name><name><surname>Darrah</surname><given-names>PA</given-names></name><name><surname>Ishizuka</surname><given-names>AS</given-names></name><name><surname>Balaci</surname><given-names>AJ</given-names></name><name><surname>Dulcey</surname><given-names>AE</given-names></name><etal></etal></person-group>. <article-title><italic>In vivo</italic> characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity</article-title>. <source>Nat Biotechnol</source>. (<year>2015</year>) <volume>33</volume>:<fpage>1201</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.3371</pub-id><pub-id pub-id-type="pmid">26501954</pub-id></mixed-citation></ref><ref id="B134"><label>134.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldinger</surname><given-names>SM</given-names></name><name><surname>Dummer</surname><given-names>R</given-names></name><name><surname>Baumgaertner</surname><given-names>P</given-names></name><name><surname>Mihic-Probst</surname><given-names>D</given-names></name><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Hammann-Haenni</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Nano-particle vaccination combined with TLR-7 and−9 ligands triggers memory and effector CD8<sup>+</sup> T-cell responses in melanoma patients</article-title>. <source>Eur J Immunol.</source> (<year>2012</year>) <volume>42</volume>:<fpage>3049</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201142361</pub-id><pub-id pub-id-type="pmid">22806397</pub-id></mixed-citation></ref><ref id="B135"><label>135.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>DJ</given-names></name><name><surname>Scott</surname><given-names>EA</given-names></name><name><surname>Scheid</surname><given-names>A</given-names></name><name><surname>Bergelson</surname><given-names>I</given-names></name><name><surname>Joshi</surname><given-names>S</given-names></name><name><surname>Pietrasanta</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Toll-like receptor 8 agonist nanoparticles mimic immunomodulating effects of the live BCG vaccine and enhance neonatal innate and adaptive immune responses</article-title>. <source>J Allergy Clin Immunol</source>. (<year>2017</year>) <volume>140</volume>:<fpage>1339</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaci.2016.12.985</pub-id><pub-id pub-id-type="pmid">28343701</pub-id></mixed-citation></ref><ref id="B136"><label>136.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moradi</surname><given-names>B</given-names></name><name><surname>Sankian</surname><given-names>M</given-names></name><name><surname>Amini</surname><given-names>Y</given-names></name><name><surname>Meshkat</surname><given-names>Z</given-names></name></person-group>. <article-title>Construction of a novel DNA vaccine candidate encoding an HspX-PPE44-EsxV fusion antigen of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Reports Biochem Mol Biol</source>. (<year>2016</year>) <volume>4</volume>:<fpage>89</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="pmid">27536702</pub-id></mixed-citation></ref><ref id="B137"><label>137.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>T</given-names></name><name><surname>Stavropoulos</surname><given-names>E</given-names></name><name><surname>Yang</surname><given-names>M</given-names></name><name><surname>Ragno</surname><given-names>S</given-names></name><name><surname>Vordermeier</surname><given-names>M</given-names></name><name><surname>Chambers</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>RNA encoding the MPT83 antigen induces protective immune responses against Mycobacterium tuberculosis infection</article-title>. <source>Infect Immun</source>. (<year>2004</year>) <volume>72</volume>:<fpage>6324</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.72.11.6324-6329.2004</pub-id><pub-id pub-id-type="pmid">15501761</pub-id></mixed-citation></ref><ref id="B138"><label>138.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romalde</surname><given-names>JL</given-names></name><name><surname>Luzardo-Alvárez</surname><given-names>A</given-names></name><name><surname>Ravelo</surname><given-names>C</given-names></name><name><surname>Toranzo</surname><given-names>AE</given-names></name><name><surname>Blanco-Méndez</surname><given-names>J</given-names></name></person-group><article-title>Oral immunization using alginate microparticles as a useful strategy for booster vaccination against fish lactoccocosis</article-title>. <source>Aquaculture</source> (<year>2004</year>) <volume>236</volume>:<fpage>119</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1016/j.aquaculture.2004.02.028</pub-id></mixed-citation></ref><ref id="B139"><label>139.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wendorf</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>M</given-names></name><name><surname>Chesko</surname><given-names>J</given-names></name><name><surname>Kazzaz</surname><given-names>J</given-names></name><name><surname>Soewanan</surname><given-names>E</given-names></name><name><surname>Ugozzoli</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>A practical approach to the use of nanoparticles for vaccine delivery</article-title>. <source>J Pharm Sci</source>. (<year>2006</year>) <volume>95</volume>:<fpage>2738</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1002/jps.20728</pub-id><pub-id pub-id-type="pmid">16927245</pub-id></mixed-citation></ref><ref id="B140"><label>140.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stieneker</surname><given-names>F</given-names></name><name><surname>Kreuter</surname><given-names>J</given-names></name><name><surname>Löwer</surname><given-names>J</given-names></name></person-group>. <article-title>High antibody titres in mice with polymethylmethacrylate nanoparticles as adjuvant for HIV vaccines</article-title>. <source>AIDS</source> (<year>1991</year>) <volume>5</volume>:<fpage>431</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="pmid">2059385</pub-id></mixed-citation></ref><ref id="B141"><label>141.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Mitchell</surname><given-names>AR</given-names></name><name><surname>Johnson</surname><given-names>SL</given-names></name><name><surname>Wagner-Bartak</surname><given-names>C</given-names></name><name><surname>Morcol</surname><given-names>T</given-names></name><name><surname>Bell</surname><given-names>SJ</given-names></name></person-group>. <article-title>Calcium phosphate nanoparticle adjuvant</article-title>. <source>Clin Diagn Lab Immunol</source>. (<year>2000</year>) <volume>7</volume>:<fpage>899</fpage>–<lpage>903</lpage>. <pub-id pub-id-type="doi">10.1128/CDLI.7.6.899-903.2000</pub-id><pub-id pub-id-type="pmid">11063495</pub-id></mixed-citation></ref><ref id="B142"><label>142.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oyewumi</surname><given-names>MO</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Cui</surname><given-names>Z</given-names></name></person-group>. <article-title>Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses</article-title>. <source>Expert Rev Vaccines</source> (<year>2010</year>) <volume>9</volume>:<fpage>1095</fpage>–<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1586/erv.10.89</pub-id><pub-id pub-id-type="pmid">20822351</pub-id></mixed-citation></ref><ref id="B143"><label>143.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biabanikhankahdani</surname><given-names>R</given-names></name><name><surname>Alitheen</surname><given-names>NBM</given-names></name><name><surname>Ho</surname><given-names>KL</given-names></name><name><surname>Tan</surname><given-names>WS</given-names></name></person-group>. <article-title>pH-responsive virus-like nanoparticles with enhanced tumour-targeting ligands for cancer drug delivery</article-title>. <source>Sci Rep</source>. (<year>2016</year>) <volume>6</volume>:<fpage>37891</fpage>. <pub-id pub-id-type="doi">10.1038/srep37891</pub-id><pub-id pub-id-type="pmid">27883070</pub-id></mixed-citation></ref><ref id="B144"><label>144.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slütter</surname><given-names>B</given-names></name><name><surname>Soema</surname><given-names>PC</given-names></name><name><surname>Ding</surname><given-names>Z</given-names></name><name><surname>Verheul</surname><given-names>R</given-names></name><name><surname>Hennink</surname><given-names>W</given-names></name><name><surname>Jiskoot</surname><given-names>W</given-names></name></person-group>. <article-title>Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen</article-title>. <source>J Control Release</source> (<year>2010</year>) <volume>143</volume>:<fpage>207</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2010.01.007</pub-id><pub-id pub-id-type="pmid">20074597</pub-id></mixed-citation></ref><ref id="B145"><label>145.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giddam</surname><given-names>AK</given-names></name><name><surname>Giddam</surname><given-names>AK</given-names></name><name><surname>Zaman</surname><given-names>M</given-names></name><name><surname>Skwarczynski</surname><given-names>M</given-names></name><name><surname>Toth</surname><given-names>I</given-names></name></person-group>. <article-title>Liposome-based delivery system for vaccine candidates: constructing an effective formulation</article-title>. <source>Nanomedicine</source> (<year>2012</year>) <volume>7</volume>:<fpage>1877</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.2217/nnm.12.157</pub-id><pub-id pub-id-type="pmid">23249332</pub-id></mixed-citation></ref><ref id="B146"><label>146.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glück</surname><given-names>R</given-names></name><name><surname>Moser</surname><given-names>C</given-names></name><name><surname>Metcalfe</surname><given-names>IC</given-names></name></person-group>. <article-title>Influenza virosomes as an efficient system for adjuvanted vaccine delivery</article-title>. <source>Expert Opin Biol Ther</source>. (<year>2004</year>) <volume>4</volume>:<fpage>1139</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1517/14712598.4.7.1139</pub-id><pub-id pub-id-type="pmid">15268680</pub-id></mixed-citation></ref><ref id="B147"><label>147.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morein</surname><given-names>B</given-names></name><name><surname>Sundquist</surname><given-names>B</given-names></name><name><surname>Höglund</surname><given-names>S</given-names></name><name><surname>Dalsgaard</surname><given-names>K</given-names></name><name><surname>Osterhaus</surname><given-names>A</given-names></name></person-group>. <article-title>Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses</article-title>. <source>Nature</source> (<year>1984</year>) <volume>308</volume>:<fpage>457</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="pmid">6709052</pub-id></mixed-citation></ref><ref id="B148"><label>148.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homhuan</surname><given-names>A</given-names></name><name><surname>Prakongpan</surname><given-names>S</given-names></name><name><surname>Poomvises</surname><given-names>P</given-names></name><name><surname>Maas</surname><given-names>RA</given-names></name><name><surname>Crommelin</surname><given-names>DJA</given-names></name><name><surname>Kersten</surname><given-names>GFA</given-names></name><etal></etal></person-group>. <article-title>Virosome and ISCOM vaccines against Newcastle disease: preparation, characterization and immunogenicity</article-title>. <source>Eur J Pharm Sci</source>. (<year>2004</year>) <volume>22</volume>:<fpage>459</fpage>–<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejps.2004.05.005</pub-id><pub-id pub-id-type="pmid">15265516</pub-id></mixed-citation></ref><ref id="B149"><label>149.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedersen</surname><given-names>JS</given-names></name><name><surname>Oliveira</surname><given-names>CLP</given-names></name><name><surname>Hübschmann</surname><given-names>HB</given-names></name><name><surname>Arleth</surname><given-names>L</given-names></name><name><surname>Manniche</surname><given-names>S</given-names></name><name><surname>Kirkby</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Structure of immune stimulating complex matrices and immune stimulating complexes in suspension determined by small-angle X-ray scattering</article-title>. <source>Biophys J</source>. (<year>2012</year>) <volume>102</volume>:<fpage>2372</fpage>–<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1016/j.bpj.2012.03.071</pub-id><pub-id pub-id-type="pmid">22677391</pub-id></mixed-citation></ref><ref id="B150"><label>150.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reid</surname><given-names>G</given-names></name></person-group>. <article-title>Soluble proteins incorporate into ISCOMs after covalent attachment of fatty acid</article-title>. <source>Vaccine</source> (<year>1992</year>) <volume>10</volume>:<fpage>597</fpage>–<lpage>602</lpage>. <pub-id pub-id-type="doi">10.1016/0264-410X(92)90439-Q</pub-id><pub-id pub-id-type="pmid">1323901</pub-id></mixed-citation></ref><ref id="B151"><label>151.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gregory</surname><given-names>AE</given-names></name><name><surname>Williamson</surname><given-names>ED</given-names></name><name><surname>Prior</surname><given-names>JL</given-names></name><name><surname>Butcher</surname><given-names>WA</given-names></name><name><surname>Thompson</surname><given-names>IJ</given-names></name><name><surname>Shaw</surname><given-names>AM</given-names></name><etal></etal></person-group>. <article-title>Conjugation of Y. pestis F1-antigen to gold nanoparticles improves immunogenicity</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>6777</fpage>–<lpage>82</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.09.021</pub-id><pub-id pub-id-type="pmid">23000121</pub-id></mixed-citation></ref><ref id="B152"><label>152.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>ST</given-names></name><name><surname>Rehor</surname><given-names>A</given-names></name><name><surname>Schmoekel</surname><given-names>HG</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name><name><surname>Swartz</surname><given-names>MA</given-names></name></person-group>. <article-title><italic>In vivo</italic> targeting of dendritic cells in lymph nodes with poly (propylene sulfide) nanoparticles</article-title>. <source>J Control Release</source> (<year>2006</year>) <volume>112</volume>:<fpage>26</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2006.01.006</pub-id><pub-id pub-id-type="pmid">16529839</pub-id></mixed-citation></ref><ref id="B153"><label>153.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sunshine</surname><given-names>JC</given-names></name><name><surname>Perica</surname><given-names>K</given-names></name><name><surname>Schneck</surname><given-names>JP</given-names></name><name><surname>Green</surname><given-names>JJ</given-names></name></person-group>. <article-title>Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells</article-title>. <source>Biomaterials</source> (<year>2014</year>) <volume>35</volume>:<fpage>269</fpage>–<lpage>77</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2013.09.050</pub-id><pub-id pub-id-type="pmid">24099710</pub-id></mixed-citation></ref><ref id="B154"><label>154.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yameen</surname><given-names>B</given-names></name><name><surname>Choi</surname><given-names>W Il</given-names></name><name><surname>Vilos</surname><given-names>C</given-names></name><name><surname>Swami</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Farokhzad</surname><given-names>OC</given-names></name></person-group>. <article-title>Insight into nanoparticle cellular uptake and intracellular targeting</article-title>. <source>J Control Release</source> (<year>2014</year>) <volume>190</volume>:<fpage>485</fpage>–<lpage>99</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.06.038</pub-id><pub-id pub-id-type="pmid">24984011</pub-id></mixed-citation></ref><ref id="B155"><label>155.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrovolskaia</surname><given-names>MA</given-names></name><name><surname>Aggarwal</surname><given-names>P</given-names></name><name><surname>Hall</surname><given-names>JB</given-names></name><name><surname>McNeil</surname><given-names>SE</given-names></name></person-group>. <article-title>Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution</article-title>. <source>Mol Pharm</source>. (<year>2008</year>) <volume>5</volume>:<fpage>487</fpage>–<lpage>95</lpage>. <pub-id pub-id-type="doi">10.1021/mp800032f</pub-id><pub-id pub-id-type="pmid">18510338</pub-id></mixed-citation></ref><ref id="B156"><label>156.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zolnik</surname><given-names>BS</given-names></name><name><surname>González-Fernández</surname><given-names>Á</given-names></name><name><surname>Sadrieh</surname><given-names>N</given-names></name><name><surname>Dobrovolskaia</surname><given-names>MA</given-names></name></person-group><article-title>Minireview: nanoparticles and the immune system</article-title>. <source>Endocrinology</source> (<year>2010</year>) <volume>151</volume>:<fpage>458</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1210/en.2009-1082</pub-id><pub-id pub-id-type="pmid">20016026</pub-id></mixed-citation></ref><ref id="B157"><label>157.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joshi</surname><given-names>VB</given-names></name><name><surname>Geary</surname><given-names>SM</given-names></name><name><surname>Salem</surname><given-names>AK</given-names></name></person-group>. <article-title>Biodegradable particles as vaccine delivery systems: size matters</article-title>. <source>AAPS J</source>. (<year>2013</year>) <volume>15</volume>:<fpage>85</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1208/s12248-012-9418-6</pub-id><pub-id pub-id-type="pmid">23054976</pub-id></mixed-citation></ref><ref id="B158"><label>158.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manolova</surname><given-names>V</given-names></name><name><surname>Flace</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>M</given-names></name><name><surname>Schwarz</surname><given-names>K</given-names></name><name><surname>Saudan</surname><given-names>P</given-names></name><name><surname>Bachmann</surname><given-names>MF</given-names></name></person-group>. <article-title>Nanoparticles target distinct dendritic cell populations according to their size</article-title>. <source>Eur J Immunol.</source> (<year>2008</year>) <volume>38</volume>:<fpage>1404</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200737984</pub-id><pub-id pub-id-type="pmid">18389478</pub-id></mixed-citation></ref><ref id="B159"><label>159.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishioka</surname><given-names>Y</given-names></name><name><surname>Yoshino</surname><given-names>H</given-names></name></person-group>. <article-title>Lymphatic targeting with nanoparticulate system</article-title>. <source>Adv Drug Deliv Rev</source>. (<year>2001</year>) <volume>47</volume>:<fpage>55</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-409X(00)00121-6</pub-id><pub-id pub-id-type="pmid">11251245</pub-id></mixed-citation></ref><ref id="B160"><label>160.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reddy</surname><given-names>ST</given-names></name><name><surname>van</surname><given-names>der Vlies AJ</given-names></name><name><surname>Simeoni</surname><given-names>E</given-names></name><name><surname>Angeli</surname><given-names>V</given-names></name><name><surname>Randolph</surname><given-names>GJ</given-names></name><name><surname>O'Neil</surname><given-names>CP</given-names></name><etal></etal></person-group>. <article-title>Exploiting lymphatic transport and complement activation in nanoparticle vaccines</article-title>. <source>Nat Biotechnol</source>. (<year>2007</year>) <volume>25</volume>:<fpage>1159</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1038/nbt1332</pub-id><pub-id pub-id-type="pmid">17873867</pub-id></mixed-citation></ref><ref id="B161"><label>161.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kostarelos</surname><given-names>K</given-names></name><name><surname>Lacerda</surname><given-names>L</given-names></name><name><surname>Pastorin</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Wieckowski</surname><given-names>S</given-names></name><name><surname>Luangsivilay</surname><given-names>J</given-names></name><etal></etal></person-group>. <article-title>Cellular uptake of functionalized carbon nanotubes is independent of functional group and cell type</article-title>. <source>Nat Nanotechnol</source>. (<year>2007</year>) <volume>2</volume>:<fpage>108</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1038/nnano.2006.209</pub-id><pub-id pub-id-type="pmid">18654229</pub-id></mixed-citation></ref><ref id="B162"><label>162.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foged</surname><given-names>C</given-names></name><name><surname>Brodin</surname><given-names>B</given-names></name><name><surname>Frokjaer</surname><given-names>S</given-names></name><name><surname>Sundblad</surname><given-names>A</given-names></name></person-group>. <article-title>Particle size and surface charge affect particle uptake by human dendritic cells in an <italic>in vitro</italic> model</article-title>. <source>Int J Pharm</source>. (<year>2005</year>) <volume>298</volume>:<fpage>315</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2005.03.035</pub-id><pub-id pub-id-type="pmid">15961266</pub-id></mixed-citation></ref><ref id="B163"><label>163.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiele</surname><given-names>L</given-names></name><name><surname>Merkle</surname><given-names>HP</given-names></name><name><surname>Walter</surname><given-names>E</given-names></name></person-group>. <article-title>Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages</article-title>. <source>Pharm Res</source>. (<year>2003</year>) <volume>20</volume>:<fpage>221</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1023/A:1022271020390</pub-id><pub-id pub-id-type="pmid">12636160</pub-id></mixed-citation></ref><ref id="B164"><label>164.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niikura</surname><given-names>K</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Kobayashi</surname><given-names>S</given-names></name><name><surname>Yamaguchi</surname><given-names>H</given-names></name><name><surname>Orba</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses <italic>in vitro</italic> and <italic>in vivo</italic></article-title>. <source>ACS Nano</source> (<year>2013</year>) <volume>7</volume>:<fpage>3926</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1021/nn3057005</pub-id><pub-id pub-id-type="pmid">23631767</pub-id></mixed-citation></ref><ref id="B165"><label>165.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>ST</given-names></name><name><surname>Saha</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>C</given-names></name><name><surname>Rotello</surname><given-names>VM</given-names></name></person-group>. <article-title>The role of surface functionality in determining nanoparticle cytotoxicity</article-title>. <source>Acc Chem Res</source>. (<year>2013</year>) <volume>46</volume>:<fpage>681</fpage>–<lpage>91</lpage>. <pub-id pub-id-type="doi">10.1021/ar3000647</pub-id><pub-id pub-id-type="pmid">23294365</pub-id></mixed-citation></ref><ref id="B166"><label>166.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hillaireau</surname><given-names>H</given-names></name><name><surname>Couvreur</surname><given-names>P</given-names></name></person-group>. <article-title>Nanocarriers' entry into the cell: relevance to drug delivery</article-title>. <source>Cell Mol Life Sci</source>. (<year>2009</year>) <volume>66</volume>:<fpage>2873</fpage>–<lpage>96</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-009-0053-z</pub-id><pub-id pub-id-type="pmid">19499185</pub-id></mixed-citation></ref><ref id="B167"><label>167.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name></person-group>. <article-title>Signalling pathways involved in the activation of dendritic cells by layered double hydroxide nanoparticles</article-title>. <source>Biomaterials</source> (<year>2010</year>) <volume>31</volume>:<fpage>748</fpage>–<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2009.09.095</pub-id><pub-id pub-id-type="pmid">19853910</pub-id></mixed-citation></ref><ref id="B168"><label>168.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Du</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>The induction of maturation on dendritic cells by TiO2 and Fe3O4@TiO2 nanoparticles via NF-κB signaling pathway</article-title>. <source>Mater Sci Eng C</source> (<year>2014</year>) <volume>39</volume>:<fpage>305</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1016/j.msec.2014.03.005</pub-id></mixed-citation></ref><ref id="B169"><label>169.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nawwab</surname><given-names>AL-Deen FM</given-names></name><name><surname>Selomulya</surname><given-names>C</given-names></name><name><surname>Kong</surname><given-names>YY</given-names></name><name><surname>Xiang</surname><given-names>SD</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Coppel</surname><given-names>RL</given-names></name><etal></etal></person-group><article-title>Design of magnetic polyplexes taken up efficiently by dendritic cell for enhanced DNA vaccine delivery</article-title>. <source>Gene Ther</source>. (<year>2014</year>) <volume>21</volume>:<fpage>212</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1038/gt.2013.77</pub-id><pub-id pub-id-type="pmid">24352195</pub-id></mixed-citation></ref><ref id="B170"><label>170.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toki</surname><given-names>S</given-names></name><name><surname>Omary</surname><given-names>RA</given-names></name><name><surname>Wilson</surname><given-names>K</given-names></name><name><surname>Gore</surname><given-names>JC</given-names></name><name><surname>Peebles</surname><given-names>RS</given-names></name><name><surname>Pham</surname><given-names>W</given-names></name></person-group>. <article-title>A comprehensive analysis of transfection-assisted delivery of iron oxide nanoparticles to dendritic cells</article-title>. <source>Nanomedicine</source> (<year>2013</year>) <volume>9</volume>:<fpage>1235</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1016/j.nano.2013.05.010</pub-id><pub-id pub-id-type="pmid">23747738</pub-id></mixed-citation></ref><ref id="B171"><label>171.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>YT</given-names></name><name><surname>Ko</surname><given-names>EJ</given-names></name><name><surname>Hwang</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>KH</given-names></name><name><surname>Kwon</surname><given-names>YM</given-names></name><etal></etal></person-group>. <article-title>Respiratory syncytial virus-like nanoparticle vaccination induces long-term protection without pulmonary disease by modulating cytokines and T-cells partially through alveolar macrophages</article-title>. <source>Int J Nanomed.</source> (<year>2015</year>) <volume>10</volume>:<fpage>4491</fpage>–<lpage>505</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S83493</pub-id><pub-id pub-id-type="pmid">26203246</pub-id></mixed-citation></ref><ref id="B172"><label>172.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Zhuang</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Erythrocyte membrane-enveloped polymeric nanoparticles as nanovaccine for induction of antitumor immunity against melanoma</article-title>. <source>ACS Nano</source> (<year>2015</year>) <volume>9</volume>:<fpage>6918</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.5b01042</pub-id><pub-id pub-id-type="pmid">26153897</pub-id></mixed-citation></ref><ref id="B173"><label>173.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Han</surname><given-names>S</given-names></name></person-group>. <article-title>Treatment of Dutch rat models of glioma using EphrinA1-PE38/GM-CSF chitosan nanoparticles by in situ activation of dendritic cells</article-title>. <source>Tumor Biol</source>. (<year>2015</year>) <volume>36</volume>:<fpage>7961</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s13277-015-3486-z</pub-id><pub-id pub-id-type="pmid">25957892</pub-id></mixed-citation></ref><ref id="B174"><label>174.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>DF</given-names></name><name><surname>Saenz</surname><given-names>R</given-names></name><name><surname>Bharati</surname><given-names>IS</given-names></name><name><surname>Seible</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Esener</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles</article-title>. <source>Breast Cancer Res</source>. (<year>2015</year>) <volume>17</volume>:<fpage>48</fpage>. <pub-id pub-id-type="doi">10.1186/s13058-015-0552-9</pub-id><pub-id pub-id-type="pmid">25882711</pub-id></mixed-citation></ref><ref id="B175"><label>175.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hernández-Gil</surname><given-names>J</given-names></name><name><surname>Cobaleda-Siles</surname><given-names>M</given-names></name><name><surname>Zabaleta</surname><given-names>A</given-names></name><name><surname>Salassa</surname><given-names>L</given-names></name><name><surname>Calvo</surname><given-names>J</given-names></name><name><surname>Mareque-Rivas</surname><given-names>JC</given-names></name></person-group>. <article-title>An iron oxide nanocarrier loaded with a Pt(IV) prodrug and immunostimulatory dsRNA for combining complementary cancer killing effects</article-title>. <source>Adv Healthc Mater</source>. (<year>2015</year>) <volume>4</volume>:<fpage>1034</fpage>–<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1002/adhm.201500080</pub-id><pub-id pub-id-type="pmid">25846677</pub-id></mixed-citation></ref><ref id="B176"><label>176.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>F</given-names></name><name><surname>Mencia</surname><given-names>A</given-names></name><name><surname>Bi</surname><given-names>L</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>HogenEsch</surname><given-names>H</given-names></name></person-group>. <article-title>Dendrimer-like alpha-d-glucan nanoparticles activate dendritic cells and are effective vaccine adjuvants</article-title>. <source>J Control Release</source> (<year>2015</year>) <volume>204</volume>:<fpage>51</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2015.03.002</pub-id><pub-id pub-id-type="pmid">25747143</pub-id></mixed-citation></ref><ref id="B177"><label>177.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sehgal</surname><given-names>K</given-names></name><name><surname>Ragheb</surname><given-names>R</given-names></name><name><surname>Fahmy</surname><given-names>TM</given-names></name><name><surname>Dhodapkar</surname><given-names>M V</given-names></name><name><surname>Dhodapkar</surname><given-names>KM</given-names></name></person-group>. <article-title>Nanoparticle-mediated combinatorial targeting of multiple human Dendritic Cell (DC) subsets leads to enhanced T cell activation via IL-15–dependent DC crosstalk</article-title>. <source>J Immunol</source>. (<year>2014</year>) <volume>193</volume>:<fpage>2297</fpage>–<lpage>305</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1400489</pub-id><pub-id pub-id-type="pmid">25080481</pub-id></mixed-citation></ref><ref id="B178"><label>178.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoang</surname><given-names>MD</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Lee</surname><given-names>HJ</given-names></name><name><surname>Jung</surname><given-names>SH</given-names></name><name><surname>Choi</surname><given-names>NR</given-names></name><name><surname>Vo</surname><given-names>MC</given-names></name><etal></etal></person-group>. <article-title>Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) improve the immunogenicity of tumor antigens and enhance Th1 polarization of dendritic cells</article-title>. <source>J Immunol Res.</source> (<year>2015</year>) <volume>2015</volume>:<fpage>706379</fpage>. <pub-id pub-id-type="doi">10.1155/2015/706379</pub-id><pub-id pub-id-type="pmid">26221615</pub-id></mixed-citation></ref><ref id="B179"><label>179.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mundayoor</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>RA</given-names></name><name><surname>Dhanasooraj</surname><given-names>S</given-names></name></person-group>. <article-title>Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles</article-title>. <source>Int J Nanomedicine</source> (<year>2013</year>) <volume>8</volume>:<fpage>835</fpage>. <pub-id pub-id-type="doi">10.2147/IJN.S40238</pub-id><pub-id pub-id-type="pmid">23486691</pub-id></mixed-citation></ref><ref id="B180"><label>180.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amini</surname><given-names>Y</given-names></name><name><surname>Moradi</surname><given-names>B</given-names></name><name><surname>Tafaghodi</surname><given-names>M</given-names></name><name><surname>Meshkat</surname><given-names>Z</given-names></name><name><surname>Ghazvini</surname><given-names>K</given-names></name><name><surname>Fasihi-Ramandi</surname><given-names>M</given-names></name></person-group><article-title>TB trifusion antigen adsorbed on calcium phosphate nanoparticles stimulates strong cellular immunity in mice</article-title>. <source>Biotechnol Bioprocess Eng</source>. (<year>2016</year>) <volume>21</volume>:<fpage>653</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1007/s12257-016-0326-y</pub-id></mixed-citation></ref><ref id="B181"><label>181.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Speth</surname><given-names>MT</given-names></name><name><surname>Repnik</surname><given-names>U</given-names></name><name><surname>Müller</surname><given-names>E</given-names></name><name><surname>Spanier</surname><given-names>J</given-names></name><name><surname>Kalinke</surname><given-names>U</given-names></name><name><surname>Corthay</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>Poly(I:C)-encapsulating nanoparticles enhance innate immune responses to the tuberculosis vaccine Bacille Calmette–Guérin (BCG) via synergistic activation of innate immune receptors</article-title>. <source>Mol Pharm</source>. (<year>2017</year>) <volume>14</volume>:<fpage>4098</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.7b00795</pub-id><pub-id pub-id-type="pmid">28974092</pub-id></mixed-citation></ref><ref id="B182"><label>182.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poecheim</surname><given-names>J</given-names></name><name><surname>Barnier-Quer</surname><given-names>C</given-names></name><name><surname>Collin</surname><given-names>N</given-names></name><name><surname>Borchard</surname><given-names>G</given-names></name></person-group>. <article-title>Ag85A DNA vaccine delivery by nanoparticles: influence of the formulation characteristics on immune responses</article-title>. <source>Vaccines</source> (<year>2016</year>) <volume>4</volume>:<fpage>32</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines4030032</pub-id><pub-id pub-id-type="pmid">27626449</pub-id></mixed-citation></ref><ref id="B183"><label>183.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballester</surname><given-names>M</given-names></name><name><surname>Nembrini</surname><given-names>C</given-names></name><name><surname>Dhar</surname><given-names>N</given-names></name><name><surname>de</surname><given-names>Titta A</given-names></name><name><surname>de</surname><given-names>Piano C</given-names></name><etal></etal></person-group>. <article-title>Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis</article-title>. <source>Vaccine</source> (<year>2011</year>) <volume>29</volume>:<fpage>6959</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2011.07.039</pub-id><pub-id pub-id-type="pmid">21787826</pub-id></mixed-citation></ref><ref id="B184"><label>184.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nel</surname><given-names>AE</given-names></name><name><surname>Mädler</surname><given-names>L</given-names></name><name><surname>Velegol</surname><given-names>D</given-names></name><name><surname>Xia</surname><given-names>T</given-names></name><name><surname>Hoek</surname><given-names>EM V</given-names></name><name><surname>Somasundaran</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Understanding biophysicochemical interactions at the nano-bio interface</article-title>. <source>Nat Mater</source>. (<year>2009</year>) <volume>8</volume>:<fpage>543</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1038/nmat2442</pub-id><pub-id pub-id-type="pmid">19525947</pub-id></mixed-citation></ref><ref id="B185"><label>185.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>I</given-names></name><name><surname>Dawson</surname><given-names>KA</given-names></name></person-group><article-title>Protein-nanoparticle interactions</article-title>. (<year>2008</year>) <volume>3</volume>:<fpage>40</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/S1748-0132(08)70014-8</pub-id></mixed-citation></ref><ref id="B186"><label>186.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vertegel</surname><given-names>AA</given-names></name><name><surname>Siegel</surname><given-names>RW</given-names></name><name><surname>Dordick</surname><given-names>JS</given-names></name></person-group>. <article-title>Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme</article-title>. <source>Langmuir</source> (<year>2004</year>) <volume>20</volume>:<fpage>6800</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1021/la0497200</pub-id><pub-id pub-id-type="pmid">15274588</pub-id></mixed-citation></ref><ref id="B187"><label>187.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>PR</given-names></name><name><surname>Martinez-Pomares</surname><given-names>L</given-names></name><name><surname>Stacey</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>HH</given-names></name><name><surname>Brown</surname><given-names>GD</given-names></name><name><surname>Gordon</surname><given-names>S</given-names></name></person-group>. <article-title>Macrophage receptors and immune recognition</article-title>. <source>Annu Rev Immunol.</source> (<year>2005</year>) <volume>23</volume>:<fpage>901</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.immunol.23.021704.115816</pub-id><pub-id pub-id-type="pmid">15771589</pub-id></mixed-citation></ref><ref id="B188"><label>188.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beduneau</surname><given-names>A</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Grotepas</surname><given-names>CB</given-names></name><name><surname>Kabanov</surname><given-names>A</given-names></name><name><surname>Rabinow</surname><given-names>BE</given-names></name><name><surname>Gong</surname><given-names>N</given-names></name><etal></etal></person-group>. <article-title>Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles</article-title>. <source>PLoS ONE</source> (<year>2009</year>) <volume>4</volume>:<fpage>e4343</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0004343</pub-id><pub-id pub-id-type="pmid">19183814</pub-id></mixed-citation></ref><ref id="B189"><label>189.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laroui</surname><given-names>H</given-names></name><name><surname>Viennois</surname><given-names>E</given-names></name><name><surname>Xiao</surname><given-names>B</given-names></name><name><surname>Canup</surname><given-names>BSB</given-names></name><name><surname>Geem</surname><given-names>D</given-names></name><name><surname>Denning</surname><given-names>TL</given-names></name><etal></etal></person-group>. <article-title>Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis</article-title>. <source>J Control Release</source> (<year>2014</year>) <volume>186</volume>:<fpage>41</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.04.046</pub-id><pub-id pub-id-type="pmid">24810114</pub-id></mixed-citation></ref><ref id="B190"><label>190.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verma</surname><given-names>A</given-names></name><name><surname>Stellacci</surname><given-names>F</given-names></name></person-group>. <article-title>Effect of surface properties on nanoparticle-cell interactions</article-title>. <source>Small</source> (<year>2010</year>) <volume>6</volume>:<fpage>12</fpage>–<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1002/smll.200901158</pub-id><pub-id pub-id-type="pmid">19844908</pub-id></mixed-citation></ref><ref id="B191"><label>191.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolaczkowska</surname><given-names>E</given-names></name><name><surname>Kubes</surname><given-names>P</given-names></name></person-group>. <article-title>Neutrophil recruitment and function in health and inflammation</article-title>. <source>Nat Rev Immunol</source>. (<year>2013</year>) <volume>13</volume>:<fpage>159</fpage>–<lpage>75</lpage>. <pub-id pub-id-type="doi">10.1038/nri3399</pub-id><pub-id pub-id-type="pmid">23435331</pub-id></mixed-citation></ref><ref id="B192"><label>192.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamaly</surname><given-names>N</given-names></name><name><surname>Fredman</surname><given-names>G</given-names></name><name><surname>Subramanian</surname><given-names>M</given-names></name><name><surname>Gadde</surname><given-names>S</given-names></name><name><surname>Pesic</surname><given-names>A</given-names></name><name><surname>Cheung</surname><given-names>L</given-names></name><etal></etal></person-group>. <article-title>Development and <italic>in vivo</italic> efficacy of targeted polymeric inflammation-resolving nanoparticles</article-title>. <source>Proc Natl Acad Sci USA.</source>, (<year>2013</year>) <volume>110</volume>:<fpage>6506</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1303377110</pub-id><pub-id pub-id-type="pmid">23533277</pub-id></mixed-citation></ref><ref id="B193"><label>193.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>D</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group>. <article-title>Neutrophil-mediated delivery of therapeutic nanoparticles across blood vessel barrier for treatment of inflammation and infection</article-title>. <source>ACS Nano</source> (<year>2015</year>) <volume>9</volume>:<fpage>11800</fpage>–<lpage>11</lpage>. <pub-id pub-id-type="doi">10.1021/acsnano.5b05583</pub-id><pub-id pub-id-type="pmid">26516654</pub-id></mixed-citation></ref><ref id="B194"><label>194.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endsley</surname><given-names>AN</given-names></name><name><surname>Ho</surname><given-names>RJY</given-names></name></person-group>. <article-title>Enhanced anti-HIV efficacy of indinavir after inclusion in CD4-targeted lipid nanoparticles</article-title>. <source>JAIDS J Acquir Immune Defic Syndr</source>. (<year>2012</year>) <volume>61</volume>:<fpage>417</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0b013e3182653c1f</pub-id><pub-id pub-id-type="pmid">22743598</pub-id></mixed-citation></ref><ref id="B195"><label>195.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perisé-Barrios</surname><given-names>AJ</given-names></name><name><surname>Jiménez</surname><given-names>JL</given-names></name><name><surname>Domínguez-Soto</surname><given-names>A</given-names></name><name><surname>de</surname><given-names>la Mata FJ</given-names></name><name><surname>Corbí</surname><given-names>AL</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>Carbosilane dendrimers as gene delivery agents for the treatment of HIV infection</article-title>. <source>J Control Release</source> (<year>2014</year>) <volume>184</volume>:<fpage>51</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2014.03.048</pub-id><pub-id pub-id-type="pmid">24721235</pub-id></mixed-citation></ref><ref id="B196"><label>196.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>C V</given-names></name><name><surname>Collins</surname><given-names>DS</given-names></name><name><surname>Slot</surname><given-names>JW</given-names></name><name><surname>Geuze</surname><given-names>HJ</given-names></name><name><surname>Unanue</surname><given-names>ER</given-names></name></person-group>. <article-title>Liposome-encapsulated antigens are processed in lysosomes, recycled, and presented to T cells</article-title>. <source>Cell</source> (<year>1991</year>) <volume>64</volume>:<fpage>393</fpage>–<lpage>401</lpage>. <pub-id pub-id-type="doi">10.1016/0092-8674(91)90647-H</pub-id><pub-id pub-id-type="pmid">1899049</pub-id></mixed-citation></ref><ref id="B197"><label>197.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stano</surname><given-names>A</given-names></name><name><surname>Nembrini</surname><given-names>C</given-names></name><name><surname>Swartz</surname><given-names>MA</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name><name><surname>Simeoni</surname><given-names>E</given-names></name></person-group>. <article-title>Nanoparticle size influences the magnitude and quality of mucosal immune responses after intranasal immunization</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>7541</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.050</pub-id><pub-id pub-id-type="pmid">23103199</pub-id></mixed-citation></ref><ref id="B198"><label>198.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YM</given-names></name><name><surname>Pan</surname><given-names>JYJ</given-names></name><name><surname>Korbel</surname><given-names>GA</given-names></name><name><surname>Peperzak</surname><given-names>V</given-names></name><name><surname>Boes</surname><given-names>M</given-names></name><name><surname>Ploegh</surname><given-names>HL</given-names></name></person-group>. <article-title>Monovalent ligation of the B cell receptor induces receptor activation but fails to promote antigen presentation</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2006</year>) <volume>103</volume>:<fpage>3327</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0511315103</pub-id><pub-id pub-id-type="pmid">16492756</pub-id></mixed-citation></ref><ref id="B199"><label>199.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chackerian</surname><given-names>B</given-names></name><name><surname>Lowy</surname><given-names>DR</given-names></name><name><surname>Schiller</surname><given-names>JT</given-names></name></person-group>. <article-title>Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies</article-title>. <source>J Clin Invest</source>. (<year>2001</year>) <volume>108</volume>:<fpage>415</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1172/JCI11849</pub-id><pub-id pub-id-type="pmid">11489935</pub-id></mixed-citation></ref><ref id="B200"><label>200.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friede</surname><given-names>M</given-names></name><name><surname>Muller</surname><given-names>S</given-names></name><name><surname>Briand</surname><given-names>JP</given-names></name><name><surname>Van</surname><given-names>Regenmortel MH</given-names></name><name><surname>Schuber</surname><given-names>F</given-names></name></person-group>. <article-title>Induction of immune response against a short synthetic peptide antigen coupled to small neutral liposomes containing monophosphoryl lipid A</article-title>. <source>Mol Immunol</source>. (<year>1993</year>) <volume>30</volume>:<fpage>539</fpage>–<lpage>47</lpage>. <pub-id pub-id-type="doi">10.1016/0161-5890(93)90028-A</pub-id><pub-id pub-id-type="pmid">8487776</pub-id></mixed-citation></ref><ref id="B201"><label>201.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bershteyn</surname><given-names>A</given-names></name><name><surname>Hanson</surname><given-names>MC</given-names></name><name><surname>Crespo</surname><given-names>MP</given-names></name><name><surname>Moon</surname><given-names>JJ</given-names></name><name><surname>Li</surname><given-names>A V</given-names></name><name><surname>Suh</surname><given-names>H</given-names></name><etal></etal></person-group>. <article-title>Robust IgG responses to nanograms of antigen using a biomimetic lipid-coated particle vaccine</article-title>. <source>J Control Release</source> (<year>2012</year>) <volume>157</volume>:<fpage>354</fpage>–<lpage>65</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2011.07.029</pub-id><pub-id pub-id-type="pmid">21820024</pub-id></mixed-citation></ref><ref id="B202"><label>202.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Temchura</surname><given-names>VV</given-names></name><name><surname>Kozlova</surname><given-names>D</given-names></name><name><surname>Sokolova</surname><given-names>V</given-names></name><name><surname>Uberla</surname><given-names>K</given-names></name><name><surname>Epple</surname><given-names>M</given-names></name></person-group>. <article-title>Targeting and activation of antigen-specific B-cells by calcium phosphate nanoparticles loaded with protein antigen</article-title>. <source>Biomaterials</source> (<year>2014</year>) <volume>35</volume>:<fpage>6098</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.04.010</pub-id><pub-id pub-id-type="pmid">24776487</pub-id></mixed-citation></ref><ref id="B203"><label>203.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joffre</surname><given-names>OP</given-names></name><name><surname>Segura</surname><given-names>E</given-names></name><name><surname>Savina</surname><given-names>A</given-names></name><name><surname>Amigorena</surname><given-names>S</given-names></name></person-group>. <article-title>Cross-presentation by dendritic cells</article-title>. <source>Nat Rev Immunol</source>. (<year>2012</year>) <volume>12</volume>:<fpage>557</fpage>–<lpage>69</lpage>. <pub-id pub-id-type="doi">10.1038/nri3254</pub-id><pub-id pub-id-type="pmid">22790179</pub-id></mixed-citation></ref><ref id="B204"><label>204.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brode</surname><given-names>S</given-names></name><name><surname>Macary</surname><given-names>PA</given-names></name></person-group>. <article-title>Cross-presentation: dendritic cells and macrophages bite off more than they can chew!</article-title><source>Immunology</source> (<year>2004</year>) <volume>112</volume>:<fpage>345</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2004.01920.x</pub-id><pub-id pub-id-type="pmid">15196201</pub-id></mixed-citation></ref><ref id="B205"><label>205.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amigorena</surname><given-names>S</given-names></name><name><surname>Savina</surname><given-names>A</given-names></name></person-group>. <article-title>Intracellular mechanisms of antigen cross presentation in dendritic cells</article-title>. <source>Curr Opin Immunol</source>. (<year>2010</year>) <volume>22</volume>:<fpage>109</fpage>–<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.coi.2010.01.022</pub-id><pub-id pub-id-type="pmid">20171863</pub-id></mixed-citation></ref><ref id="B206"><label>206.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacsovics-Bankowski</surname><given-names>M</given-names></name><name><surname>Clark</surname><given-names>K</given-names></name><name><surname>Benacerraf</surname><given-names>B</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name></person-group>. <article-title>Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>1993</year>) <volume>90</volume>:<fpage>4942</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.90.11.4942</pub-id><pub-id pub-id-type="pmid">8506338</pub-id></mixed-citation></ref><ref id="B207"><label>207.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovacsovics-Bankowski</surname><given-names>M</given-names></name><name><surname>Rock</surname><given-names>KL</given-names></name></person-group>. <article-title>A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules</article-title>. <source>Science</source> (<year>1995</year>) <volume>267</volume>:<fpage>243</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1126/science.7809629</pub-id><pub-id pub-id-type="pmid">7809629</pub-id></mixed-citation></ref><ref id="B208"><label>208.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Reis</surname><given-names>e Sousa C</given-names></name><name><surname>Germain</surname><given-names>RN</given-names></name></person-group><article-title>Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis</article-title>. <source>J Exp Med</source>. (<year>1995</year>) <volume>182</volume>:<fpage>841</fpage>–<lpage>51</lpage>.<pub-id pub-id-type="pmid">7650490</pub-id></mixed-citation></ref><ref id="B209"><label>209.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harding</surname><given-names>C V</given-names></name><name><surname>Song</surname><given-names>R</given-names></name></person-group>. <article-title>Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules</article-title>. <source>J Immunol</source>. (<year>1994</year>) <volume>153</volume>:<fpage>4925</fpage>–<lpage>33</lpage>. <pub-id pub-id-type="pmid">7963555</pub-id></mixed-citation></ref><ref id="B210"><label>210.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Yap</surname><given-names>WT</given-names></name><name><surname>Irvine</surname><given-names>DJ</given-names></name></person-group>. <article-title>Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigen-presenting cells</article-title>. <source>Biomacromolecules</source> (<year>2005</year>) <volume>6</volume>:<fpage>2590</fpage>–<lpage>600</lpage>. <pub-id pub-id-type="doi">10.1021/bm0503221</pub-id><pub-id pub-id-type="pmid">16153096</pub-id></mixed-citation></ref><ref id="B211"><label>211.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamdy</surname><given-names>S</given-names></name><name><surname>Elamanchili</surname><given-names>P</given-names></name><name><surname>Alshamsan</surname><given-names>A</given-names></name><name><surname>Molavi</surname><given-names>O</given-names></name><name><surname>Satou</surname><given-names>T</given-names></name><name><surname>Samuel</surname><given-names>J</given-names></name></person-group>. <article-title>Enhanced antigen-specific primary CD4+ and CD8+ responses by codelivery of ovalbumin and toll-like receptor ligand monophosphoryl lipid A in poly(D,L-lactic-co-glycolic acid) nanoparticles</article-title>. <source>J Biomed Mater Res A</source> (<year>2007</year>) <volume>81</volume>:<fpage>652</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1002/jbm.a.31019</pub-id><pub-id pub-id-type="pmid">17187395</pub-id></mixed-citation></ref><ref id="B212"><label>212.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>Y</given-names></name><name><surname>Taneichi</surname><given-names>M</given-names></name><name><surname>Kasai</surname><given-names>M</given-names></name><name><surname>Kakiuchi</surname><given-names>T</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name></person-group>. <article-title>Liposome-coupled antigens are internalized by antigen-presenting cells via pinocytosis and cross-presented to CD8 T cells</article-title>. <source>PLoS ONE</source> (<year>2010</year>) <volume>5</volume>:<fpage>e15225</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0015225</pub-id><pub-id pub-id-type="pmid">21179411</pub-id></mixed-citation></ref><ref id="B213"><label>213.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandtzaeg</surname><given-names>P</given-names></name></person-group>. <article-title>Induction of secretory immunity and memory at mucosal surfaces</article-title>. <source>Vaccine</source> (<year>2007</year>) <volume>25</volume>:<fpage>5467</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.12.001</pub-id><pub-id pub-id-type="pmid">17227687</pub-id></mixed-citation></ref><ref id="B214"><label>214.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macho</surname><given-names>Fernandez E</given-names></name><name><surname>Chang</surname><given-names>J</given-names></name><name><surname>Fontaine</surname><given-names>J</given-names></name><name><surname>Bialecki</surname><given-names>E</given-names></name><name><surname>Rodriguez</surname><given-names>F</given-names></name><name><surname>Werkmeister</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Activation of invariant Natural Killer T lymphocytes in response to the α-galactosylceramide analogue KRN7000 encapsulated in PLGA-based nanoparticles and microparticles</article-title>. <source>Int J Pharm</source>. (<year>2012</year>) <volume>423</volume>:<fpage>45</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2011.04.068</pub-id><pub-id pub-id-type="pmid">21575695</pub-id></mixed-citation></ref><ref id="B215"><label>215.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van</surname><given-names>der Vlies AJ</given-names></name><name><surname>O'Neil</surname><given-names>CP</given-names></name><name><surname>Hasegawa</surname><given-names>U</given-names></name><name><surname>Hammond</surname><given-names>N</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name></person-group><article-title>Synthesis of pyridyl disulfide-functionalized nanoparticles for conjugating thiol-containing small molecules, peptides, and proteins</article-title>. <source>Bioconjug Chem</source>. (<year>2010</year>) <volume>21</volume>:<fpage>653</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1021/bc9004443</pub-id><pub-id pub-id-type="pmid">20369815</pub-id></mixed-citation></ref><ref id="B216"><label>216.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirosue</surname><given-names>S</given-names></name><name><surname>Kourtis</surname><given-names>IC</given-names></name><name><surname>van</surname><given-names>der Vlies AJ</given-names></name><name><surname>Hubbell</surname><given-names>JA</given-names></name><name><surname>Swartz</surname><given-names>MA</given-names></name></person-group>. <article-title>Antigen delivery to dendritic cells by poly(propylene sulfide) nanoparticles with disulfide conjugated peptides: cross-presentation and T cell activation</article-title>. <source>Vaccine</source> (<year>2010</year>) <volume>28</volume>:<fpage>7897</fpage>–<lpage>906</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2010.09.077</pub-id><pub-id pub-id-type="pmid">20934457</pub-id></mixed-citation></ref><ref id="B217"><label>217.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nembrini</surname><given-names>C</given-names></name><name><surname>Stano</surname><given-names>A</given-names></name><name><surname>Dane</surname><given-names>KY</given-names></name><name><surname>Ballester</surname><given-names>M</given-names></name><name><surname>van</surname><given-names>der Vlies AJ</given-names></name><name><surname>Marsland</surname><given-names>BJ</given-names></name><etal></etal></person-group>. <article-title>Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination</article-title>. <source>Proc Natl Acad Sci USA</source>. (<year>2011</year>) <volume>108</volume>:<fpage>E989</fpage>–<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.1104264108</pub-id><pub-id pub-id-type="pmid">21969597</pub-id></mixed-citation></ref><ref id="B218"><label>218.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swartz</surname><given-names>MA</given-names></name></person-group>. <article-title>The physiology of the lymphatic system</article-title>. <source>Adv Drug Deliv Rev</source>. (<year>2001</year>) <volume>50</volume>:<fpage>3</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/S0169-409X(01)00150-8</pub-id><pub-id pub-id-type="pmid">11489331</pub-id></mixed-citation></ref><ref id="B219"><label>219.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cubas</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Sevick-Muraca</surname><given-names>EM</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes</article-title>. <source>J Immunother</source>. (<year>2009</year>) <volume>32</volume>:<fpage>118</fpage>–<lpage>28</lpage>. <pub-id pub-id-type="doi">10.1097/CJI.0b013e31818f13c4</pub-id><pub-id pub-id-type="pmid">19238010</pub-id></mixed-citation></ref><ref id="B220"><label>220.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dane</surname><given-names>KY</given-names></name><name><surname>Nembrini</surname><given-names>C</given-names></name><name><surname>Tomei</surname><given-names>AA</given-names></name><name><surname>Eby</surname><given-names>JK</given-names></name><name><surname>O'Neil</surname><given-names>CP</given-names></name><name><surname>Velluto</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Nano-sized drug-loaded micelles deliver payload to lymph node immune cells and prolong allograft survival</article-title>. <source>J Control Release</source> (<year>2011</year>) <volume>156</volume>:<fpage>154</fpage>–<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jconrel.2011.08.009</pub-id><pub-id pub-id-type="pmid">21864593</pub-id></mixed-citation></ref><ref id="B221"><label>221.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>TM</given-names></name><name><surname>Hansen</surname><given-names>CB</given-names></name><name><surname>Guo</surname><given-names>LS</given-names></name></person-group>. <article-title>Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection</article-title>. <source>Biochim Biophys Acta</source> (<year>1993</year>) <volume>1150</volume>:<fpage>9</fpage>–<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1016/0005-2736(93)90115-G</pub-id><pub-id pub-id-type="pmid">8334142</pub-id></mixed-citation></ref><ref id="B222"><label>222.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vetro</surname><given-names>M</given-names></name><name><surname>Safari</surname><given-names>D</given-names></name><name><surname>Fallarini</surname><given-names>S</given-names></name><name><surname>Salsabila</surname><given-names>K</given-names></name><name><surname>Lahmann</surname><given-names>M</given-names></name><name><surname>Penadés</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Preparation and immunogenicity of gold glyco-nanoparticles as antipneumococcal vaccine model</article-title>. <source>Nanomedicine (Lond)</source> (<year>2017</year>) <volume>12</volume>:<fpage>13</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.2217/nnm-2016-0306</pub-id><pub-id pub-id-type="pmid">27879152</pub-id></mixed-citation></ref><ref id="B223"><label>223.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Margaroni</surname><given-names>M</given-names></name><name><surname>Agallou</surname><given-names>M</given-names></name><name><surname>Athanasiou</surname><given-names>E</given-names></name><name><surname>Kammona</surname><given-names>O</given-names></name><name><surname>Kiparissides</surname><given-names>C</given-names></name><name><surname>Gaitanaki</surname><given-names>C</given-names></name><etal></etal></person-group>. <article-title>Vaccination with poly(D,L-lactide-co-glycolide) nanoparticles loaded with soluble Leishmania antigens and modified with a TNFα-mimicking peptide or monophosphoryl lipid A confers protection against experimental visceral leishmaniasis</article-title>. <source>Int J Nanomedicine</source> (<year>2017</year>) <volume>12</volume>:<fpage>6169</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.2147/IJN.S141069</pub-id><pub-id pub-id-type="pmid">28883727</pub-id></mixed-citation></ref><ref id="B224"><label>224.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>XE</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Intranasal nanovaccine confers homo- and hetero-subtypic influenza protection</article-title>. <source>Small</source> (<year>2018</year>) <volume>14</volume>:<fpage>e1703207</fpage>. <pub-id pub-id-type="doi">10.1002/smll.201703207</pub-id><pub-id pub-id-type="pmid">29430819</pub-id></mixed-citation></ref><ref id="B225"><label>225.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sawaengsak</surname><given-names>C</given-names></name><name><surname>Mori</surname><given-names>Y</given-names></name><name><surname>Yamanishi</surname><given-names>K</given-names></name><name><surname>Mitrevej</surname><given-names>A</given-names></name><name><surname>Sinchaipanid</surname><given-names>N</given-names></name></person-group>. <article-title>Chitosan nanoparticle encapsulated hemagglutinin-split influenza virus mucosal vaccine</article-title>. <source>AAPS PharmSciTech</source> (<year>2014</year>) <volume>15</volume>:<fpage>317</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1208/s12249-013-0058-7</pub-id><pub-id pub-id-type="pmid">24343789</pub-id></mixed-citation></ref><ref id="B226"><label>226.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Figueiredo</surname><given-names>L</given-names></name><name><surname>Cadete</surname><given-names>A</given-names></name><name><surname>Gonçalves</surname><given-names>L</given-names></name><name><surname>Corvo</surname><given-names>M</given-names></name><name><surname>Almeida</surname><given-names>AJ</given-names></name></person-group>. <article-title>Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems</article-title>. <source>Vaccine</source> (<year>2012</year>) <volume>30</volume>:<fpage>6551</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.08.050</pub-id><pub-id pub-id-type="pmid">22947139</pub-id></mixed-citation></ref><ref id="B227"><label>227.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatri</surname><given-names>K</given-names></name><name><surname>Goyal</surname><given-names>AK</given-names></name><name><surname>Gupta</surname><given-names>PN</given-names></name><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Vyas</surname><given-names>SP</given-names></name></person-group>. <article-title>Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B</article-title>. <source>Int J Pharm</source> (<year>2008</year>) <volume>354</volume>:<fpage>235</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijpharm.2007.11.027</pub-id><pub-id pub-id-type="pmid">18182259</pub-id></mixed-citation></ref><ref id="B228"><label>228.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ai</surname><given-names>W</given-names></name><name><surname>Yue</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name></person-group>. <article-title>Enhanced protection against pulmonary mycobacterial challenge by chitosan-formulated polyepitope gene vaccine is associated with increased pulmonary secretory IgA and gamma-interferon(+) T cell responses</article-title>. <source>Microbiol Immunol</source> (<year>2013</year>) <volume>57</volume>:<fpage>224</fpage>–<lpage>35</lpage>. <pub-id pub-id-type="doi">10.1111/1348-0421.12027</pub-id><pub-id pub-id-type="pmid">23489083</pub-id></mixed-citation></ref><ref id="B229"><label>229.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meerak</surname><given-names>J</given-names></name><name><surname>Wanichwecharungruang</surname><given-names>SP</given-names></name><name><surname>Palaga</surname><given-names>T</given-names></name></person-group>. <article-title>Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system</article-title>. <source>Vaccine</source> (<year>2013</year>) <volume>31</volume>:<fpage>784</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2012.11.075</pub-id><pub-id pub-id-type="pmid">23228812</pub-id></mixed-citation></ref></ref-list></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000A90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000A90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:6180194
|texte= Nanoparticle Vaccines Against Infectious Diseases
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:30337923" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidV2
| This area was generated with Dilib version V0.6.33. |  |